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Abstract
Brugada syndrome (BS) is a genetic arrhythmogenic disease characterized by a distinctive
electrocardiographic pattern, associated with a high risk for sudden cardiac death (SCD) due to
ventricular fibrillation (VF) in absence of structural cardiopathies. Its complex and multifactorial
nature turns risk stratification into a major challenge. Although variations in autonomic
modulation are commonly related to arrhythmic events in this population, novel markers with
higher predictive values are still needed so as to identify those patients at high risk.
The autonomic function can be better characterized through the application of standardized
maneuvers stimulating the autonomic nervous system (ANS), such as exercise testing or the head-
up tilt (HUT) test. This PhD thesis is based on the hypothesis that a thorough analysis of the
ANS response of BS patients may provide additional information to improve risk stratification
in this population. The main objective is thus to evaluate the cardiovascular response to
ANS modulations on a clinical database composed of BS patients with different levels of risk
(symptomatic and asymptomatic subjects), using different autonomic maneuvers, in order to
identify novel potential markers for risk stratification.
In this context, the autonomic function was assessed by three main approaches. First,
through the characterization and comparison of previously described methods capturing heart
rate complexity, baroreflex sensitivity, and non-stationary heart rate variability, never before
studied in the context of BS patients; in order to identify new markers capable of distinguishing
between symptomatic and asymptomatic patients. According to the results, a lower variability
and complexity overnight, as well as a higher vagal tone and a lower sympathetic activity both
during exercise and HUT testing, was observed in the symptomatic group.
In a second analysis, in order to address the multifactorial nature of the disease, a multivariate
approach based on a step-based machine learning method was introduced. By employing features
extracted at signal-processing analysis, robust classifiers capable of identifying patients at high
risk were proposed. The classifier based on autonomic features extracted during nighttime
analysis presented the best performance (AUC = 95%), improving previously reported predictive
models of risk in BS based on non-invasive parameters.
Finally, the third part of this work was focused on the implementation of novel mathematical
models and the associated model analysis methods, so as to study the autonomic mechanisms
regulating the mechanical and circulatory functions of the cardiovascular system in this population.
First, by the integration and evaluation of a computational model capturing the cardiovascular
system’s dynamics and its autonomic regulation in response to HUT testing. Likewise, a second
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model-based approach based on a recursive identification of the sympathetic and parasympathetic
contributions to ANS regulation was proposed in order to estimate the time-varying autonomic
response to exertion and subsequent recovery. The results showed a reduced contractility function,
as well as a significantly greater parasympathetic activity during exercise, in symptomatic patients.
Finally, in order to combine characteristics extracted from model-based approaches, a prospective
study introduced a multivariate classifier based on estimated model parameters.
Overall, the obtained results indicate significant trends of clinical relevance that provide
new insights into the underlying autonomic mechanisms regulating the cardiovascular system in
BS, improving physiopathology and prognosis interpretation, with a potential future impact on
diagnostic and therapeutic strategies. The proposed approach may be used as an instrument for
the identification of those asymptomatic patients at high risk who may benefit from a cardioverter
defibrillator implantation.
Resumen
El síndrome de Brugada (SB) es una enfermedad genética asociada a un patrón electrocar-
diográfico característico y a un elevado riesgo de muerte súbita cardíaca (MSC), causada por
fibrilación ventricular (FV) en ausencia de cardiopatías estructurales. Debido a su naturaleza
compleja y multifactorial, la estratificación del riesgo supone, en la actualidad, uno de los aspectos
más controvertidos. Ciertas alteraciones en la modulación del sistema nervioso autónomo (SNA)
se han relacionado con eventos arrítmicos en esta población; no obstante, nuevos marcadores con
valores predictivos más elevados que permitan identificar a aquellos pacientes con un alto riesgo
de sufrir MSC son todavía necesarios.
El uso de maniobras estandarizadas con el objetivo de estimular el SNA permite una mejor
caracterización de la función autonómica. El principal objetivo de esta tesis doctoral es, por
tanto, la evaluación exhaustiva de la respuesta cardiovascular a la modulación del SNA en una
serie de pacientes con SB y diferentes niveles de riesgo (sujetos sintomáticos y asintomáticos), a
través de diferentes maniobras autonómicas, con la finalidad de identificar nuevos marcadores
potencialmente útiles para la estratificación de riesgo en esta población.
En este contexto, la evaluación de la función autonómica se llevó a cabo mediante tres estra-
tegias principales. En primer lugar, se caracterizaron y compararon la variabilidad y complejidad
del ritmo cardíaco, así como la sensibilidad barorrefleja, en pacientes sintomáticos y asintomáticos,
con el objetivo de identificar nuevos marcadores capaces de distinguir entre grupos de pacientes.
Los resultados mostraron, en el grupo sintomático, una menor variabilidad y complejidad durante
la noche, así como un mayor tono vagal y una menor actividad simpática tanto durante el
ejercicio como en respuesta a la prueba de mesa inclinada.
En un segundo análisis, se abordó la etiología multifactorial del síndrome mediante un
enfoque multivariado basado en un método de aprendizaje automático por etapas. A partir
de marcadores extraídos en la etapa anterior, se propusieron modelos predictivos capaces de
clasificar pacientes diagnosticados con SB en función de su nivel de riesgo. El mejor clasificador
(AUC = 95 %) fue diseñado a partir de marcadores autonómicos obtenidos durante la noche,
superando modelos predictivos previamente descritos para la estratificación del riesgo en el SB a
partir de la combinación de parámetros no invasivos.
Finalmente, se analizaron las interacciones entre las funciones mecánica, circulatoria y
autonómica de estos pacientes a partir de modelos fisiológicos. En primer lugar, mediante la
implementación y evaluación de un modelo computacional integrando la dinámica del sistema
cardiovascular y su respuesta autonómica a la prueba de mesa inclinada. Asimismo, se propuso la
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identificación recursiva de un modelo implementado para el análisis de la evolución temporal de las
contribuciones simpática y parasimpática del SNA durante una prueba de esfuerzo. Los resultados
mostraron una menor contractilidad, así como una actividad parasimpática significativamente
mayor durante el ejercicio, en pacientes sintomáticos. Con el objetivo de combinar características
extraídas del modelado fisiológico, un último estudio prospectivo propuso el diseño de un
clasificador multivariado integrando los parámetros estimados en esta última etapa.
Los resultados obtenidos indican importantes tendencias de relevancia clínica que aportan
nuevos conocimientos sobre los mecanismos autonómicos encargados de regular el sistema
cardiovascular en el SB. Su interpretación permite mejorar la estratificación del riesgo en estos
pacientes y, por tanto, optimizar las estrategias terapéuticas aplicadas. La metodología propuesta
se presenta como un instrumento para la identificación de aquellos pacientes con alto riesgo de
MSC que podrían beneficiarse de la implantación de desfibriladores automáticos.
Résumé
Le syndrome de Brugada (BS) est une maladie cardiaque caractérisée par la survenue d’une
syncope ou mort subite, provoquées par une arythmie cardiaque, chez les patients avec un cœur
structurellement normal, mais présentant des altérations électrocardiographiques spécifiques.
Cependant, ces modifications sont intermittentes et varient avec la température ou les traitements
appliqués, ce qui rend particulièrement difficile le diagnostic chez un patient donné. En outre,
elles sont fortement modulées par le système nerveux autonome (SNA), partie du système
nerveux périphérique responsable de la régulation des organes internes. Les défibrillateurs
implantables (DI) sont le traitement principal pour les patients symptomatiques, c’est-à-dire
les patients documentés d’arythmie ventriculaire, syncope ou ayant survécu à un épisode de
mort subite. Cependant, la décision d’implanter un DI peut être très difficile pour des patients
asymptomatiques sans antécédents familiaux de morte subite.
Dans ce contexte, l’objectif de la thèse était d’améliorer la compréhension de l’influence du
SNA chez les patients souffrant du BS. Une méthodologie globale fusionnant traitement du signal,
machine learning et modélisation a été proposée durant la thèse. Cette chaine de traitement
originale a pu être mise en œuvre sur trois bases de données de patients BS symptomatiques
et asymptomatiques. Les bases de données cliniques utilisées dans ce travail sont le résultat
d’une étude prospective, multicentrique dont l’objectif était de provoquer des modifications de
l’activité du SNA chez les patients BS. L’acquisition des données s’est déroulée entre 2009 et 2013
dans le service de cardiologie du CHU de Rennes et les participants provenaient de 8 hôpitaux
français situés à La Rochelle, Angers, Bordeaux, Brest, Nantes, Rennes, Poitiers et Tours. Afin
de caractériser les patients présentant différents niveaux de risque, les participants ont été classés
en patients symptomatiques et asymptomatiques, selon leurs historiques cliniques. Les patients
symptomatiques devaient présenter les symptômes documentés suivants : arrêt cardiaque dû à
une fibrillation ventriculaire, syncopes, vertiges, palpitations et convulsions nocturnes.
La base de données est constituée des ECG (12 dérivations) de 87 patients, collectés pendant
24 heures, incluant un test d’orthostatisme (tilt-test) et une épreuve d’effort. L’acquisition était
réalisée à l’aide d’un moniteur Holter (ELA medical, Sorin Group, Le Plessis Robinsson, France)
à une fréquence d’échantillonnage de 1000 Hz. Par ailleurs, des tilt-tests ont été réalisés sur 32
patients en mesurant de manière non-invasive la pression artérielle et l’ECG avec le moniteur
Task Force (CN Systems, Graz, Autriche) à une fréquence d’échantillonnage de 100 Hz et 1000
Hz, respectivement. Des signaux ECG à 12 dérivations échantillonnés à 1000 Hz ont été acquis
chez 36 autres patients BS lors d’un test d’exercice avec le moniteur ECG (Cardionics, Webster,
vii
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Texas). Par conséquent, l’analyse de l’activité du système nerveux autonome est basée sur 3
périodes différentes : 1) une épreuve d’effort, 2) un test d’orthostatisme (tilt-test) et 3) un recueil
de données pendant la nuit.
La réponse du système nerveux autonome, à ces trois tests, a tout d’abord été évaluée avec des
méthodes d’estimation du gain du baroréflexe, de variabilité et de complexité cardiaque. L’une
des difficultés du traitement des signaux associés à l’épreuve d’effort et au test d’orthostatisme
réside dans leurs natures non-stationnaires. L’analyse spectrale de ces signaux nécessite la mise
en œuvre d’outils spécifiques permettant de décrire une évolution temporelle des caractéristiques
fréquentielles. Des analyses temps-fréquence, basées sur la transformée de Wigner-Ville, ont ainsi
été utilisées afin d’étudier conjointement, le contenu spectral des signaux, et leurs évolutions
temporelles. Cependant, ces méthodes classiques d’analyse de la variabilité cardiaque ne per-
mettent pas de capturer la non-linéarité de la dynamique cardiovasculaire. Ainsi, des méthodes
spécifiques d’analyse de la complexité des séries cardiaques ont pu être utilisées. La sensibilité
du baroréflexe de ces patients a été évaluée à partir de différentes méthodes proposées dans la
littérature. Une série d’indices a ainsi été déduite des signaux avant d’être analysée pour trouver
des différences significatives entre les patients symptomatiques et asymptomatiques. Les résultats
ont mis en évidence que les indices calculés chez les patients symptomatiques sont associés à une
baisse de la variabilité et de la complexité cardiaque pendant la nuit. Par ailleurs, pendant le test
d’exercice, les patients symptomatiques ont montré une activité vagale augmentée et un tonus
sympathique réduit. Lors de la réponse au tilt-test, les patients symptomatiques ont présenté
une augmentation du tonus parasympathique et une réduction de l’équilibre sympatho-vagal par
rapport aux patients asymptomatiques.
L’étiologie multifactorielle du BS nécessite l’utilisation d’approches complexes capables de
capturer les multiples mécanismes sous-jacents à la maladie. Ainsi, une analyse multivariée
a été réalisée à partir de la série d’indices calculés précédemment. L’approche globale, basée
sur des méthodes de machine learning, permet de combiner de manière optimale les indices
autonomiques extraits précédemment, afin de concevoir des classificateurs capables de différencier
les patients BS, en fonction de leur symptomatologie. La sélection de ces indicateurs autonomiques,
permettant une meilleure caractérisation du BS, peut être difficile surtout lorsque le nombre de
sources dépasse la quantité d’observations et que les variabilités entre patients sont significatives.
Ainsi, une approche robuste basée sur un processus de sélection de paramètres en deux étapes
a été mise en œuvre. La méthodologie proposée a été optimisée, évaluée et comparée sur les
données extraites lors de différents tests autonomiques. Les résultats montrent que le meilleur
classificateur (AUC = 95%) a été conçu à partir de marqueurs autonomiques obtenus pendant
la nuit, améliorant des modèles prédictifs décrits précédemment pour la stratification du risque
dans le BS à partir de la combinaison de paramètres non invasifs.
Bien que l’analyse multivariée proposée montre une amélioration des performances de clas-
sification par rapport à la littérature, les méthodes utilisées n’intègrent pas de connaissance
physiologique dans le traitement des données. Or le BS étant une pathologie complexe et multi-
factorielle, l’utilisation de modèles mathématiques de connaissance peut s’avérer pertinente car
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cela permet l’intégration d’information physiologique dans le traitement des données et l’analyse
de mécanismes sous-jacents qui sont difficiles ou impossibles à observer en clinique avec des
méthodes non-invasives, comme le tonus vagal ou sympathique. Une analyse à base de modèle a
été proposée durant la thèse afin : 1) d’étudier la réponse autonomique et hémodynamique au
test d’orthostatisme chez des sujets sains et des patients BS, 2) de simuler les réponses vagales et
sympathiques durant l’épreuve d’effort chez les patients BS symptomatiques et asymptomatiques.
Concernant l’étude de la réponse au test d’orthostatisme, un modèle a été proposé de manière
à intégrer les représentations : i) de l’activité électrique cardiaque, ii) de la mécanique des
ventricules et des oreillettes, iii) des circulations systémique et pulmonaire et iv) du baroréflexe
incluant les voies vagale et sympathique. Le modèle complet permet de simuler les réponses
hémodynamiques et autonomiques au test d’orthostatisme. Des analyses de sensibilité, basées sur
des méthodes globales et de criblage, ont mis en évidence l’importance de certains paramètres
du baroréflexe et en lien avec la description des propriétés diastoliques des ventricules. Ces
paramètres ont pu être identifiés, à l’aide d’algorithmes évolutionnaires, afin de créer des modèles
spécifiques-patients de 8 sujets sains et 12 patients BS. Les résultats ont montré des différences
significatives concernant la réponse sympathique au tilt-test entre sujets sains et BS. Par ailleurs,
les patients symptomatiques et asymptomatiques sont associés des modifications significatives
des paramètres diastoliques ventriculaires.
Concernant les simulations de la réponse autonomique durant l’épreuve d’effort, un algorithme
d’identification récursif a pu être mis en œuvre sur un modèle composé des cavités cardiaques,
des circulations systémique et pulmonaire, couplées au baroréflexe. L’identification récursive
réalisée sur le modèle a permis une estimation des activités vagale et sympathique durant l’effort
chez 13 patients BS symptomatiques et 31 asymptomatiques. Les patients symptomatiques ont
montré une élévation significative de l’activité vagale, spécialement à la fin de l’échauffement. Les
analyses réalisées sur les modèles proposés, concernant le test d’orthostatisme et l’épreuve d’effort,
ont permis une exploration de variables physiologiques, difficilement observables. Les résultats
obtenus avec les modèles mettent en évidence des modifications de la réponse hémodynamique
cardiaque et confirment des modifications de la balance sympatho-vagale entre les patients
symptomatiques et asymptomatiques.
En résumé, les résultats obtenus mettent en évidence un déséquilibre de la balance sympatho-
vagale entre les patients symptomatiques et asymptomatiques et montrent l’utilité des indices de
variabilité cardiaque pour la classification des patients en fonction de la symptomatologie. Les
résultats obtenus sont cohérents avec la littérature, rapportant un tonus vagal plus élevé, ainsi
qu’une activité sympathique, variabilité et complexité cardiaques plus faibles, chez les patients
symptomatiques. Des études précédentes ont rapporté que la plupart des événements cardiaques
majeurs se produisent au repos et pendant le sommeil, ainsi que l’apparition des altérations
électrocardiographiques caractéristiques du BS augmente avec la stimulation vagale. Les résultats
obtenus pendant la nuit, lorsque l’activité parasympathique est prédominante, ont montré des
résultats particulièrement pertinents pour la différentiation des populations de patients. De plus,
étant donnée qu’il existe une activité parasympathique significativement plus élevée chez les
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patients symptomatiques pendant les tests d’exercice et d’orthostatisme par rapport aux sujets
asymptomatiques, les résultats soulignent le rôle de l’analyse du tonus vagal pour la stratification
du risque dans cette population. Enfin, l’analyse basée sur un modèle du système cardiovasculaire
a permis de mettre en évidence des différences concernant les propriétés diastoliques cardiaques
et la réponse du baroréflexe pendant le test d’orthostatisme. L’ensemble des résultats de la thèse
permet une meilleure caractérisation des profils autonomiques des patients atteints du syndrome
de Brugada et laisse envisager une amélioration de la sélection des patients pour implantation
d’un DI.
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CHAPTER1
Introduction
Brugada syndrome (BS) is a genetic arrhythmogenic disorder presenting an abnormal pattern
on the electrocardiogram (ECG), characterized by a distinctive ST-segment elevation in right
precordial leads; associated with a high risk for unexpected sudden cardiac death (SCD) due to
ventricular fibrillation (VF) in absence of structural cardiopathies (Priori et al., 2015; Priori
et al., 2013). Since its first description in 1992 as a distinct clinical entity (Brugada et al.,
1992), BS continues to spark research interest due to its high incidence, particularly in Southeast
Asia, and due to its association with SCD in young adults and, less frequently, in children and
infants. The syndrome is estimated to be responsible for at least 4% of the total amount of
SCD and for 20% of SCD in structurally normal hearts (Antzelevitch, 2005; Brugada et al.,
1998).
After diagnosis, implantable cardioverter defibrillators (ICD) are the only proven effective
treatment thus far. These devices can detect and revert most life-threatening ventricular
arrhythmias by delivering electrical shocks. However, they can present some complications, such
as inappropriate discharges or risks related to surgery (Miyazaki et al., 2013). According to
international guidelines (Priori et al., 2015), ICD implantation is recommended in BS patients
having survived from an SCD and/or having a history of spontaneous sustained ventricular
arrhythmias (VA), and should be considered in subjects with a spontaneous type 1 Brugada-like
ECG pattern presenting documented syncopes of ventricular origin. However, the decision of
implanting an ICD on asymptomatic patients is still complex, since they present a relatively low
risk for cardiac events, estimated at less than 1% (Probst et al., 2010).
Although the prognostic value for VF occurrence of several methods has been evaluated,
studies based on the largest clinical series have only confirmed two reliable predictors: spontaneous
type 1 Brugada-like ECG pattern and documented symptoms (Antzelevitch, 2005; Probst
et al., 2010). As a consequence, risk stratification in order to determine the best therapeutic
strategy for asymptomatic patients still remains challenging, even if they represent around 60%
of diagnosed patients.
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The autonomic nervous system (ANS) plays a determinant role in the pathophysiology,
arrhythmogenesis and prognosis of the disease. Major cardiac events in BS most commonly occur
during parasympathetic dominance at rest or during sleep (Kies et al., 2004; Matsuo et al.,
1999) and studies based on positron emission tomography have confirmed autonomic dysfunctions
in this population (Kies et al., 2004; Paul et al., 2011; Wichter et al., 2002). Thus, indicators
capturing changes in ANS modulation may provide useful knowledge for the prediction of VF
occurrence at follow-up. However, previous studies on the autonomic function of BS patients
have lead to conflicting results when based on long-term measurements (Behar et al., 2016;
Hermida et al., 2003; Kostopoulou et al., 2010; Krittayaphong et al., 2003; Nakazawa
et al., 2003; Pierre et al., 2007; Tokuyama et al., 2014). In order to better characterize
autonomic modulation, standard maneuvers, such as physical stress testing or the head-up tilt
(HUT) test, can be applied. Indeed, some studies have already reported the potential of exercise
testing (Amin et al., 2009; Makimoto et al., 2010; Subramanian et al., 2017), among other
autonomic tests (Bigi et al., 2008; Ikeda et al., 2006), for the prediction of cardiac events in BS.
Nevertheless, the multifactorial etiology of BS requires complex approaches capable of
capturing multiple mechanisms underlying the pathology. Accordingly, previous works based
on multivariate analysis have proposed predictive models combining several indicators in order
to assess VF risk in BS patients (Delise et al., 2014, 2011; Kawazoe et al., 2016; Okamura
et al., 2015). Moreover, since experimental data represent indirect estimations of the regulatory
mechanisms involved in the cardiovascular system, the selection of those indicators best explaining
the syndrome can be challenging, especially when the number of sources exceeds the amount of
observations, in a biomedical context where intra- and inter-patient variabilities are significant.
Another limitation of previous methods applied to study the autonomic response in BS patients
is that they are based on generic models assuming strong hypotheses about data statistical
properties, and do not integrate explicit biological and/or physiological a priori knowledge.
Although some approaches based on the simulation of Brugada syndrome through mathematical
models have been proposed (Clancy et al., 2002; Hoogendijk et al., 2011; Miyoshi et al.,
2003; Xia et al., 2006), they are focused on an electrophysiological perspective. The description
of computational models integrating physiological knowledge on interactions between the cardiac
function, the circulatory system and the ANS could be a step forward towards the understanding
of autonomic modulation in BS.
In this contex, the main objective of this work is the assessment of the autonomic function in
Brugada syndrome through the application of previously described methods and the development
of novel approaches better accounting for the complexity and multifactorial nature of biomedical
signals. These methods include signal processing, machine learning and model-based techniques
evaluated on clinical databases composed of cardiovascular signals from subjects at different levels
of risk (symptomatic and asymptomatic BS patients), acquired for 24 hours including exercise
testing and a head-up tilt test. The description of new biomarkers capable of identifying a high-risk
group of patients could provide new insights into the underlying autonomic mechanisms regulating
the cardiovascular system in BS, improving physiopathology and prognosis interpretation, with a
3potential future impact on therapeutic strategies for these patients. Figure 1.1 represents the
global methodological approach developed in this thesis, decomposed in four main chapters.
Figure 1.1– Global methodological approach to study the autonomic function of BS patients. A)
Cardiovascular signals are obtained from clinical databases acquired overnight and during exercise and
head-up tilt (HUT) testing on BS patients. B) Feature extraction is divided in two major blocks: B1)
signal-processing feature extraction, where heart rate variability (HRV), heart rate complexity (HRC)
and baroreflex sensitivity (BRS) parameters are estimated; and B2) model-based feature extraction,
where patient-specific models integrating the cardiovascular system (CVS), the cardiac electrical system
(CES) and the autonomic nervous system (ANS) are identified. First, extracted features are compared
between symptomatic and asymptomatic groups of patients. C) In a second phase, these same parameters
are included in a step-based machine learning approach in order to design predictive models capable of
identifying patients at high risk of SCD.
The next chapter provides the clinical context in which this thesis is framed. After a
brief review about cardiovascular physiology and its regulation through the autonomic nervous
system, a general overview of the BS, including diagnostic criteria, epidemiology, genetic basis,
risk stratification, clinical management, as well as a state-of-the-art review of the autonomic
function in this population, is presented. Finally, the clinical databases exploited in this research,
containing cardiovascular signals overnight and during different autonomic tests (Figure 1.1A),
are described.
Chapter 3 focuses on the application of signal processing methods to evaluate the autonomic
function of BS patients (Figure 1.1B1), by estimating their heart rate variability (HRV), heart
rate complexity (HRC) and baroreflex sensitivity (BRS). Symptomatic and asymptomatic groups
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of patients are characterized and compared in order to identify markers presenting significant
differences between groups that could provide useful information for the detection of patients at
high risk for major cardiac events.
However, since univariate analyses are unable to capture the multifactorial nature of the
syndrome, chapter 4 proposes a multivariate approach based on a step-based machine learning
method (Figure 1.1C) exploiting the features extracted in the previous chapter, in order to
improve classification performance.
In chapter 5, a system-level model-based approach is developed so as to study not only
the autonomic function of BS patients, but also their underlying mechanic and circulatory
characteristics (Figure 1.1B2). By means of a thorough sensitivity analysis and model-parameter
identifications, patient-specific models integrating the cardiovascular response to the autonomic
modulation during HUT testing are implemented. Moreover, a recursive model to estimate the
time-varying autonomic response to exercise is introduced. Finally, a prospective application
based on a multivariate classifier combining features extracted from model-based approaches is
introduced (dotted arrow in Figure 1.1).
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CHAPTER2
Brugada syndrome and autonomic
nervous system modulation
This chapter describes the clinical context in which this thesis is framed. First, a brief
review on the physiological basis of the cardiovascular system and its modulation through the
autonomic nervous system is introduced. Then, a general overview of the disease under study,
the Brugada syndrome, is presented. This genetic disorder is characterized by a distinctive
electrocardiographic pattern, associated with an elevated risk for sudden cardiac death due to
malignant ventricular arrythmias in patients having structurally normal hearts. The complexity
and multifactorial nature of its prognosis turns risk stratification into a major challenge nowadays.
Since autonomic nervous system (ANS) modulation plays a significant role in the pathophysiology,
arrhythmogenesis and prognosis of the disease, the application of specific maneuvers stimulating
the ANS, such as exercise or the head-up tilt (HUT) test, could improve autonomic assessment
and, thus, risk stratification in BS. Therefore, the last section is dedicated to the description of
the clinical databases applied in this research, containing cardiovascular signals overnight and
during exercise and HUT testing, in order to assess the autonomic function of BS patients at
different levels of risk.
2.1. Neural regulation of the cardiovascular system
2.1.1. The cardiovascular system
The cardiovascular system (CVS) is a closed circulatory system mainly composed of the
heart, blood vessels and blood. Its function is to transport nutrients, oxygen, carbon dioxide,
hormones, and blood cells throughout the organism in order to provide nourishment, protect
from diseases, regulate body temperature and pH, and maintain homeostasis.
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2.1.1.1. Circulatory physiology
The CVS is divided in two circulatory paths: pulmonary and systemic circulations (Guyton
et al., 2006). In the former, oxygen-deprived blood is pumped from the heart to the lungs, via
the pulmonary artery, and returns, oxygenated, back into the heart through the pulmonary vein.
On the other hand, systemic circulation transports oxygenated blood from the heart to the rest
of the body, via the aorta, and returns oxygen-poor blood back into the heart through the venae
cavae.
Arteries, which are vessels with muscular and elastic thick walls, branch into smaller structures
called arterioles and then into capillaries, which are tiny extremely thin-walled vessels connecting
arterial and venous systems. After their passage through body tissues to exchange gases and
nutrients, capillaries merge again into venules and then into veins, which are thin-walled vessels
resisting lower pressures than arteries. Figure 2.1 illustrates the cardiovascular system, where
blue represents oxygen-poor and CO2-rich blood circulation, whereas red refers to oxygen-rich
and CO2-poor blood.
Figure 2.1– Cardiovascular system, composed of the heart and the pulmonary and systemic circulations.
Blood pressure reflects the force exerted by circulating blood on the walls of blood vessels,
usually refering to systemic arterial pressure. In most clinical applications, it is expressed by
the systolic and diastolic pressures, which account for the pressure measured during ventricular
contraction (systole), and during ventricular relaxation (diastole), respectively.
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2.1.1.2. Anatomy of the heart
The heart is a muscular organ pumping blood through the circulatory system. It is composed
of four chambers: two atria and two ventricles. The right atrium (RA) receives deoxygenated
blood from the systemic circulation, through the superior and inferior venae cavae; while
oxygenated blood arrives to the left atrium (LA) back from the lungs, through the pulmonary
veins (Whitaker, 2014).
Atrioventricular valves connect atria and ventricles, ensuring unidirectional blood flows. The
tricuspid valve separates the RA from the right ventricle (RV), whereas the mitral valve separates
the left heart. Two additional semilunar valves are located at the exit of each ventricle to prevent
blood backflow: the pulmonary valve between the RV and the pulmonary artery, and the aortic
valve between the left ventricle (LV) and the aorta. Both atria and ventricles are separated by the
interatrial and interventricular septums, respectively. Figure 2.2 displays the main anatomical
structures of the heart.
Figure 2.2– Anatomical structure of the heart.
Each cardiac cycle begins with both atria and ventricles relaxed. Since blood circulates from
areas of higher to lower pressures, atria begin to fill until pressure rises and blood moves into the
ventricles. Likewise, this causes ventricular pressure to rise, which leads to the contraction of
ventricles in order to pump blood from the RV into the pulmonary artery, as well as from the LV
into the aorta. This mechanical cardiac cycle is controlled by the electrical activity generated at
the cellular level.
2.1.1.3. Cardiac electrical conduction
In normal conditions, the heart rhythm is established by the sinoatrial (SA) node, the heart’s
pacemaker, where an electrical impulse causing heart muscles to contract is generated and
propagated through the heart (Anderson et al., 2009).
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This electrical impulse, known as the action potential (AP), excites the RA and travels through
Bachmann’s bundle to simultaneously excite the LA. Then, it propagates through internodal
pathways in the RA to the atrioventricular (AV) node. From this node, the impulse travels
through the bundle of His and down the bundle branches on either side of the interventricular
septum: the right bundle branch (RBB) and the left bundle branch (LBB). Both branches
lead into the Purkinje fibers that finally transmit the electrical impulse to the muscle tissue
(myocardium) of the ventricles. Figure 2.3 illustrates the cardiac electrical conduction pathway.
Figure 2.3– Cardiac electrical conduction system.
In the cellular level, the cardiac AP is composed of the following 5 phases (Nerbonne et al.,
2005), represented in Figure 2.4 for both nodal and myocardial cell types:
Phase 0. When cardiac cells are in resting state, their membranes are negatively charged.
However, a rapid influx of sodium (Na+) ions causes the membrane potential to become
positive. This phenomenon is called depolarization and, in pacemaker cells, occurs sponta-
neously. In ventricular cells, though, this fast depolarization or fast flow of Na+ ions into
the cell is caused by the electrical excitation of nearby cells.
Phase 1. Only in non-pacemaker cells, the rapid inactivation of Na+ channels followed by
an outgoing flow of potassium (K+) ions causes a brief repolarization where the membrane
potential slightly becomes more negative. This is referred to as a notch on the AP waveform.
Phase 2. Known as the plateau phase due to a nearly balanced charge caused by the
influx of calcium (Ca2+) ions and the outgoing flow of K+ ions, the membrane potential of
non-pacemaker cells remains relatively constant.
Phase 3. When Ca2+ channels close, the positive outward current of K+ ions that remains
causes a negative change in the membrane potential and, thus, a rapid repolarization. Once
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the cell is sufficiently negatively charged, K+ channels close and membrane potential is
restored to a resting value.
Phase 4. It refers to the resting state, when the cell is more easily excitable.
Figure 2.4– Phases of the action potential from a SA node (left) and a ventricular (right) cell.
Depolarization causes Na+ channels to close and inactivate. The refractory period of a cardiac
cell is the time from phase 0 until the next possible depolarization. Indeed, different degrees of
refractoriness are encountered during an AP, depending on the amount of Na+ channels no longer
inactivated and capable of reopening. During the absolute refractory period (ARP), which starts
with phase 0 until halfway of phase 3, channels cannot be opened regardless of the strength of
the stimulus received. The ARP is immediately followed, until the end of phase 3, by the relative
refractory period (RRP), during which a stronger-than-usual stimulus can initiate another AP.
This is due to the membrane potential’s hyperpolarization caused by the leaking of K+ ions at
the end of phase 3, which opens the inactivation gates of Na+ channels, but still leaves those
channels closed.
2.1.1.4. The electrocardiogram
The electric currents generated during the depolarization and repolarization phases of
myocardial cells can be detected and recorded by placing surface electrodes on the thorax.
This measurable cardiac electrical activity is known as the electrocardiogram (ECG) and is
composed of three main parts: the P wave (atrial depolarization), the QRS complex (ventricular
depolarization) and the T wave (ventricular repolarization).
From the time difference between consecutive QRS complex locations (RR intervals), heart
rate can be estimated. In addition, from the heartbeart waveform, the following segments and
intervals can be measured (Figure 2.5):
PR interval. It is the time between P-wave onset and the beginning of the QRS complex,
and it represents the time the electrical impulse takes to travel from the SA node through
the AV node.
PR segment. It is measured between the end of P wave and QRS-complex onset, and it
reflects the duration of depolarization through the AV node.
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ST segment. It is the time between the end of the QRS complex and T-wave onset, and
it represents the time during which the ventricles are depolarized. In normal conditions, it
should be isoelectric. The J wave is a positive deflection occurring at the junction between
the QRS complex and the ST segment (Maruyama et al., 2004), where the S point, also
known as the J point, has a myocardial infarction-like, or Brugada-like, elevation.
QT interval. It is measured between QRS-complex onset and the end of the T wave and
indicates the duration of ventricular depolarization and repolarization.
Figure 2.5– Main waves, intervals and segments measured in a normal ECG waveform.
In a conventional 12-lead ECG, 10 electrodes are placed on the patient’s limbs and chest, their
locations being specified in Table 2.1. The overall magnitude of the heart’s electrical potential
is then measured from 12 different angles or leads: three bipolar limb leads (I, II, III), three
augmented limb leads (aVL, aVR, aVF) and six precordial leads (V1-V6).
Limb leads are bipolar measures calculated by comparing two electrodes located at different
sides of the heart, in this case, on different limbs: right arm (RA), left arm (LA) and left leg
(LL). These locations define the Einthoven’s triangle, drawn around the area of the heart (Figure
2.6a). Lead I is recorded by placing the negative terminal of the electrocardiograph on the RA
and the positive terminal on the LA. In lead II, the negative terminal is connected to the RA
and the positive terminal to the LL; and in lead III, the positive terminal stays in the LL, while
the negative terminal is placed on the LA. Einthoven’s law states that if the electrical potentials
of any two of the three bipolar limb leads are known at any given instant, the third one can be
determined mathematically (Guyton et al., 2006).
The second group of typically used leads consists of the unipolar augmented limb leads. In
this case, two limbs are connected to the negative terminal of the electrocardiograph, and the
third limb is connected to the positive terminal. When this positive terminal is on the RA, the
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Table 2.1– Electrodes placement on a conventional 12-lead ECG recording.
Electrode name Electrode placement
RA Right arm
LA Left arm
RL Right leg
LL Left leg
V1 Fourth intercostal space, at the right border of the sternum
V2 Fourth intercostal space, at the left border of the sternum
V3 Midway between V2 and V4
V4 Fifth intercostal space, at the mid-clavicular line
V5 Horizontally even with V4, at the anterior axillary line
V6 Horizontally even with V4 and V5, at the mid-axillary line
lead is known as the aVR lead; when on the LA, the aVL lead; and when on the LL, the aVF
lead. Based on Einthoven’s law, they can be determined mathematically from bipolar limb leads
as follows:
Lead aVL = −I− II2
Lead aVR = −I + II2
Lead aVF = −II− I2
Finally, precordial leads (Figure 2.6b) are unipolar measures compared to a reference lead,
typically the Wilson’s central terminal (WCT), calculated as the centroid of the Einthoven’s
triangle: WCT= 13(RA + LA + LL).
Figure 2.6– a) Einthoven’s triangle and representation of the bipolar (I, II , III) and augmented (aVL,
aVR, aVF) limb leads. b) Precordial leads placement on the thorax.
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2.1.2. The nervous system
The nervous system is a complex network of billions of nerve cells called neurons that, together
with the brain and spinal cord, monitor and control body functions by sending, receiving and
interpreting information from the entire organism (Guyton et al., 2006). It is subdivided in the
following subsystems:
The Central Nervous System (CNS), composed of the brain and spinal cord, and
responsible for the supervision and coordination of the entire nervous system.
The Peripheral Nervous System (PNS), which consists of glands and nerves, in
order to connect and transport information between the CNS and any part of the body.
Nerves transmitting signals from the brain are called motor or efferent nerves, while those
transmitting information from the body to the CNS are sensory or afferent nerves. The
PNS is likewise divided into:
• The somatic nervous system (SNS), which is composed of the nerves that mediate
voluntary movement, and thus that innervate skeletal muscles and external sensory
organs such as the skin.
• The autonomic nervous system (ANS), which innervates internal organs and
glands, in order to regulate involuntary body functions. It is further divided in the
enteric, sympathetic and parasympathetic nervous systems. The former regulates
bowel motility in digestion; the sympathetic nervous system is generally activated in
cases of stress such as exercise to mobilize energy; and the parasympathetic nervous
system is activated when organisms are in a relaxed state, in order to save energy.
2.1.2.1. Autonomic nervous system
The ANS regulates internal body functions such as the heart rate or respiration. It is mainly
divided in two complementary branches: the sympathetic and the parasympathetic systems.
In general, each effector organ is connected with its respective sympathetic and/or parasym-
pathetic system through preganglionic and postganglionic neurons, synapsed together in the
autonomic ganglia (Figure 2.7). All preganglionic neurons are cholinergic, since they release a
neurotransmitter called acetylcholine (Ach). In the parasympathetic system and in some cases of
the sympathetic system, postganglionic neurons are also cholinergic. However, most sympathetic
postganglionic neurons are adrenergic, since they release norepinephrine (NE).
Both sympathetic and parasympathetic systems can cause excitatory or inhibitory responses,
depending on the effector organ’s receptors. Moreover, for those organs having both sympathetic
and parasympathetic innervations, their respective functions are typically opposed and it is
the balance of the relative sympathetic to parasympathetic tone which dictates the organ
action. For example, sympathetic stimulation of the SA node increases heart rate (HR), while
parasympathetic stimulation does the contrary. Thus, the actual heart rate depends on the
relative balance between these two systems.
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Figure 2.7– Neural connection between the central nervous system (CNS) and effector organs by the
sympathetic and parasympathetic branches, through preganglionic and postganglionic neurons, synapsed
together in the autonomic ganglia.
2.1.2.2. Autonomic regulation of the cardiovascular system
Autonomic nervous system controls the cardiovascular system by innervating the heart with
both sympathetic and parasympathetic neurons, as well as blood vessels through the sympathetic
system, in order to regulate heart rate and blood pressure (Thomas, 2011).
On the one hand, parasympathetic neurons release acetylcholine, a cholinergic hormone that
activates muscarinic M2-receptors on the heart, causing HR to decrease by slowing down nodal
conduction. This phenomenon is known as the negative chronotropic effect. Hyperstimulation
of the parasympathetic influence on the heart promotes bradyarrhythmias, predisposing to
conduction block at the AV node. Since parasympathetic innervation is mainly provided by the
vagus nerve, parasympathetic tone is commonly referred to as vagal tone. At rest, although both
sympathetic and parasympathetic tones are exerted on the heart, vagal tone predominates.
On the other hand, sympathetic neurons release norepinephrine (NE), a catecholamine, which
activates β1 receptors on the heart, causing the following effects:
Chronotropic. It increases heart rate, by rising SA node discharge rate.
Dromotropic. It speeds up conduction through the AV node.
Inotropic. It increases cardiac contractility.
Lusitropic. It causes a faster relaxation after contraction.
Regarding blood vessels, sympathetic neurons also cause vasoconstriction and, thus, a blood
pressure rise through the increase of peripheral resistance. In the closed-loop system formed
by both autonomic and cardiovascular systems, the short-term regulation of blood pressure is
known as the baroreflex arc (Figure 2.8). The nervous signals coming from arterial baroreceptors
are transmitted to the ANS centers, which modulate heart rate, cardiac contractility and blood
vessels resistance through the sympathetic and parasympathetic systems.
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Figure 2.8– Autonomic and cardiovascular closed-loop system regulating blood vessels resistance,
heart rate and cardiac contractility based on the pressure detected at arterial baroreceptors.
Arterial baroreceptors are stretch receptors mainly located in the carotid sinus and in the
aortic arch, firing at a rate proportional to their stretch state and related to blood pressure in a
sigmoid manner. When blood pressure is close to the point of maximum sensitivity and increases,
stretch and, thus, baroreceptors firing rate rise, making cardiac centers to decrease sympathetic
stimulation and increase parasympathetic tone.
2.2. Brugada syndrome
In 1992, eight individuals having resuscitated from sudden cardiac death (SCD), showing
a characteristic ST-segment elevation in the right precordial leads and presenting structurally
normal hearts, were reported as a base for a distinct clinical entity (Brugada et al., 1992).
Nowadays, and since 1996 (Miyazaki et al., 1996), the "right bundle branch block, persistent
ST-segment elevation, and sudden death syndrome" is known as the Brugada syndrome (BS).
Since 1997, several studies have recognized BS as the same disease as the sudden unexplained
nocturnal death syndrome (SUNDS), also known as Bangungut in Philippines, Pokkuri in Japan
or Lai Tai in Thailand (Nademanee et al., 1997; Vatta et al., 2002). In 1998, the genetic
basis of BS was established by associating the disease with mutations in the SCN5A gene, which
encodes the α-subunit of the voltage-gated Nav1.5 cardiac sodium channel (Chen et al., 1998).
At present, BS is known as a rare, inherited disease caused by alterations on the cardiac
electrical conduction system that lead to SCD. It is characterized by a distinct electrocardiographic
(ECG) pattern, but variable expressivity and incomplete penetrance complicate the diagnosis
(Brugada et al., 2013). Since its description, although major advances in clinical and genetic
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knowledge have provided valuable information about the disease, risk stratification and clinical
management still remain challenging, propeling an extensive research activity on the subject.
2.2.1. Clinical diagnosis
2.2.1.1. Diagnostic criteria
Based on the second BS consensus report (Antzelevitch, 2005), three different abnormal
ECG patterns, represented in Figure 2.9, have been associated with the Brugada syndrome:
Type 1, which consists of a coved-type ST-segment elevation > 2 mm (0.2 mV), followed
by a negative T wave.
Type 2, defined as a saddleback-shaped pattern, with a high initial increase followed by
an ST-segment elevation > 2 mm, a trough displaying > 1 mm ST elevation, and either a
positive or biphasic T wave.
Type 3, which refer to saddleback-shaped patterns with a high initial increase followed by
an ST-segment elevation < 2 mm.
Figure 2.9– ECG patterns in precordial leads (V1-V6) associated with the BS (Nishizaki et al., 2013).
However, according to current guidelines (Priori et al., 2015), BS is only diagnosed in
patients presenting the type 1 Brugada-like ECG pattern in at least one right precordial lead;
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located in the second, third or fourth intercostal space; and appearing either spontaneously or
after provocative drug tests with intravenous administration of sodium channel blockers, when
baseline ECG presents a type 2 or type 3 morphology.
Although BS patients present no apparent structural cardiopathy, some microscopic myocar-
dial alterations have been reported, suggesting that the disease may induce cardiomyopathic
changes in some patients (Frustaci et al., 2005, 2009).
2.2.1.2. Diagnostic tools
Concealed forms of the disease may be unmasked through the intravenous administration of
class IC antiarrhythmic agents, such as ajmaline, flecainide or procainamide. Since these drugs
can promote sodium channel blockade, they stimulate the appearance of the diagnostic ECG
pattern (Morita et al., 2009). On the basis of comparative studies, though, ajmaline was found
to be the most sensitive drug in unmasking the coved-type morphology (Wolpert et al., 2005).
In 2014, the ajmaline drug test was repeated after puberty, in a cohort who showed negative
drug tests during childhood (Conte et al., 2014). They were able to unmask a diagnostic ECG
pattern in 23% of cases, suggesting a potential role for hormonal, autonomic, and epigenetic
factors in the response to antiarrhythmic agents, such as ajmaline, during childhood. Indeed,
since nearly 25% of drug-induced tests may lead to false-negative results (Hong et al., 2004),
clinical experience suggests that these tests should be repeated.
Moreover, (Calvo et al., 2015a) analyzed the influence of time in the interpretation of drug-
induced tests, reporting that longer periods of ECG recording seem to increase the probability of
type 1 ECG pattern detection.
2.2.2. Epidemiology
Brugada syndrome is thought to be responsible for 4 to 12% of the total amount of SCD
and for up to 20% of SCD in subjects with structurally normal hearts (Antzelevitch, 2005).
Its prevalence is estimated at 5 in 10,000 inhabitants, although this rate should be carefully
interpreted. First, because many patients present concealed forms of the disease, thus probably
underestimating BS prevalence; second, because important ethnic and geographic differences
have been reported (Antzelevitch, 2005). Indeed, while the prevalence of BS is estimated at 1
in 10,000 people from western countries, it seems to increment up to 12 in 10,000 in Southest
Asia (Fowler et al., 2009), where the syndrome is endemic and, apart from accidents, it is the
leading cause of death among young healthy men (Nademanee et al., 1997).
The syndrome is inherited with an autosomal dominant pattern and shows age- and sex-
related penetrance. The clinical phenotype is eightfold more frequent in men than in women
(Gehi et al., 2006), and it is mainly manifested in adulthood, at a mean age of 41 ± 15 years,
usually during rest or sleep (Priori et al., 2002). Fever, excessive alcohol intake and large meals
are triggers that unmask the type 1 ECG pattern and predispose to VF.
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2.2.3. Genetic basis
In 1998, the first work relating the syndrome to the gene SCN5A, which encodes the α-subunit
of the cardiac sodium channel, was published (Chen et al., 1998). To date, nearly 300 pathogenic
variations associated with BS have been reported in 22 different genes (Campuzano et al., 2016),
which primarily encode for sodium, potassium, and calcium channels, or proteins associated with
these channels (Table 2.2). Pathogenic variations in genes encoding desmosomal proteins have
also been associated with BS (Cerrone et al., 2014).
Table 2.2– Genes associated with Brugada syndrome.
Channel Inheritance Gene Percentage
Sodium Autosomal dominant SCN5A 25-35%
GPD1-L < 1%
SCN1B < 1%
SCN3B < 1%
SCN2B < 1%
SCN10A < 1%
HEY2 < 1%
RANGRF < 1%
SLMAP < 1%
FGF12 < 1%
PKP2 < 1%
Potassium Autosomal dominant ABCC9 < 1%
KCNE3 < 1%
KCNJ8 < 1%
HCN4 < 1%
KCND3 < 1%
SEMA3A < 1%
Chromosome X KCNE5 < 1%
Calcium Autosomal dominant CACNA1C < 1%
CACNB2B < 1%
CACNA2D1 < 1%
TRPM4 < 1%
However, only 30–35% of BS patients are genetically diagnosed, and most of them (25–30%)
result from pathogenic alterations in SCN5A (Kapplinger et al., 2010). Since this gene directly
affects phase 0 of the cardiac AP, pathogenic variants in SCN5A lead to sodium channel loss of
function due to either: 1) a decreased sodium channel current (INa); 2) alterations in voltage-
and time-dependent INa activation, inactivation, or reactivation; 3) intermediate state of INa
inactivation from which it recovers more slowly; or 4) early INa inactivation.
The last mechanism involving an accelerated inactivation of sodium channels has never been
observed at room temperature, and it has been proved to be accentuated at temperatures above
the physiologic range (Dumaine et al., 1999). Thus, BS patients, and particularly children
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(Probst et al., 2007), may be at an increased risk during febrile periods. Indeed, several BS
patients displaying fever-induced polymorphic ventricular tachycardia (VT) have been identified
(Antzelevitch et al., 2002).
2.2.4. Cellular mechanisms
Two main cellular mechanisms have been proposed to explain the characteristic Brugada-like
ST segment elevation (Meregalli et al., 2005): 1) a depolarization hypothesis, based on a
conduction delay in the right ventricular outflow tract (RVOT); and 2) a repolarization hypothesis,
based on a disequilibrium between Na+ and K+ ionic currents.
According to the second theory, during repolarization, a reduced inward Na+ current (INa)
and a prominent outward K+ current (Ito) lead to an accentuation of the AP notch in the RV
epicardium with respect to the endocardium, producing a transmural voltage gradient which
manifests electrocardiographically as the Brugada-like ST-segment elevation. At the end of phase
1, some epicardial sites undergo all-or-none repolarizations, losing their AP dome and leading
to an heterogenous repolarization environment that facilitates phase 2 re-entry and, thus, the
occurrence of VT and VF events (Antzelevitch, 2006; Yan et al., 1999).
In normal conditions (Figure 2.10a), the absence of transmural voltage gradients at the
level of the AP plateau leads to isoelectric ST segments. However, under pathophysiological
conditions, accentuation of the epicardial RV notch leads to the appereance of voltage gradients
and thus of the J-wave (or ST-segment elevation). When epicardial repolarization precedes
repolarization in the M and endocardial regions, the T wave remains positive, resulting in a
saddleback configuration of the ECG (Figure 2.10b). Further accentuation of the AP notch may
lengthen the epicardial AP, reversing transmural voltage and repolarization direction across the
RV wall, which leads to an inversion of the T wave and, thus, to the development of a coved-type
ST-segment elevation (Figure 2.10c).
Figure 2.10– AP changes in the right ventricular epicardium leading to the Brugada-like ECG pattern.
a) Healthy individual, b) Saddleback-shaped BS pattern (type 2/3) and c) Coved-type BS pattern (type
1). Endo: endocardium; Epi: epicardium; M: midmyocardium. Modified from (Sieira et al., 2016)
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As mentioned before, despite equal genetic transmission of the disease, the clinical phenotype
is 8 to 10 times more frequent in men than in women. The basis for this gender-related distinction
is thought to be due to a more prominent Ito-mediated AP notch in the RV epicardium of males
(Di Diego et al., 2002). In this study, RV epicardial AP at the end of phase 1 was found to be
more negative in arterially perfused wedge preparations from males; facilitating a loss of the AP
dome and, thus, the development of phase 2 re-entry that can lead to polymorphic VT.
2.2.5. Risk stratification
2.2.5.1. Main risk factors
Although the prognostic value for VF occurrence of several variables has been evaluated, only
spontaneous type 1 Brugada-like ECG and documented symptoms are recognized as reliable
and consistent predictors (Adler et al., 2016). As a consequence, risk stratification in order to
determine the best therapeutic strategy for asymptomatic patients still remains challenging.
The risk of major arrhythmic events, such as sustained VT, VF, or SCD, among previously
asymptomatic BS patients varies according to the clinical series: 8% recurrence rate at 33± 39
months of follow-up reported by (Brugada et al., 2003), 6% recurrence rate at 34± 44 months
by (Priori et al., 2002); 1% recurrence rate after 40±50 months and 30±21 months of follow-up,
respectively, by (Eckardt et al., 2005) and (Giustetto et al., 2009), and 1.5% recurrence rate
at 31 months of follow-up reported by (Probst et al., 2010).
Results from a meta-analysis estimated the incidence of arrhythmic events per year at: 13.5%
in patients with documented sudden cardiac arrest, 3.2% in patients with history of syncope and
1% in asymptomatic individuals (Fauchier et al., 2013).
A more recent study showed a 0.5% annual incidence rate in asymptomatic patients. Moreover,
inducibility of ventricular arrhythmias (VA), spontaneous type 1 ECG pattern and presence of
sinus node dysfunction were proposed as risk factors (Sieira et al., 2015a). Another recently
published meta-analysis showed that asymptomatic subjects presenting either a spontaneous
type 1 ECG pattern or inducible VA seem to be at increased risk for arrhythmic events (Letsas
et al., 2015).
From the results, it can be noted that reported rates of events have decreased over time,
probably due to the inherent bias during the first years following the description of a novel
disorder, in which particularly severe forms of the disease are most likely to be diagnosed.
2.2.5.2. Clinical factors
Male sex has consistently shown a tendency to more frequently present arrhythmic events
in all studies, and it has even been defined as an independent predictor for a worse prognosis
(Gehi et al., 2006).
Brugada syndrome can also be aggravated by supraventricular arrhythmias (Liu et al., 2015).
Spontaneous atrial fibrillation (AF), which can appear in 10% to 53% of cases, has demonstrated
to be related to a higher incidence of VF and syncopal episodes (Kusano et al., 2008).
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A family history of SCD or the presence of an SCN5A mutation have not been proven to be
risk markers in any of the large studies conducted thus far (Gehi et al., 2006).
2.2.5.3. Programmed ventricular stimulation
Although large registries agree that VA inducibility during an electrophysiological study
(EPS) is greatest among BS patients with documented SCD or syncope, there is no consensus on
its prognostic value in asymptomatic BS patients (Priori et al., 2012).
Some published results indicate that inducibility during programmed ventricular stimulation
(PVS) is an independent predictor of cardiac events (Brugada et al., 2003). However, other
studies stress the negative predictive value of EPS testing (Giustetto et al., 2009), and in those
studies performed on the largest clinical series of BS patients published so far, inducibility did
not predict arrhythmic events (Probst et al., 2010).
In a recent study including over 400 BS patients, the authors concluded that EPS might be a
suitable screening tool to reassure non-inducible asymptomatic individuals (Sieira et al., 2015b).
2.2.5.4. Electrocardiographic variables
In an effort to improve risk stratification in BS, several non-invasive methods have been
proposed as predictors of cardiac events (Campuzano et al., 2016). For instance, an S-wave
width in V1 ≥ 80 ms; an ST-segment elevation ≥ 0.18 mV in V2; spontaneous changes in the ST
segment; a corrected QT interval (QTc) > 460 ms in V2; a prolonged Tpeak-Tend (Tp-e) interval
and Tp-e dispersion; the aVR sign (R wave ≥ 0.3 mV in lead aVR); or a prolonged QRS-complex
duration in precordial leads, among others.
Several studies have suggested late potentials (LP), assessed by signal-averaged ECG
(SAECG), as a marker of high risk and even a prospective study concluded that LP was
an independent predictor of high risk in BS patients (Priori et al., 2012). However, more
prospective studies including larger clinical series and longer follow-up periods are still needed in
order to prove the usefulness of LP and other non-invasive markers in predicting SCD in the
context of BS.
Moreover, previous works based on multivariate analyses have proposed predictive models
combining several indicators in order to assess VF risk in BS patients. (Delise et al., 2014,
2011) found that spontaneous type 1 ECG in combination with documented syncope, family
history of SCD, and positive EPS were associated with an increased risk. Similarly, (Okamura
et al., 2015) reported that the combination of spontaneous type 1 ECG, documented syncope,
and positive EPS were relevant for stratifying risk in BS patients. More recently, (Kawazoe
et al., 2016) proposed a logistic regression model for VF risk stratification in BS patients based
on non-invasive parameters including documented syncope, QRS duration in V6, and Tpeak-Tend
dispersion.
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2.2.5.5. Autonomic function
There is increasing evidence that autonomic imbalance significantly contributes to the
arrhythmogenesis and prognosis of BS patients. Data on cardiac ANS analyzed by positron
emission tomography has confirmed that these patients display an autonomic dysfunction,
caused by an increased presynaptic norepinephrine (NE) recycling and thus a reduction in the
concentration of NE at the synaptic cleft. This imbalance is thought to decrease intracellular
levels of 3–5-cyclic adenosine monophosphate (cAMP), thus disrupting the subsequent signaling
pathway with potential implications for arrhythmogenesis (Kies et al., 2004; Paul et al., 2011;
Wichter et al., 2002). In addition, this autonomic imbalance might be aggravated due to
physiological downregulation of the adrenergic activity, justifying the occurrence of VA and SCD
during parasympathetic dominance at rest or during sleep (Matsuo et al., 1999; Mizumaki
et al., 2004; Yan et al., 1999).
Although several studies on the autonomic function of BS patients have been published,
they report conflicting results; particularly when based on long-term measurements obtained
from 24-hour analysis. (Krittayaphong et al., 2003) concluded that BS patients showed a
decreased HRV and vagal tone at night compared to controls; as well as lower diurnal and higher
overnight HR when symptomatic patients were compared to asymptomatic subjects and controls.
Likewise, (Hermida et al., 2003) found significantly lower HRV values at night when comparing
symptomatic and asymptomatic patients; and (Pierre et al., 2007) also observed a decreased
HRV in BS patients, with respect to healthy subjects. Results from (Tokuyama et al., 2014)
also showed a significant reduction on the HRV in BS patients with respect to controls, as well as
on both sympathetic and parasympathetic tones and on their circadian variation over 24 hours.
However, HRV analysis in (Kostopoulou et al., 2010) did not reveal any significant difference
between BS patients and controls; and in (Nakazawa et al., 2003) the results showed higher
vagal and reduced sympathetic tones in symptomatic BS patients. Likewise, in a recent work
from (Behar et al., 2016), symptomatic subjects showed an increased parasympathetic activity
during both daytime and nighttime, when compared to asymptomatic patients.
Thus, although a decreased HRV is commonly related to symptomatic patients with higher
risk, there is still no consensus regarding changes on the vagal tone of these patients. In order
to better characterize autonomic modulation, standard maneuvers, such as exercise testing or
the head-up tilt (HUT) test, can be applied. Indeed, some studies have already reported the
potential of exercise testing (Masrur et al., 2015) or the full stomach test (Ikeda et al., 2006),
among other autonomic tests (Bigi et al., 2008), for the prediction of cardiac events in BS.
Previous studies on the full stomach test have demonstrated that vagal stimulation induced
by a large meal increase distinctive Brugada-like ECG changes (Ikeda et al., 2005). Moreover,
patients resulting in a positive full stomach test seem to be more frequently related to life-
threatening events than patients with a negative test result (Ikeda et al., 2006).
In a recent study, (Subramanian et al., 2017) proved the usefulness of some ECG markers
extracted during exercise testing for risk stratification in asymptomatic BS patients. The work
from (Amin et al., 2009), though, was the first large study measuring the autonomic function in
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a clinical series of patients suffering from BS during exercise, finding a higher parasympathetic
reactivation during early recovery after exertion in individuals with prior VF events. Likewise,
(Makimoto et al., 2010) assessed the autonomic function during recovery from treadmill exercise
testing. By analyzing the parasympathetic reactivation of BS patients and controls through the
Heart Rate Recovery (HRR) after peak exercise, they concluded that a higher vagal activity was
related to the occurrence of cardiac events in BS.
2.2.6. Treatment
To date, the only proven effective therapeutic strategy for the prevention of SCD in BS patients
is the implantation of cardioverter defibrillators (ICD); therefore the device is recommended in
patients with documented VT or VF and in patients presenting with a spontaneous type 1 ECG
and a history of syncope (Priori et al., 2015).
However, it is important to remark that ICDs can present several complications, especially in
active young individuals, facing a long-lasting coexistence with the device and, thus, needing
multiple replacements. Indeed, some series have reported low rates of appropriate shocks (8-15%,
from a median follow-up of 45 months) and high rates of complications, mainly consisting of
inappropriate shocks (20-36% from 21 to 47 months of follow-up) (Rosso et al., 2008; Sarkozy
et al., 2007; Zipes et al., 2006).
Since quinidine may rebalance ionic currents involved in the cardiac AP affected in BS, it
has also been proposed as a preventive pharmacologic therapy. Although published reports
show that it reduces VA inducibility during EPS testing, there is still no data confirming its
ability to reduce the risk of SCD. Therefore, it is currently used in patients carrying an ICD but
presenting complications, and it has been suggested for BS treatment in children, as a bridge to
ICD implantation or as an alternative treatment approach (Schweizer et al., 99).
Recently, it has been suggested that epicardial catheter ablation over the anterior RVOT
may prevent electrical storms in patients with recurring episodes (Nademanee et al., 2011).
Although larger studies with longer follow-up periods are still required, a study conducted in
a cohort of BS patients demonstrated that epicardial ablation of the arrythmogenic electrical
substrate identified in the presence of flecainide could eliminate the BS phenotype and, thus, VF
inducibility without complications (Brugada et al., 2015).
2.3. Clinical data
The main clinical database used in this work was acquired during a prospective, multicentric
study aimed at inducing autonomic changes in BS patients through the application of standard
autonomic tests while a 24-hour ECG was obtained. It was conducted between 2009 and 2013 in
the Cardiology department of the Rennes University Hospital, in France, and participants were
enrolled in 8 French hospitals located in La Rochelle, Angers, Bordeaux, Brest, Nantes, Rennes,
Poitiers and Tours.
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Other 2 databases including patients from the Rennes University Hospital, were composed
of additional signals during the application of the same autonomic tests. The protocols were
approved by each local ethics committee and all patients granted their informed consent to
participate in the study.
2.3.1. Study population
In accordance with current guidelines (Priori et al., 2015; Priori et al., 2013), BS was
diagnosed when a coved ST-segment elevation (≥ 0.2 mV) was detected in at least one right
precordial lead placed in the second to fourth intercostal space, in the presence or absence of
sodium-channel-blocking agent.
In order to characterize patients with different levels of risk, participants were classified in
symptomatic and asymptomatic patients, based on their clinical history. Patients from the first
group could present the following documented symptoms: cardiac arrest due to VF, syncopes,
dizziness, palpitations and nocturnal convulsions. Since each substudy was performed with
different groups of patients, data are described in detail in the corresponding sections.
2.3.2. Data acquisition
In the first database, the standard 12-lead ECG of 87 patients was collected for 24 hours,
including a head-up tilt (HUT) test and a physical exercise test, with the Holter monitor
(ELA medical, Sorin Group, Le Plessis Robinsson, France) at a sampling frequency of 1000 Hz.
Additionally, HUT tests were performed in 32 patients while non-invasive blood pressure and
ECG recordings were acquired with the Task Force monitor (CN Systems, Graz, Austria) at a
sampling frequency of 100 Hz and 1000 Hz, respectively. The 12-lead ECG signals sampled at
1000 Hz of other 36 BS patients were acquired during exercise testing with the ECG monitor
(Cardionics, Webster, Texas).
Hence, autonomic analysis was focused on 3 different periods: overnight and during the
realization of exercise and HUT tests. Figure 2.11 specifies the sources (hereafter named the
Holter, Cardionics and Task Force databases) for each autonomic analysis, and the following
sections describe in more detail the protocols applied.
2.3.2.1. Overnight analysis
Since major cardiac events in BS typically occur during sleep (Matsuo et al., 1999; Mizumaki
et al., 2004; Yan et al., 1999) and some previous studies have already shown significant differences
between patients at different levels of risk overnight (Behar et al., 2016; Hermida et al., 2003),
the autonomic function during this period was carefully studied. First, by the application of
previously reported indicators in order to validate previous results in our clinical series; second,
by proposing new approaches never before studied in BS so as to analyze their predictive value.
For autonomic evaluations at night, only the period from midnight to 6 a.m. was identified,
so as to make sure that HR was being assessed while patients were asleep.
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Figure 2.11– Autonomic studies were based on 3 different analyses: exercise testing, overnight analysis
and head-up tilt testing. Each colour represents the source signals coming from different clinical databases.
2.3.2.2. Exercise testing
Exertion causes a sympathetic activation that, together with a parasympathetic inhibition,
increases heart rate, a reliable indicator to evaluate cardiac autonomic function (Lahiri et al.,
2008). Similarly, post-exercise cardiodeceleration is adjusted by parasympathetic activation
and sympathetic withdrawal (Arai et al., 1989), generally expected to accentuate ST-segment
elevation in BS (Mizumaki et al., 2004).
In contrast to long-term analysis, there are limited data on the role of exercise testing in
the autonomic function of BS patients (Amin et al., 2009; Makimoto et al., 2010). Therefore,
patients underwent a triangular stress test recommended by the American Heart Association (Gib-
bons et al., 2002), where the load was progressively increased until the patient reached, at least,
the 80% of his/her theoretical maximum heart rate (MHR), defined as MHR = 220 − age
(Fox 3rd et al., 1968). The test was performed in a cyclo ergometer (Ergoline 900 Egamed,
Piestany, Slovakia) and divided in the following phases:
Exercise phase:
• Warm-up phase: for men, initial load of 50 W; for women, initial load of 30 W, both
for 2 minutes.
• Incremental exercise phase: for men, initial load of 80 W for 2 minutes and then
incrementing 20 W every 2 minutes; for women, initial load of 50 W increasing load
20 W every 2 minutes.
Recovery phase:
• Active recovery: for men, fixed load of 50 W; for women, fixed load of 30 W, both for
3 minutes.
• Passive recovery: total cessation of effort for 3 minutes.
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2.3.2.3. Head-up tilt testing
Head-up tilt (HUT) testing provokes hemodynamic changes mainly based on the redistribution
of blood volume to the lower part of the body, causing a decrease in both central venous and
ventricular filling pressures, as well as in stroke volume (Blomqvist et al., 1983; Smith, 1990).
Consequently, cardiovascular regulatory mechanisms such as the arterial baroreceptors stimulate
a reflex increase in sympathetic activity and a vagal inhibition, inducing an increase in heart
rate, peripheral vascular resistance, venous tone and heart contractility (Kirchheim, 1976).
Although several studies have analyzed the role of HUT testing on BS patients for risk
stratification (Behar et al., 2016; Kostopoulou et al., 2010; Letsas et al., 2008), the
autonomic function under these conditions has never been analyzed in this population. Therefore,
patients also underwent head-up tilt (HUT) tests in the morning in fasting conditions, according
to the following protocol:
Pre-tilt resting phase: 10 minutes in supine position.
Tilting phase: 45 minutes at 60◦ of table (Sissel, Sautron, France) inclination.
Post-tilt resting phase: 10 minutes in supine position.
2.4. Conclusion
The autonomic nervous system (ANS) innervates the heart with both sympathetic and
parasympathetic branches, as well as blood vessels through the sympathetic system, in order
to regulate heart rate and blood pressure. One of the primary sensory receptors in the closed
loop between autonomic and cardiovascular systems are the arterial baroreceptors. Abnormal
behavior of the ANS can lead to serious pathological conditions; and in the context of the
Brugada syndrome (BS), there is increasing evidence that autonomic imbalance significantly
contributes to the arrhythmogenesis and prognosis of this population.
BS is defined as a rare, genetic disease caused by alterations on the cardiac electrical conduction
system that lead to sudden cardiac death (SCD) due to ventricular fibrillation (VF), in absence of
structural cardiopathies. To date, though, only 22 genes representing the 30%–35% of diagnosed
cases have been associated with the disease, being SCN5A the most common. It is characterized
by a distinct ECG pattern, but variable expressivity and incomplete penetrance complicate clinical
diagnosis, risk stratification and treatment. Implantable cardioverter defibrillators (ICD) are the
only proven effective therapy for patients at high risk thus far; despite other approaches, such as
quinidine or epicardial ablation, have been suggested for patients suffering ICD complications.
Patients presenting spontaneous Brugada-like ECG morphology or having suffered previous
symptoms, such as syncopes or SCD, are considered at high risk for major cardiac events. Thus,
in an effort to improve risk stratification in asymptomatic BS patients, several non-invasive
methods have been proposed as predictors of SCD. However, more prospective studies including
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larger clinical series and longer follow-up periods are still needed in order to prove the usefulness
of these markers in predicting SCD.
Since ANS modulation plays a significant role in the disease, biomarkers accounting for
autonomic differences in BS patients at high risk of SCD could provide valuable information to
improve risk stratification and, thus, therapeutic strategies in asymptomatic patients. Moreover,
the application of specific maneuvers stimulating the ANS, such as exercise or the head-up
tilt (HUT) test, could improve autonomic assessment. Therefore, this research evaluates the
autonomic function of a clinical series of BS patients overnight and during exercise and HUT
testing. The following chapters will develop the methods applied on the presented databases.
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CHAPTER3
Univariate analysis of the autonomic
function in Brugada syndrome:
signal-processing feature extraction
The previous chapter introduced the problem of risk stratification and, thus, clinical manage-
ment in patients suffering from Brugada syndrome (BS). Despite the increasing evidence that
BS prognosis significantly depends on autonomic imbalance, it is still unclear which autonomic
tests and indicators yield the highest predictive values. Indeed, previous works assessing the
autonomic function of BS patients through heart rate variability (HRV) analysis have lead to
contradictory results. Therefore, in this chapter, classic HRV markers are evaluated in the clinical
series previously described, in order to compare the outcomes with reported studies.
Moreover, there are still limited data on the role of standard autonomic maneuvers in this
population, and the temporal evolution and non-linear dynamics of cardiovascular signals in
the context of BS have yet to be exploited. Therefore, in order to find new biomarkers capable
of identifying BS patients at high risk of major cardiac events, this chapter also estimates and
compares the time-varying HRV, heart rate complexity (HRC) and baroreflex sensitivity (BRS)
of the symptomatic and asymptomatic groups of patients composing our clinical databases.
The subsequent sections introduce the extraction of cardiovascular series as a preprocessing
stage, followed by a concise explanation of the methods applied to capture the autonomic function
of BS patients. Finally, along with a description of the clinical data used, the results obtained
for each substudy are presented and discussed.
3.1. Data preprocessing
From the standard 12-lead ECG recordings, RR-interval and R-peak amplitude series were
extracted by using a noise-robust wavelet-based algorithm for QRS complex detection and
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subsequent R-wave peak location (Dumont et al., 2010). Based on a Pan & Tompkins detector
(Pan et al., 1985), the algorithm includes a high-pass filter that attenuates low-frequency
components (P and T waves) and retains high-frequency information (mainly the QRS complex).
Then, the detector converts the filtered signal through a derivative, a squaring function and a
temporal averaging, and an adaptive threshold applied to the transformed signal identifies a time
window in which the maximum amplitude on the raw ECG signal corresponds to the R-wave
peak location.
The systolic blood pressure associated to each heartbeat was also detected from blood
pressure (BP) signals, as the maxima above a manually adjusted threshold. Figure 3.1 displays a
representative example of five consecutive beats where the systolic pressures and R-wave peaks
were detected.
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200
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Figure 3.1– Representative SBP and R-wave peak detections from BP and ECG signals, where the
latter displays a Brugada-like saddleback pattern.
Systolic blood pressure (SBP) and ECG-derived respiration (EDR) series were extracted
from the systolic pressure and R-wave peak amplitudes of each heartbeat; whereas the RR (or
RR-interval) series was obtained from the time difference between consecutive R-wave peak
locations. Manual corrections to the extracted series were performed when necessary and, for
frequency analysis, in order to obtain uniformly sampled data at a rate of 4 Hz, a cubic splines
interpolation was applied.
3.2. Feature extraction
In order to evaluate the autonomic function of BS patients, several methods capturing the
heart rate variability (HRV), heart rate complexity (HRC) and baroreflex sensitivity (BRS),
described in the following subsections, were applied to the previously extracted series.
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3.2.1. Heart rate variability
Heart rate variability (HRV) analysis is widely employed in clinical practice to characterize
the autonomic nervous system function. Although HRV is mainly assessed in long-term stationary
conditions, other approaches accounting for the time-varying autonomic response to transitory
changes have been proposed.
3.2.1.1. Stationary conditions
On stationary conditions, according to the Task Force on HRV (European Society of
Cardiology et al., 1996), the following time-domain variables were computed: mean and
standard deviation of RR series (RR and SDNN), NN50 as the number of pairs of adjacent RR
intervals differing by more than 50 ms and pNN50 as the proportion of NN50 divided by the
total number of intervals. Additionally, MIRR was calculated as the interquartile range of the
RR sequence, SDANN as the standard deviation of the entire 5-min RR means, SDNN5min
as the mean of the 5-min RR standard deviations, and rMSSD as the root mean square of the
successive difference between adjacent RR intervals.
Classical spectral HRV parameters were estimated for each patient by an autoregressive model
based on the Burg method (Burg, 1975) and the Broersen’s combined information criterion
(Broersen, 2000) to optimize model orders. Total power (TP ) was calculated as the sum of
the four spectral bands: ultra-low frequency (ULF : 0− 0.003 Hz), very-low frequency (V LF :
0.003 − 0.04 Hz), low frequency (LF : 0.04 − 0.15 Hz) and high frequency (HF : 0.15 − 0.4
Hz). The HF component reflects the parasympathetic activity, whereas the LF component is
modulated by both sympathetic and parasympathetic autonomic contributions (Malliani et al.,
1994; Ori et al., 1992). They were calculated as the average of 5-min intervals and normalized
by subtracting the VLF component from the TP in order to reduce the effect of noise artifacts:
LFnu =
LF
TP − V LF (3.1)
HFnu =
HF
TP − V LF (3.2)
Moreover, the global sympathovagal balance was estimated through the LF
HF
ratio.
3.2.1.2. Non-stationary conditions
Given that signals during ANS stimulations, such as exercise or HUT testing, are typically
non-stationary, spectral characteristics associated with HRV were analyzed using a time-frequency
(TF) approach. In order to remove the very low frequency component, RR series were high-pass
filtered at 0.03 Hz with a 4th order Butterworth filter applied in both forward and backward
directions so as to remove phase distortion. Then, a smoothed pseudo Wigner-Ville distribution
(SPWVD) transform from the Time-Frequency toolbox (Auger et al., 1996) was employed since
it has proved its usefulness for the analysis of cardiovascular signals (Orini et al., 2010).
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The Wigner Ville distribution is a quadratic time-frequency method defined as the Fourier
transform of the instantaneous autocorrelation function (Hlawatsch et al., 1992). However,
since it is affected by significant interference terms, the SPWVD introduces a smoothing kernel
function Ψ(τ, υ), defined in Costa et al (Costa et al., 1995), that attenuates interferences while
maintaining a suitable time-frequency resolution. Being ARR(τ, υ) the Ambiguity Function of
the RR series, xRR(t), the SPWVD is defined as:
ARR(τ, υ) =
∞ˆ
−∞
xRR
(
t+ τ2
)
x∗RR
(
t− τ2
)
e−j2piυtdt (3.3)
ψ(τ, υ) = exp
−pi
[(
υ
υo
)2
+
(
τ
τo
)2]2λ (3.4)
CRR(t, f) =
ˆ ˆ
ψ(τ, υ)ARR(τ, υ)ej2pi(tυ−τf)dυdτ (3.5)
Kernel parameters were adjusted to υ0 = 0.06 and τ0 = 0.03, obtaining temporal and spectral
resolutions of 16.7 seconds and 0.033 Hz, respectively. Among all the analyzed combinations,
this one lead to the most efficient interference terms cancellation for the lowest TF filtering.
HRV was measured as the total power in LF and HF bands (noted as LFb and HFb),
obtained from the SPWVD:
LF (t) =
ˆ
LFb
CRR(t, f)df (3.6)
HF (t) =
ˆ
HFb
CRR(t, f)df (3.7)
Assuming that sympathetic activity always lies within the standard LF band, this band was
fixed between 0.04 and 0.15 Hz for the whole stress test. However, the total power in the HF
band captures parasympathetic activity, closely related to respiratory sinus arrhythmia (RSA).
Since respiratory frequency during ANS stimulation, especially during exertion, may not be
restricted to the classic HF band (0.15− 0.4 Hz) and can increase up to 0.7 Hz, HRV analysis
within the standard frequency band would lead to unreliable measures of the parasympathetic
activity. In order to overcome this limitation, a time-varying HF band, based on an estimation
of the respiration activity captured by the ECG-Derived respiration (EDR) series was defined
(Bailón et al., 2007).
The applied EDR method estimates respiratory information from the amplitude modulation of
R-wave peaks (Moody et al., 1986). The estimated respiration signal was then band-pass filtered
by a 4th order Butterworth filter between 0.15 and 0.7 Hz, applied in both forward and backward
directions to remove frequencies out of the respiratory range. The same SPWVD transform used
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for RR series was then applied to EDR filtered signals to estimate the instantaneous respiratory
frequency.
The simplest estimation method consists in finding the frequency presenting the largest peak
in the spectrum at each time instant fˆ(t). However, in order to avoid spurious peak detections,
for each time instant tk, the search interval was limited to frequencies between 2δ Hz, centered
around a reference frequency fr(tk) : [fr(tk)− δ, fr(tk) + δ]. This reference frequency was defined
as the exponential average of previous estimates:
fr(tk) = βfr(tk−1) + (1− β)fˆ(tk−1), (3.8)
where β is the forgetting factor. As in (Bailón et al., 2006), a value of β=0.7 was used, based
on real respiratory patterns during exercise testing, and δ=0.01, since respiratory frequency
variations are not supposed to be faster than 0.01 Hz per 0.25 s. Moreover, to reduce the risk of
spurious frequency detections in the initialization of fr(t), the first instantaneous respiratory
frequency fr(t0) was selected within the standard HF band (0.15− 0.4 Hz). Once the estimated
respiratory frequency series fr(t) was obtained, the time-varying HF band for HRV analysis was
defined as HFb(t) = [fr(t)− 0.125, fr(t) + 0.125] Hz, with t covering the whole test.
Unlike classical HRV parameters, SPWVD leads to time-frequency HRV estimators that are
indeed time series that vary during the application of autonomic maneuvers. These markers,
accounting for the sympathetic and parasympathetic influences of the ANS on heart rate, were
normalized by the total power (TP ), defined as the sum of both spectral bands (TP (t) =
LF (t) +HF (t)), leading to the time series LFnu(t) and HFnu(t):
LFnu(t) =
LF (t)
TP (t) · 100 (3.9)
HFnu(t) =
HF (t)
TP (t) · 100 (3.10)
From this definition of normalization, it should be noted that LFnu = 100−HFnu and, thus,
statistical results for both time series are identical. LF
HF
(t) was also calculated from dividing
LF (t) by HF (t), so as to obtain the time-varying global sympathovagal balance.
3.2.2. Heart rate complexity
Non-linear HRV markers have been developed to characterize HR dynamics that may not
be captured by classical approaches. Since RR series in healthy subjects have been found to
fluctuate following a complex non-uniform pattern associated with a 1/f-like distribution (inverse
power law), heart rate complexity (HRC) was assessed by power-law scaling analysis, along with
another widely used measure of HRC, known as sample entropy.
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3.2.2.1. Power-law scaling analysis
The scaling exponent β measures the power-law behavior as the slope of the regression line
calculated by the least-squares method on the linear portion of power spectral density (PSD)
against frequency plots on a bi-logarithmic scale. Several studies on power-law scaling analysis
have employed the frequency band [0.0001− 0.01] Hz to analyze long-term fluctuations when
evaluating SCD and myocardial infarction (Huikuri et al., 1998; Tapanainen et al., 2002).
However, for short-term recordings, this technique has also been applied using the [0.003− 0.1]
Hz band (Lombardi et al., 2000).
PSD was estimated using the Burg method and the Broersen’s combined information criterion
to optimize the autoregressive model orders. Since the analysis was performed in short segments
of the RR series during exercise testing, the scaling exponent β was extracted from the frequency
band [0.003− 0.1] Hz; -2.5 to -1 on a logarithmic scale.
3.2.2.2. Sample entropy
Heart rate complexity, or irregularity, may also be quantified by the sample entropy (SampEn)
method. As a refined version of the traditionally used Approximate Entropy (Richman JS,
2000), it is defined as the negative natural logarithm of the conditional probability that two
sequences of m consecutive data points, which are similar to each other with a tolerance r, will
remain similar when one more consecutive point is included.
Thus, from a given time series of L points, x = {x(1), x(2), · · · , x(L)}, based on the embedded
dimension m and tolerance r, SampEn is calculated as follows:
1. L−m+ 1 new time series of size m are constructed as:
Xm(i) = {x(i), x(i+ 1), · · · , x(i+m− 1)}, where i = 1, · · · , L−m+ 1 (3.11)
2. Then, the distance between each couple of time series, including itself, is computed as:
d[Xm(i), Xm(j)] = max[|x(i+ k)− x(j + k)|], where 0 ≤ k ≤ m− 1 (3.12)
3. For each vector Xm(i), the number of template matchings is calculated as:
Nm(i) = card(d[Xm(i), Xm(j)]) ≤ r (3.13)
4. Being Cmr (i) = Nm(i)/(L−m+ 1) the probability that any vector Xm(j) matches Xm(i),
the average of Cmr over i is:
φm(r) = 1
L−m+ 1
L−m+1∑
i=1
Crm(i) (3.14)
5. By increasing the size of time series to m+ 1 and repeating the previous step to obtain
φm+1(r), the theoretical value of SampEn is defined as:
SampEn(m, r) = lim
L→∞
[ln(φm(r)− φm+1(r))] (3.15)
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Thus, for a finite value of L, SampEn is estimated as:
SampEn(m, r, L) = ln(φm(r)− φm+1(r)) (3.16)
Large values of SampEn indicate high irregularity and great complexity, whereas smaller
values refer to a more regular and predictable signal, commonly associated with disease (Javorka
et al., 2008; Khandoker AH, 2009; Tuzcu et al., 2006). Based on (Lake et al., 2002), the
embedding dimension was chosen as m = 3 and the tolerance distance as r = 0.2 · SD, in order
to study the HRC of BS patients overnight.
3.2.3. Baroreflex sensitivity
Several methods have been proposed to non-invasively estimate spontaneous baroreflex
sensitivity (BRS) from variations in SBP and RR series. Since they are difficult to compare and
often lead to conflicting results, previous works have already analyzed different BRS estimates in
health and disease (Bernardi et al., 2010; Laude et al., 2004). In this work, eight previously
described BRS approaches, summarized in Table 3.1, were computed and compared in a BS
context, during HUT testing.
3.2.3.1. Temporal BRS estimates
First, BRS was estimated by the sequence method for positive (BRS+/+) and negative
(BRS−/−) sequences. This approach considers three or more consecutive beats in which in-
creasing/decreasing SBP values are followed by progressive lengthening/shortening in RR series
(Di Rienzo et al., 1985). Those slopes of the regression lines relating positive/negative changes
in both signals with a fitting coefficient higher than 0.8 are then averaged to obtain, respectively,
BRS+/+ and BRS−/−.
Then, BRS − SD (Bernardi et al., 2010) was computed as the standard deviation of
detrended RR series (σRR), divided by the standard deviation of detrended SBP series (σSBP ).
BRS − SD = σRR
σSBP
(3.17)
3.2.3.2. Spectral BRS estimates
Regarding spectral methods, BRS − LF , BRS −HF and BRS − LHF were calculated as
the square root of the ratio of the autoregressive powers of RR (PRR) and SBP (PSBP ) series
in the LF (0.04− 0.15 Hz), HF (0.15− 0.40 Hz) and simultaneously in both frequency bands
LHF (0.04− 0.40 Hz) (Pagani et al., 1988), when coherence between both series was greater
than a threshold γ. Figure 3.2 illustrates the application of this threshold to the coherence
function in order to determine the spectral bands used to calculate BRS − LF , BRS −HF and
BRS − LHF estimates.
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Figure 3.2– Schematic representation of BRS estimation, based on the spectral power of bands LF, HF
and LHF; at frequencies where the coherence between SBP and RR signals is greater than a threshold γ.
BRS −X =
√
PRR
PSBP
∣∣∣∣∣
X
, where X ∈ {LF,HF,LHF} (3.18)
Spectral power was obtained as the average of applying the Burg method with optimized
orders based on the Broersen’s combined information criterion on 5-min intervals. Coherence
was estimated from a Welch periodogram with a 50% overlap and Hanning windowing, and the
threshold γ was based on the approach defined in (Gallet et al., 2011):
γ = 1− α
1
Kˆ−1 (3.19)
Kˆ = K
1 + 2(K−1K )ρ2w
(3.20)
where α = 0.05 refers to the significance level, ρw = 0.17 is the overlap coefficient for the
Hanning-window 50% overlap and K accounts for the number of analyzed segments, which
depends on signal length.
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3.2.3.3. Transfer-function BRS estimates
Finally, BRS−TFTH was extracted from the averaged transfer function magnitude (|TFSBP,RR|)
within the LF range (Robbe et al., 1987), at frequencies of maximum coherence upon the thresh-
old γ defined in (Gallet et al., 2011). However, since the coherence criterion has been refused
to guarantee accurate BRS measurements when the baroreflex becomes strongly depressed,
BRS−TFLF was also obtained from the average of |TFSBP,RR| over the whole LF band, without
considering coherence values (Pinna et al., 2002). In both cases, the transfer function was
estimated from a Welch periodogram with 50% overlap and Hanning windowing. Figure 3.3
represents the spectral bands used to calculate BRS estimates based on the transfer function of
SBP and RR series.
BRS − TFX = 1
NX
∑
X
|TFRR,SBP |, where X ∈ {LF, TH} (3.21)
Figure 3.3– Schematic representation of BRS estimation, based on the averaged transfer function
magnitude of SBP and RR series, at bands LF and TH.
3.3. Inter-patient analysis
Methods described in the previous section were applied to different clinical datasets, in order
to characterize and compare the autonomic function of symptomatic and asymptomatic BS
patients under different conditions.
Table 3.2 summarizes the analyzed markers, data sources and number of patients of each
substudy. First, the HRV and HRC of 87 patients included in the Holter database were analyzed
overnight. HRV was also assessed during exercise in 105 patients composing both Holter and
Cardionics databases. Then, HRC during exercise was evaluated in the 69 BS patients coming
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Table 3.1– Brief description of the analyzed BRS estimates.
BRS estimate Description
BRS+/+ Averaged slopes of the regression lines relating positive
changes in both RR and SBP series for sequences of 3
or more consecutive beats
BRS−/− Averaged slopes of the regression lines relating negative
changes in both RR and SBP series for sequences of 3
or more consecutive beats
BRS − SD Ratio of the standard deviation of RR and SBP series
BRS − LF Square root of the ratio of the spectral powers of RR
and SBP series at the LF band, at frequencies where
coherence > γ
BRS −HF Square root of the ratio of the spectral powers of RR
and SBP series at the HF band, at frequencies where
coherence > γ
BRS − LHF Square root of the ratio of the spectral powers of RR
and SBP series at both LF and HF bands (LHF band),
at frequencies where coherence > γ
BRS − TFTH Averaged transfer function magnitude at the LF band,
at frequencies where coherence > γ
BRS − TFLF Averaged transfer function magnitude at the LF band
from the Holter database, in order to include resting phases, before and after the test, to the
analysis. The HRV during HUT testing of 65 patients from the Holter database was likewise
characterized. Finally, since the Task Force database included both BP and ECG signals of 32
BS patients, a study on their BRS was conducted.
The following subsections describe the methodology and clinical data used for each substudy,
as well as the main results obtained.
3.3.1. Heart rate variability and complexity at night
Previous studies assessing the autonomic function through HRV analysis along 24-hour
ECG recordings have led to contradictory results (Behar et al., 2016; Hermida et al., 2003;
Kostopoulou et al., 2010; Krittayaphong et al., 2003; Nakazawa et al., 2003; Pierre
et al., 2007; Tokuyama et al., 2014). Although linear temporal and spectral HRV parameters
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Table 3.2– Analyzed indices, sample of patients included in the study and source database for each
autonomic analysis.
Autonomic analysis Indices Sample Source database
Night analysis HRV 87 Holter
HRC 87 Holter
Exercise testing HRV 105 Holter + Cardionics
HRC 69 Holter
HUT testing HRV 65 Holter
BRS 32 Task Force
are unable to capture the complexity of HR regulation, indices accounting for the non-linear
dynamics of RR series, such as SampEn, could unmask autonomic differences in BS patients at
different levels of risk. Therefore, in this section, the HRV and HRC, as well as their circadian
fluctuations, of 23 symptomatic and 64 asymptomatic BS patients are assessed and compared
overnight.
3.3.1.1. Clinical data description
Patients’ age ranged from 19 to 79 years old (45.63 ± 13.03 years old) and 71.26% were males.
Twenty-three patients had the following documented symptoms: syncope (60.87%), cardiac arrest
(34.78%), dizziness (13.04%) and, less frequently, palpitations (4.35%) and nocturnal convulsions
(4.35%). The remaining 64 patients were considered as asymptomatic.
Cardioverter defibrillator implantations (ICD) had been performed in 15 of 64 (23.44%)
asymptomatic patients, based on a positive EPS (Electrophysiological Study) test, whereas
all symptomatic patients were ICD carriers. Genetic testing in search of SCN5A mutations
was completed in 71 patients (21 were symptomatic) and is pending in 6 asymptomatic and
1 symptomatic subjects. The test was not performed in 9 patients (1 symptomatic), since no
mutations had been identified in their families. Among 27 patients in whom the SCN5A mutation
was found, 10 were symptomatic. Table 3.3 summarizes patients’ clinical characteristics.
3.3.1.2. Methods
Heart rate variability was measured by means of the classic temporal and spectral indices
described in Section 3.2.1.1 for stationary conditions, and complexity of RR series was evaluated
through the SampEn method described in Section 3.2.2.2.
Comparisons between symptomatic and asymptomatic patients overnight (midnight to 6
a.m.), as well as for each interval of one hour, were evaluated by Mann-Whitney U non-parametric
tests. Moreover, fluctuations in HRV and HRC at night were calculated as in (Behar et al.,
2016), using a coefficient of variation δ = (maximum − minimum value)/maximum value.
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Table 3.3– Clinical characteristics of asymptomatic and symptomatic study groups at night.
Asymptomatic Symptomatic p-value
(n=64) (n=23)
Age, years old 45.50 ± 13.08 46.00 ± 13.16 0.996
Male sex, n(%) 43 (67.19%) 19 (82.61%) 0.163
ICD implantation, n (%) 15 (23.44%) 23 (100%) < 0.001
Presence of SCN5A mutation, n (%) 17 (34.00%) 10 (47.62%) 0.284
Values are mean ± standard deviation or number of observations (%).
All between-groups differences, apart from ICD implantation, are statistically non-significant.
Logistic regression is a statistical method that finds the best fitting model to describe the
relationship between a dichotomous outcome (here the presence/absence of symptoms) and a set
of independent variables X1, · · · , Xk. It generates the coefficients bo, b1, · · · , bk (and its standard
errors and significance levels) that maximize the likelihood of observing the sample values in
order to predict a logit transformation of the probability of suffering symptoms from the following
formula:
logit(p) = ln p1− p = b0 + b1X1 + · · ·+ bkXk (3.22)
Therefore, binary logistic regression models were applied to each variable differing significantly
between groups in order to predict the probability of experiencing symptoms related to those
HRV and HRC measures.
3.3.1.3. Results
When the whole night was taken into account, similar results with no significant differences
between study groups were found. However, the variation coefficient of SDANN , δSDANN ,
was significantly higher in symptomatic patients between 1 a.m. and 5 a.m. (p < 0.005).
Regarding HRV and HRC differences analyzed for each interval of one hour, some relevant
tendencies, represented by some exemplifying indices in Figure 3.4, were observed. Table 3.4
summarizes the mean ± standard deviation values for symptomatic and asymptomatic patients,
and the associated p-values for each significant case.
Based on the results, symptomatic patients showed a decreased heart rate complexity. During
nighttime, they displayed reduced values of SampEn with respect to asymptomatic subjects,
which turned to be significant between 1 a.m. - 2 a.m. and 4 a.m. - 5 a.m. Similarly, a decreased
HRV was also captured in symptomatic BS patients, which was statistically significant between
5 a.m. - 6 a.m., according to SDNN , MIRR and SDANN . Significant differences were also
captured by MIRR between midnight - 1 a.m. and by SDANN between 2 a.m. - 3 a.m.
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Table 3.4– Mean ± standard deviation, for asymptomatic and symptomatic patients, and associated
p-values in significant variables.
Asymptomatic Symptomatic p-value
(n=64) (n=23)
SampEn
1 a.m. - 2 a.m. 1.19 ± 0.25 1.04 ± 0.36 0.045
4 a.m. - 5 a.m. 1.12 ± 0.26 0.95 ± 0.37 0.017
SDNN
5 a.m. - 6 a. m. 97.04 ± 36.93 79.48 ± 33.65 0.029
MIRR
Midnight - 1 a.m. 88.95 ± 59.16 64.48 ± 29.10 0.032
5 a.m. - 6 a.m. 113.86 ± 62.46 85.74 ± 49.64 0.014
SDANN
2 a.m. - 3 a.m. 38.77 ± 23.81 26.83 ± 16.16 0.027
5 a.m. - 6 a.m. 46.65 ± 24.59 35.16 ± 22.90 0.025
δSDANN (1 a.m. - 5 a.m.) 0.56 ± 0.14 0.67 ± 0.10 < 0.005
Figure 3.4 represents the circadian variation of HRV and HRC at night for both groups of
patients, by showing the evolution of the mean at each hour for the most significant autonomic
markers: MIRR and SampEn. Likewise, the main tendency of these markers is represented by
fitted regression lines for each group of patients. The graphs show a similar evolution along the
night in terms of regression line slopes between both groups, but symptomatic patients display
lower mean HRV and HRC values.
Figure 3.4– Mean SampEn and mean MIRR for symptomatic and asymptomatic BS patients at
each hour overnight (*p <0.05). Dotted black lines are fitted linear regression lines that represent the
main tendencies of each variable along the night, for both study groups.
Finally, Table 3.5 summarizes the odds ratios (OR), 95% confidence intervals (CI) and
p-values associated with each univariate model.
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Table 3.5– Odds ratios, 95% confidence intervals and p-values from univariate analysis of significant
autonomic markers.
OR 95% CI p-value
SampEn
1 a.m. - 2 a.m. 0.171 0.032 - 0.913 0.039*
4 a.m. - 5 a.m. 0.129 0.023 - 0.714 0.019*
SDNN
5 a.m. - 6 a. m. 0.984 0.969 - 1.000 0.053
MIRR
Midnight - 1 a.m. 0.983 0.967 - 1.000 0.047*
5 a.m. - 6 a.m. 0.989 0.978 - 1.000 0.060
SDANN
2 a.m. - 3 a.m. 0.969 0.941 - 0.998 0.037*
5 a.m. - 6 a.m. 0.978 0.956 - 1.001 0.059
δSDANN (1 a.m. - 5 a.m.) 1039.321 11.293 - 95650.848 0.003*
*p < 0.05 when comparing symptomatic and asymptomatic study groups.
MIRR between midnight - 1 a.m. turned to be an independent predictor for the occurrence
of symptoms in univariate analysis with a 1.7% decreased risk per one point increase. Between 2
a.m. - 3 a.m., SDANN displayed a decreased risk of the 3.1%. δSDANN between 1 a.m. - 5
a.m. was also a significant predictor of symptoms, as well as SampEn between 1 a.m. - 2 a.m.
and between 4 a.m. - 5 a.m. showed a decreased risk of the 82.9% and 87.1%, respectively, per
one point of SampEn increase.
3.3.2. Heart rate variability during exercise testing
The autonomic function can be better characterized by stimulating the ANS in a controlled
and repeatable fashion, through the application of standardized maneuvers such as exercise
testing. Indeed, previous works have reported the potential of exercise to predict cardiac events
in BS (Masrur et al., 2015; Subramanian et al., 2017). However, cardiovascular signals during
exertion are typically non-stationary, and the temporal progression of the autonomic response to
exercise and recovery has never been analyzed in the context of BS. Therefore, in this section,
the inter-patient temporal evolution of HRV in response to exercise testing is characterized by a
time-frequency approach, and the results are compared according to the symptomatic status of
105 BS patients.
3.3.2.1. Clinical data description
Participants’ age ranged from 19 to 74 years old (45.17 ± 13.62 years old) and 76.2% were
males. Twenty-four patients presented documented symptoms of ventricular origin: syncope
(50%), cardiac arrest (41.7%), dizziness (12.5%) and, less frequently, palpitations and nocturnal
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convulsions (4.2%). ICDs had been implanted in 18 of 81 (22.2%) asymptomatic patients, based
on a positive EPS test, whereas all symptomatic patients had ICDs implanted. Among 76
patients (19 were symptomatic) in whom genetic analysis was performed, an SCN5A mutation
was found in 27 (35.5%). Table 3.6 summarizes patients’ clinical characteristics.
Table 3.6– Symptomatic and asymptomatic patients’ clinical characteristics for HRV analysis during
exercise testing.
Symptomatic Asymptomatic p-value
(n=24) (n=81)
Age, years old 46.25 ± 15.23 44.85 ± 13.20 0.852
Male sex, n (%) 60 (74.1%) 20 (83.3%) 0.352
ICD implantation, n (%) 24 (100%) 18 (22.2%) < 0.001
Presence of SCN5A mutation, n (%) 6 (31.6%) 21 (36.8%) 0.680
Values are mean ± standard deviation or number of observations (%).
All between-groups differences, apart from ICD implantation, are statistically non-significant.
3.3.2.2. Methods
HRV time series were extracted from the time-frequency analysis described in Section 3.2.1.2,
based on the smoothed pseudo Wigner-Ville distribution (SPWVD) of RR series that adapts fre-
quency bands to respiratory information resulting from EDR signals. These HRV time series were
averaged in temporal non-overlapped windows of 1 minute for each patient, leading to LF i, LF inu,
HF i, HF inu and LF/HF i, which stand for each time series intra-patient mean for the following
time periods: i ∈ {WU1,WU2, EX1, EX2, EX3, PE,AR1, AR2, AR3, PR1, PR2, PR3}. Since
each test differed in the incremental exercise phase duration and the shortest case in our clinical
series lasted less than 5 minutes, only the first 3 minutes of incremental exertion (EX1, EX2
and EX3), as well as the last minute before peak effort (PE), were assessed. In addition, the
entire warm-up (WU1 and WU2) and active (AR1, AR2 and AR3) and passive recovery (PR1,
PR2 and PR3) phases were compared between symptomatic and asymptomatic patients. Fig 3.5
displays the analyzed periods for different phases of the exercise test, indicating the peak effort
instant.
Finally, HRV features extracted during exercise and recovery were compared between symp-
tomatic and asymptomatic groups, by Mann-Whitney U non-parametric tests. In order to
compare the last minute of exertion and recovery, all patients had to be synchronized with respect
to the peak effort instant.
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Figure 3.5– Exercise testing was divided in four phases: warm-up, incremental exercise, active recovery
and passive recovery. HRV time series estimated from the RR series were averaged in the following 1-min
windows: both minutes of warm-up (WU1 and WU2), first 3 minutes of incremental exercise (EX1, EX2,
EX3), last minute of exercise before peak effort (PE), 3 minutes of active recovery (AR1, AR2, AR3)
and 3 minutes of passive recovery (PR1, PR2, PR3).
3.3.2.3. Results
The upper panel of Fig 3.6 displays an example of EDR series. Below, the SPWVD spectral
power of respiration is shown, along with its estimated instantaneous respiratory frequency fr(t),
which is represented with a dashed red line. Note that, in this example, as the patient approaches
the peak effort (dashed vertical line), respiratory frequency exceeds the standard HF band upper
limit of 0.4 Hz.
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Figure 3.6– Top: example of EDR series, calculated from the patient’s R-wave peak amplitudes.
Bottom: SPWVD spectral power associated, along with the instantaneous respiratory frequency fr(t)
estimated from a corrected version of the frequencies presenting the maximum spectral powers at each
time instant (dashed red line). Vertical dashed lines indicate the peak effort instant, before recovery.
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Based on patients’ respiratory information, the time-varying patient-specific HF bands were
computed. Following the previous example, Fig 3.7 displays the RR series and its associated
SPWVD spectral power for the same patient, where the LF and respiration-centered HF bands
are represented in dashed white lines (second panel). The third panel shows the time series
LF (t) and HF (t) extracted from TF analysis, then normalized by the total power defined as
the sum of LF and HF bands at each time instant. Finally, the last panel displays the obtained
HFnu(t) series, where the 1-min window to calculate the mean value of HFnu during the first
minute of active recovery (HFAR1nu ) is specified.
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Figure 3.7– From the RR series, the normalized SPWVD spectral power is calculated. The second
panel indicates LF and HF bands in dashed white lines. In the third panel, the total power in LF (blue
dashed line) and HF (black solid line) bands at each time instant are represented. Then, an example of
normalized time series (HFnu) accounts for the parasympathetic contribution along the exercise test. A
vertical dashed line in all panels refers to the peak effort instant. In the last panel, the time period used
to calculate HFAR1nu is indicated.
In this example, it should be noted the non-negligible power centered in the HF band as a
result of respiration. Moreover, since HF exceeds the standard band, it becomes clear that the
use of classic spectral limits would have lead to unreliable measures of the vagal tone.
Regarding inter-group comparison, during the second minute of incremental exercise, statisti-
cally significant differences were found in mean normalized HF (HFEX2nu , p = 0.041) and thus in
LFEX2nu . Symptomatic patients showed an increased HFnu, and a reduced LFnu, in this time
period with respect to asymptomatic patients. However, no significant differences were found
between groups after exertion, during recovery.
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3.3.3. Heart rate complexity during exercise testing
Since methods based on frequency-domain approaches are unable to capture the complex,
non-linear effects of HR regulation, the HRC during exercise testing on a clinical series of 69
BS patients was evaluated through the power-law scaling exponent (β), which has proved its
usefulness in detecting decreased complexity in patients with cardiovascular disorders and SCD
events (Gomis et al., 2006; Huikuri et al., 1998, 2000; Lombardi et al., 2001; Maestri et al.,
2007; Tapanainen et al., 2002). In order to assess HRC during exercise and recovery, but also
in baseline conditions, only those patients composing the Holter database were included in the
study.
3.3.3.1. Clinical data description
Patients’ age ranged from 19 to 73 years old (45.06± 12.79 years old) and 78.3% were males.
Sixteen patients had the following documented symptoms: syncope (56.25%), cardiac arrest
(25%), dizziness (18.75%) and, less frequently, palpitations (12.50%) and nocturnal convulsions
(6.25%). ICD implantation had been performed in 15 of 53 (28.3%) asymptomatic patients,
based on a positive EPS test, whereas all symptomatic patients were ICD carriers. Among 54
patients (13 were symptomatic) in whom genetic screening was performed, an SCN5A mutation
was found in 19 (35.2%), from whom 5 were symptomatic. Table 3.7 summarizes participants’
baseline characteristics.
Table 3.7– Symptomatic and asymptomatic patients’ clinical characteristics for HRC analysis during
exercise testing.
Symptomatic Asymptomatic p-value
(n=16) (n=53)
Age, years old 45.88 ± 15.31 44.81 ± 12.09 0.837
Male sex, n (%) 13 (81.3%) 41 (77.4%) 0.743
ICD implantation, n (%) 16 (100%) 15 (28.3%) <0.001
Presence of SCN5A mutation, n (%) 5 (38.5%) 14 (34.2%) 0.656
Values are mean ± standard deviation or number of observations (%).
All between-groups differences, apart from ICD implantation, are statistically non-significant.
3.3.3.2. Methods
Heart rate complexity was quantified by means of the β slope resulting from power-law scaling
analysis, described in Section 3.2.2.1. Comparisons between symptomatic and asymptomatic
patients during different phases of the test were evaluated by Mann–Whitney U non-parametric
tests. Then, binary logistic regression models were applied to variables that significantly differed
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between groups in order to predict the probability of experiencing symptoms, as a function of
HRC measures.
3.3.3.3. Results
Table 3.8 summarizes, for each phase of the test, the p-values obtained when comparing β
slopes between groups of patients, as well as the R-squared (R2) values indicating the quality of
fit between PSD and fitted models. In general, linear models reached an acceptable goodness
of fit, where R2 > 0.86. The lowest fitting qualities were found for exercise and after recovery
phases, which were then analyzed in smaller segments with higher R2, always greater than 0.92.
Table 3.8– P -values and R2 obtained when comparing symptomatic and asymptomatic patients along
the exercise test.
p-value R2
Resting 0.320 0.91
Exercise 0.418 0.86
Warm-up 0.135 0.92
Incremental exercise 0.065 0.94
After exercise 0.015* 0.94
Recovery 0.023* 0.95
Active recovery 0.118 0.96
Passive recovery 0.025* 0.96
Rest post-recovery 0.022* 0.89
*p < 0.05, Mann-Whitney U test.
Figure 3.8 displays representative examples of β slope extraction presenting good qualities of
fit, for a symptomatic and an asymptomatic patient.
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Figure 3.8– Representative examples of linear fits for β extraction after exercise in a symptomatic
(left) and in an asymptomatic (right) BS patient.
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Table 3.9 summarizes the mean ± standard deviation values for symptomatic and asymp-
tomatic patients, and the associated p-values obtained in significant cases. Symptomatic patients
showed a statistically significant reduction in β, in comparison to asymptomatic subjects, after
exertion (p = 0.015); during recovery (p = 0.023), and more specifically during the passive recov-
ery phase (p = 0.025), and at rest post-recovery (p = 0.022). Figure 3.9 reflects a significantly
decreased complexity in symptomatic patients for both recovery and post-recovery phases, with
respect to asymptomatic subjects.
Table 3.9– Mean ± standard deviation, for symptomatic and asymptomatic patients, and associated
p-values in significant variables.
Symptomatic (n=16) Asymptomatic (n=53) p-value
β, recovery -1.866 ± 0.258 -1.685 ± 0.356 0.023
β, passive recovery -1.773 ± 0.292 -1.655 ± 0.288 0.025
β, rest post-recovery -1.853 ± 0.207 -1.651 ± 0.334 0.022
β, after exercise -1.706 ± 0.335 -1.468 ± 0.423 0.015
Figure 3.9– Group average results for β during resting, exercise, recovery and post-recovery phases;
for symptomatic and asymptomatic BS patients (*p <0.05).
Table 3.10 includes the odds ratio (OR), 95% confidence intervals (CI) and p-values associated
with each univariate model. During the rest post-recovery phase, β turned to be an independent
predictor in univariate analysis with a 9.7% (p=0.030) decreased risk per one point increase.
After exercise, β was also a significant predictor of symptoms, decreasing risk by a 18.9% per
each point increase (p=0.049).
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Table 3.10– Odds ratios, 95% confidence intervals and p-values associated with significant HRC
indicators in univariate analysis.
Odds Ratio 95% CI p-value
β, recovery 0.180 0.028 - 1.146 0.069
β, passive recovery 0.230 0.029 - 1.812 0.163
β, rest post-recovery 0.097 0.012 - 0.803 0.030*
β, after exercise 0.189 0.036 - 0.992 0.049*
*p < 0.05, Mann-Whitney U test.
3.3.4. Heart rate variability during head-up tilt testing
As for exercise testing, given the non-stationarity of signals acquired during head-up tilt
(HUT) testing, the autonomic function of 65 BS patients was analyzed by a time-frequency
approach.
3.3.4.1. Clinical data description
Participants’ age ranged from 19 to 79 years old (46.77 ± 12.57 years old) and 80% were
males. Twenty patients had the following documented symptoms: syncope (55%), cardiac arrest
(35%), dizziness (15%), palpitations (10%) and nocturnal convulsions (5%). The remaining 45
patients were considered as asymptomatic.
Cardioverter defibrillator implantations (ICD) had been performed in 12 of 45 (26.67%)
asymptomatic patients, based on a positive EPS test, whereas all symptomatic patients were
ICD carriers. Genetic testing in search of SCN5A mutations was completed in 51 patients (18
were symptomatic) and among 17 patients in whom the SCN5A mutation was found, 7 were
symptomatic. Table 3.11 summarizes patients’ clinical characteristics.
Table 3.11– Clinical characteristics of symptomatic and asymptomatic study groups for HRV analysis
during HUT testing.
Symptomatic Asymptomatic p-value
(n=20) (n=45)
Age, years old 46.15 ± 13.95 47.04 ± 12.06 0.706
Male sex, n(%) 18 (90%) 34 (75.6%) 0.186
ICD implantation, n (%) 20 (100%) 12 (26.7%) < 0.001
Presence of SCN5A mutation, n (%) 7 (38.9%) 10 (30.3%) 0.444
Values are mean ± standard deviation or number of observations (%).
All between-groups differences, apart from ICD implantation, are statistically non-significant.
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3.3.4.2. Methods
HRV time series from each patient were estimated by means of the time-frequency analysis
described in Section 3.2.1.2, based on the SPWVD that centers HF-frequency bands to the
respiratory frequency estimated from EDR signals. These HRV time series were averaged for the
whole baseline period (B), in supine rest before tilting. After subtracting these reference values
from each time series, they were averaged in temporal non-overlapped windows of 1 minute,
leading to ∆LF inu, ∆HF inu and ∆LF/HF i, which stand for the time series intra-patient mean
for the following time periods: i ∈ {T1, T2, · · · , T45, S1, S2, · · · , S10}. T refers to the tilting
phase, while S accounts for the supine rest after tilting period. Fig 3.10 illustrates those phases
composing the HUT test, as well as some of the analyzed 1-min segments.
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Figure 3.10– HUT testing was divided in three phases: baseline supine rest, upright posture and
supine rest after tilting. After subtracting the mean of the baseline phase (B), HRV time series estimated
from the RR series were averaged in 1-min windows. T1 and T45 refer to the first and last minutes of
tilting, and S1 to the first minute in supine position after tilting.
The extracted HRV features were compared between symptomatic and asymptomatic groups,
by Mann-Whitney U non-parametric tests.
3.3.4.3. Results
Figure 3.11 represents the mean ∆HFnu and the mean ∆LF/HF for both groups of patients,
highlighting those 1-min segments where differences between symptomatic and asymptomatic
patients were significant. It should be noted that, since the baseline value was subtracted for
each patient, time series are represented in relative units (r.u.).
Table 3.12 summarizes the mean ± standard deviation values for symptomatic and asymp-
tomatic patients, as well as the obtained p-values for each significant case. As aforementioned,
since statistical results for both ∆LFnu and ∆HFnu are identical, the former time series’ results
have not been included in the table.
During tilting, ∆HFnu decreased with respect to baseline for both groups. However, symp-
tomatic patients presented higher ∆HFnu values. Although this difference was statistically
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Figure 3.11– Mean ∆HFnu (upper panel) and mean ∆LF/HF (lower panel) for both symptomatic
(blue) and asymptomatic (black) groups of patients, expressed in relative units (r.u.), with respect to
baseline mean. Dashed vertical lines indicate the time instant where the patient changes from upright
posture to supine rest, after 45 minutes of tilting. Pointed boxes delimit those 1-min segments where
significant differences between groups (∗p < 0.05) were found.
significant at different time periods, the largest segment was found before the 15th minute in
upright posture (∆HF T11nu : p = 0.030; ∆HF T12nu : p = 0.031; ∆HF T13nu : p = 0.010; ∆HF T15nu :
p = 0.022). After tilting, HFnu was similarly restored to baseline values for both symptomatic
and asymptomatic patients.
Conversely, ∆LF/HF increased with respect to baseline in both groups during tilting, being
asymptomatic patients those presenting the highest values. Statistically significant differences
between groups in ∆LF/HF were found in similar time periods than for ∆HFnu, including
the segment before the 15th minute in upright posture (∆LF/HF T13: p = 0.034; ∆LF/HF T15:
p = 0.014). Moreover, after tilting, asymptomatic patients reached baseline LF/HF values more
rapidly, leading to significant differences between groups during the third minute in post-tilt
supine rest (∆LF/HFS3: p = 0.047).
3.3.5. Baroreflex sensitivity during head-up tilt testing
In this section, the autonomic function of 32 BS patients is analyzed by estimating their
baroreflex sensitivity (BRS) during a standardized head-up tilt (HUT) test. However, since
there is no gold standard to non-invasively estimate BRS, eight previously described methods
are applied, in order to quantify their level of agreement and compare their robustness. Then,
the obtained results are compared between symptomatic and asymptomatic groups.
62
Chapter 3. Univariate analysis of the autonomic function in Brugada syndrome:
signal-processing feature extraction
Table 3.12– Mean ± standard deviation, for symptomatic and asymptomatic patients, and associated
p-values in significant 1-min segments.
Symptomatic (n=20) Asymptomatic (n=45) p-value
∆HF T11nu -0.96± 17.8210 -11.19 ± 18.34 0.030
∆HF T12nu -1.57 ± 19.63 -12.15 ± 16.99 0.031
∆HF T13nu -1.02 ± 21.09 -14.21 ± 16.79 0.010
∆HF T15nu -4.78 ± 18.66 -15.37 ± 18.81 0.022
∆HF T30nu -7.32 ± 19.24 -17.01 ± 16.34 0.040
∆HF T34nu -6.26 ± 22.24 -18.82 ± 16.54 0.012
∆HF T36nu -10.81 ± 19.78 -19.96 ± 14.68 0.037
∆HF T38nu -8.26 ± 17.80 -16.90 ± 19.02 0.026
∆LF/HF T8 0.06 ± 1.69 1.35 ± 2.21 0.026
∆LF/HF T13 1.24 ± 4.38 2.14 ± 2.84 0.034
∆LF/HF T15 0.67 ± 2.00 2.30 ± 2.97 0.014
∆LF/HF T34 1.55 ± 3.16 2.99 ± 2.97 0.039
∆LF/HF T38 1.27 ± 2.67 2.93 ± 3.86 0.046
∆LF/HFS3 1.85 ± 3.39 0.04 ± 1.39 0.047
3.3.5.1. Clinical data description
Patients’ age ranged from 20 to 79 years old (52.21± 14.78 years old) and 25 (78.1%) were
males. Nine patients had the following documented symptoms: 4 syncopes, 3 cardiac arrests and
2 nocturnal convulsions. ICD implantation had been performed in 2 of 23 (8.7%) asymptomatic
patients, based on a positive EPS test, whereas all symptomatic patients were ICD carriers.
Among 31 patients (9 were symptomatic) in whom genetic screening was performed, an SCN5A
mutation was found in 10 (32.3%), from whom 2 were symptomatic. Table 3.13 summarizes
participants’ baseline characteristics.
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Table 3.13– Symptomatic and asymptomatic patients’ clinical characteristics for BRS analysis during
HUT testing.
Symptomatic Asymptomatic p-value
(n=9) (n=23)
Age, years old 54.44 ± 14.46 51.35 ± 15.13 0.983
Male sex, n (%) 9 (100%) 16 (69.6%) 0.070
ICD implantation, n (%) 9 (100%) 2 (8.7%) <0.001
Presence of SCN5A mutation, n (%) 2 (22.2%) 8 (36.4%) 0.468
Values are mean ± standard deviation or number of observations (%).
All between-groups differences, apart from ICD implantation, are statistically non-significant.
3.3.5.2. Methods
Baroreflex sensitivity was evaluated and compared by means of eight different BRS estimates
described in Section 3.2.3. Since the analyzed methods require stationary data, four 10-min
segments from each recording were analyzed, leading to 128 BRS estimates for each method: i) in
supine position before the test, ii) in upright posture after 10 minutes of tilting, iii) in standing
position after 20 minutes and iv) in supine position after tilting.
The level of agreement between each method and the remaining approaches was calculated
by the intraclass correlation coefficient (ICC). Results were considered low when 0 < r < 0.5,
medium when 0.5 < r < 0.7 and high when r > 0.7.
Then, assuming an age-associated reduction in BRS, which has been previously reported
(Laitinen et al., 1998), Pearson’s correlation coefficients (PCC) and associated p-values were
calculated between BRS estimates in resting conditions and patients’ age. The closer to -1 the
PCC, the more confident the negative linear correlation between age and the BRS measure was
considered.
Finally, comparisons between symptomatic and asymptomatic patients for the different phases
of the HUT test were performed by Mann-Whitney U non-parametric tests.
3.3.5.3. Results
Figure 3.12 represents the mean and 95% confidence interval (CI) of BRS estimates, calculated
on each 10-min segment of the HUT test for the whole population.
Considering the general tendency along the four segments under study, estimates typically
decreased at the beginning of tilting, progressively incremented for the second standing phase
and remained increasing after the test, without reaching baseline values. All methods captured
a reduction in BRS after 10 minutes of tilting with respect to baseline, as well as an increase
after the HUT test. However, temporal approaches (BRS+/+, BRS−/− and BRS − SD) still
captured a reduction in BRS in the second segment of tilting, as well as BRS+/+ detected a
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Figure 3.12– Mean and 95% CI of BRS estimates, for each method and phase of the HUT test.
higher BRS recovery after the test with respect to baseline. Moreover, a strong variability in the
results coming from the sequence method could be noted from the error bars.
Since some segments did not meet the required properties to apply the analyzed methods,
some BRS estimates could not be calculated. Table 3.14 shows, for each method, the number of
missed 10-min segments, among the 128 available. The sequence method provided the highest
number of missed values, whereas BRS − SD and BRS − TFLF gave results in all cases. The
resting methods using coherence as a parameter of quality lead to two or more missed values.
Table 3.14– Missed BRS estimates, among 128 segments.
BRS estimate Missings
BRS+/+ 40
BRS−/− 43
BRS-LF 9
BRS-HF 3
BRS-LHF 2
BRS-TFTH 25
BRS-TFLF 0
BRS-SD 0
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Table 3.15 presents results from the ICC analysis for all BRS estimates and for different
phases of the HUT test.
Table 3.15– Mean ± standard deviation of ICC for each method.
BRS estimate Supine Standing Whole test
BRS+/+ 0.37 ± 0.10 0.54 ± 0.18 0.45 ± 0.17
BRS−/− 0.38 ± 0.15 0.46 ± 0.29 0.42 ± 0.23
BRS-LF 0.73 ± 0.24 0.69 ± 0.20 0.71 ± 0.22
BRS-HF 0.68 ± 0.17 0.44 ± 0.30 0.56 ± 0.27
BRS-LHF 0.76 ± 0.22 0.75 ± 0.17 0.75 ± 0.20
BRS-TFTH 0.69 ± 0.28 0.70 ± 0.26 0.69 ± 0.27
BRS-TFLF 0.59 ± 0.29 0.53 ± 0.30 0.56 ± 0.29
BRS-SD 0.72 ± 0.24 0.67 ± 0.25 0.70 ± 0.24
In supine position, estimations using the sequence method showed the lowest agreement,
whereas BRS−LF , BRS−LHF and BRS−SD were in high accordance with the other methods.
In standing position, BRS−/− and BRS −HF were in low agreement, while BRS − LHF and
BRS−TF were highly consistent with the other measures. When analyzing supine and standing
positions conjointly, both results coming from the sequence method showed low accordance,
whereas BRS − LF , BRS − LHF and BRS − SD were in high agreement.
Table 3.16 shows that the lowest correlation between age and BRS came from sequence analysis
(BRS+/+), whereas BRS − LF was the method showing the greatest correlation (p = 0.002).
Table 3.16– Pearson’s correlation coefficients (PCC) and associated p-values for each method, when
comparing age and BRS.
BRS estimate PCC p-value
BRS+/+ -0.015 0.953
BRS−/− -0.406 0.085
BRS-LF -0.520 0.002*
BRS-HF -0.325 0.074
BRS-LHF -0.505 0.003*
BRS-TFTH -0.490 0.005*
BRS-TFLF -0.505 0.003*
BRS-SD -0.344 0.054
*p < 0.05
Finally, comparisons between groups for the different phases of the HUT test showed no
significant differences in BRS related to symptomatic status (Table 3.17).
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Table 3.17– P -values when comparing the BRS of symptomatic and asymptomatic BS patients.
Supine, pre-tilt Tilt, 10-20 min Tilt, 20-30 min Supine, post-tilt
BRS+/+ 0.152 0.720 0.495 0.301
BRS−/− 0.898 0.354 0.194 0.425
BRS-LF 0.681 0.753 0.842 0.722
BRS-HF 0.842 0.642 0.520 0.363
BRS-LHF 0.967 0.520 0.774 0.509
BRS-TFTH 0.912 0.953 0.983 0.687
BRS-TFLF 0.621 0.321 0.805 0.711
BRS-SD 0.902 0.386 0.742 0.934
3.3.6. Discussion
In the previous sections, the autonomic function of BS patients was characterized and
compared between symptomatic and asymptomatic groups through several HRV, HRC and BRS
markers computed at night and during exercise and HUT tests.
In a first study where the HRV and HRC were assessed in 87 BS patients at night, according
to time-domain HRV results, symptomatic subjects showed lower MIRR, SDNN and SDANN
values, particularly during the last hour (5 a.m. - 6 a.m.). Thus, patients with higher risk for
cardiac events seem to show a decreased HRV overnight, following the tendency reported in
previous publications (Hermida et al., 2003; Krittayaphong et al., 2003; Pierre et al., 2007;
Tokuyama et al., 2014), and emphasizing differences during the last hour of sleep.
Regarding circadian fluctuations, based on δSDANN results, significantly greater variations
during nighttime were observed in symptomatic patients, which concurs with a previous study
where the night was analyzed between midnight and 4 a.m. As suggested by (Behar et al., 2016),
these results confirm an increased sinus node response to ANS in patients having experienced
symptoms, caused by wider fluctuations in autonomic tone, or by a greater sinus node autonomic
receptors sensitivity. Thus, the risk of cardiac events might be incremented by these greater
variations in sinus node response to ANS.
From HRC analysis, statistically significant differences were observed between 2 a.m. - 3 a.m.
and 4 a.m. - 5 a.m in SampEn. Symptomatic patients showed more regularity in RR series,
probably related to a worse cardiac health condition since a reduced complexity in HR has been
associated with disease (Javorka et al., 2008; Khandoker AH, 2009; Tuzcu et al., 2006). The
ANS is controlled by complex interactions resulting from feedback loops of non-linear systems
that permit the organism to adapt to particular physiological conditions, such as metabolic
variations, stress or disease. Thus, according to previous studies, a reduction in the complexity
of biological control systems reflects a decreased organism’s adaptability, generally associated
with age and disease (Goldberger et al., 2002; Magrans et al., 2010; Rabinovich et al.,
1998; Smith et al., 2005).
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The non-linear HR regulation was also compared in 69 BS subjects who took part in a
standardized exercise test. The results showed a significant reduction in β after exertion, during
recovery and rest post-recovery in symptomatic patients, with respect to the asymptomatic group.
Thus, as in the previous study overnight, subjects at higher risk showed a lower complexity in
HR dynamics. Particularly, HRC decreased significantly in symptomatic patients after exertion
and recovery, when parasympathetic activity is predominant.
These findings provide further evidence for the role of autonomic imbalance in the pathophys-
iology of BS. Although no significant differences between symptomatic and asymptomatic groups
in HRV markers characterizing the HF component that would directly relate the loss of cardiac
variability and complexity with an increase in the vagal tone were found, results highlight the
relevance of night analysis and exercise testing in order to unmask significant autonomic changes
that may not be captured at daytime, during a regular ECG examination. Indeed, this altered
autonomic cardiac system dynamics when vagal tone is predominant concurs with previous
studies reporting an increase in Brugada-like ECG changes induced during vagal stimulation
(Ikeda et al., 2005), as well as with the fact that most life-threatening cardiac arrhythmias in
BS occur at rest and during sleep, when parasympathetic activity is predominant (Kies et al.,
2004; Matsuo et al., 1999).
Moreover, the temporal evolution of the autonomic response to a standardized exercise test
was also analyzed in a group of 105 BS patients. Statistically significant differences between
symptomatic and asymptomatic groups were observed during the second minute of incremental
exercise in the mean normalized HF (HFnu), and thus in the mean normalized LF (LFnu),
suggesting that symptomatic patients showed an increased vagal tone, as well as a reduction in
the sympathetic activity in this phase, with respect to asymptomatic patients.
Similarly, according to the time-varying autonomic response to a standardized HUT test
assessed in 65 BS patients, an increased parasympathetic tone (HFnu) and a reduced sympatho-
vagal balance (LF/HF ) were observed in symptomatic patients during tilting. Some significant
differences were captured by both autonomic markers around the 35th minute of tilting and, by
the sympathovagal balance, during the third minute in supine rest after tilting. Nevertheless,
since the largest and most significant segment was found before the 15th minute in upright posture,
the results suggest the potential of employing time-reduced HUT testing for risk stratification.
Indeed, a previous work already reported the potential of 15-min HUT tests for early syncope
detection (Khodor et al., 2016).
Furthermore, the results confirm previous findings where symptomatic BS patients showed
higher vagal (Behar et al., 2016; Nakazawa et al., 2003; Tokuyama et al., 2014) and reduced
sympathetic (Nakazawa et al., 2003) tones with respect to asymptomatic patients, supporting
the idea that decreased sympathetic activity and increased vagal responses could be related to a
worse prognosis in Brugada syndrome.
Finally, interactions between blood pressure and heart rate were captured by the analysis of
the baroreflex function. Since there is no gold standard to non-invasively estimate BRS, eight
different methods were analyzed and compared in 32 BS patients who underwent a standardized
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HUT test, in order to quantify the level of agreement and robustness between such measures.
Among the studied methods, those derived from sequence analysis showed a lower robustness
when capturing baroreflex function. Although they allow for taking into account the asymmetry
of baroreceptor response by calculating distinct estimates for increasing and decreasing arterial
pressure values, they can fail to provide results in many recordings when the needed requirements
are not met. In contrast to the general tendency, BRS+/+ captured a continued decrease in
BRS along the HUT test, as well as an increase after the trial, greater than baseline values.
In addition, a large variability was found in this measure with respect to the rest of estimates.
Results obtained from sequence method were in low agreement with the other techniques and,
among all BRS estimates, they presented the lowest correlation with patients’ age. On the other
hand, BRS − LF was a reliable measure of BRS in this clinical series. Although it also failed to
provide some results, BRS − LF was in accordance with expected tendencies. It also showed a
high level of agreement with the rest of measures.
Regarding differences between symptomatic and asymptomatic patients, as in a previous
study where (Mizumaki et al., 2005) assessed the baroreflex function of BS patients through the
invasive phenylephrine method, no significant differences in BRS were observed along the HUT
test. Although cardiovascular diseases often coexist with disabilities in baroreflex mechanisms,
no association between BRS values and symptomatic status in BS was identified.
3.4. Conclusion
In this chapter, several HRV, HRC and BRS markers were compared between symptomatic
and asymptomatic groups, under different autonomic conditions.
At night, symptomatic patients showed lower HRV and HRC, but no signifficant differences
in sympathetic and parasympathetic tones were noted. Moreover, greater fluctuations in the
sinus node response to the ANS was observed in the symptomatic group.
During exercise testing, symptomatic patients showed an increased vagal function and a
reduced sympathetic activity, with respect to asymptomatic BS patients, under conditions of
incremental exercise. Moreover, lower HRC values were noted in symptomatic patients under
conditions of recovery and rest after recovery.
Regarding the autonomic response to HUT testing, symptomatic patients presented an
increased parasympathetic tone and a reduced sympathovagal balance with respect to asymp-
tomatic patients during tilting, and particularly before the 15th minute of the test. After tilting,
sympathovagal balance was more rapidly restored to baseline values in asymptomatic patients.
Although comparisons are based on a relatively small population of BS patients and, thus,
conclusions on predictors of symptoms cannot be inferred, results indicate important trends in
HRV and HRC of clinical relevance with a potential impact on the identification of BS patients
at high risk. Nevertheless, since univariate analyses are unable to capture the multifactorial
nature of the disease, they result in moderately significant differences between symptomatic
and asymptomatic groups. Therefore, in the next chapter, a multivariate approach following a
References 69
step-based machine learning method is proposed, exploiting the features extracted in this chapter,
in order to improve classification performance.
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CHAPTER4
Multivariate analysis: machine
learning approach to identify
Brugada patients at high risk
In the previous chapter, significant differences in the HRV and HRC of symptomatic and
asymptomatic BS patients were noted. However, the multifactorial etiology of BS requires
complex approaches capable of capturing multiple mechanisms underlying the disease. Therefore,
this chapter proposes a multivariate method based on a step-based machine learning approach,
designed to optimally combine the previously extracted autonomic features in order to improve
classification of BS patients, based on their symptomatic status. Although previous works have
already proposed predictive models combining several indicators to assess risk in BS (Delise
et al., 2014, 2011; Kawazoe et al., 2016; Okamura et al., 2015), multivariate approaches based
on the autonomic function of these patients have yet to be exploited.
Moreover, since the selection of those autonomic indicators best explaining the syndrome
can be challenging, especially when the number of sources exceeds the amount of observations
in a biomedical context where intra- and inter-patient variabilities are significant, a robust
approach based on a two-step feature selection process including a filter and a wrapper method is
implemented. The proposed methodology is first optimized and evaluated on the most extensive
clinical dataset available, acquired during exercise in 105 BS patients. Then, in order to validate
the model on independent datasets and compare outcomes for classifiers designed from features
extracted during different autonomic tests, a reduced clinical database acquired overnight, and
during exercise and HUT testing in 44 patients is analyzed.
4.1. Global classification methodology
Figure 4.1 illustrates the global methodology proposed in order to differentiate symptomatic
and asymptomatic BS patients. This methodology is based on a general machine learning
75
76
Chapter 4. Multivariate analysis: machine learning approach to identify
Brugada patients at high risk
approach built from the following four main steps:
A. Feature extraction. Although this step can be adapted to any method extracting autonomic
information from cardiovascular signals described in Chapter 3, Figure 4.1A represents HRV
features extraction from time-frequency analysis. In this case, the standard 12-lead ECG
signals acquired during ANS stimulation are analyzed to detect each QRS complex and
extract the RR and EDR series of each patient. A time-frequency (TF) method based on the
smoothed pseudo Wigner-Ville distribution (SPWVD) of RR series that adapts frequency
bands to respiratory information resulting from EDR signals is applied to estimate the
evolution of different spectral HRV markers. The output of this step is matrix RNM , which
contains the calculated raw HRV features, with M markers for the N patients available on
the whole database.
B. Feature conditioning. In order to handle the impact of markers measured at different
scales, all features of RNM are standardized, leading to matrix FNM . Then, in order to reduce
the effect of imbalanced classes, synthetic symptomatic patients are generated and included
in the analysis by a class balancing approach, resulting in matrix FNbM , with Nb observations.
C. Feature selection. After balancing all standardized features, FNbM is divided in a training
subset FNtrM (Ntr, 75% randomly selected patients) and the remaining testing subset FNteM .
Then, a two-step feature selection process including a filter and a wrapper method is applied
in order to capture the most relevant features. In Figure 4.1C, FNtrMf and F
Ntr
Mw indicate the
standardized training subsets kept after applying filter (Mf ) and wrapper (Mw) methods,
respectively. Based on the Mw selected features after training, a new standardized testing
subset FNteMw is defined.
D. Classification. In the final step, a linear discriminant analysis (LDA) classifier is applied to
both the training and testing subsets, to distinguish symptomatic vs. asymptomatic patients.
After training the classifier with FNtrMw , its performance is finally evaluated and quantified
based on FNteMw .
Apart from feature extraction which was already explained in the previous chapter, a more
detailed description of each step is presented in the following sections.
4.1.1. Feature conditioning
All markers obtained from the feature extraction step are considered as candidates for the
construction of a model classifying symptomatic and asymptomatic BS patients. However, in
order to equalize the contribution of all features to multivariate analysis, each raw marker j for
each patient i is standardized as follows:
F ij =
Rij − µj
σj
, (4.1)
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Figure 4.1– Data processing is composed of four major steps. A) In this example, feature extraction
is focused on the estimation of a matrix of time-frequency HRV markers (RNM , with N patients and M
different HRV features), using a time-varying frequency band that depends on the estimated instantaneous
respiratory rate. B) Feature conditioning consists on standardizing and balancing RNM , leading to matrixes
FNM and FNbM , respectively, where Nb refers to the number of observations after class balancing. C) Feature
selection, which starts by randomly defining patient subsets for training, (Ntr, 75% of patients) and
testing (Nte, the rest of patients), followed by the estimation of a minimal feature dimension Mw < M ,
that maximizes classification performance, using filtering and wrapper methods. D) The final step is
dedicated to classification and performance evaluation.
where µj is the mean and σj the standard deviation of a specific feature j = 1, · · · ,M , taking
into account the data from all patients i = 1, · · · , N . The new standardized dataset is defined in
matrix FNM .
Then, to attenuate the impact of imbalanced classes, synthetic symptomatic samples are
generated by applying the ADASYN approach (He et al., 2008), defined as follows:
1. Being FNM the input dataset with N samples {xi, yi}, i = 1, · · · , N , where xi is an instance
in the M dimensional feature space X and yi ∈ Y = {1,−1} is the class identity label
associated with xi; Ns and Na refer to the number of minority (symptomatic) and majority
(asymptomatic) class examples or observations. Therefore, Ns ≤ Na and Ns +Na = N .
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2. The number of synthetic data samples to generate for the minority class is obtained from:
G = (Na −Ns) · ζ, (4.2)
where ζ ∈ [0, 1] specifies the balance level after synthetic data generation. To obtain a fully
balanced data set, this parameter is fixed to ζ = 1.
3. For each example xi ∈ minorityclass, k nearest neighbors (k-NN) are identified, based on
the Euclidean distance in the M dimensional space, and the ratio ri is calculated as:
ri = ∆i/K i = 1, · · · , Ns (4.3)
where ∆i is the number of examples in the k-NN of xi that belong to the majority class;
therefore, ri ∈ [0, 1].
4. Then, ri is normalized according to rˆi = ri/
Ns∑
i=1
ri, and the number of synthetic data
samples to generate for each minority example xi is obtained from:
gi = rˆi ·G (4.4)
5. Finally, for each minority class example xi, each synthetic sample, among the gi to generate,
is obtained from the random selection of one minority class example xzi from the k-NN for
data xi. Then, the synthetic sample is generated as:
si = xi + (xzi − xi) · λ (4.5)
where (xzi − xi) is the difference vector in the M dimensional space, and λ is a random
number λ ∈ [0, 1].
Since this method randomly chooses examples from the minority class to generate new
samples, the algorithm is applied 50 times and the mean from all realizations is kept as the final
balanced dataset FNbM , where Nb refers to the total amount of observations after class balancing.
Figure 4.2 illustrates the feature conditioning process.
4.1.2. Feature selection
To reduce the number of attributes included in the model so as to decrease its computational
cost, a two-step feature selection approach is applied to identify the most relevant features
in distinguishing between symptomatic and asymptomatic patients. As previously mentioned,
Figure 4.1 specifies the methodology followed for feature extraction and posterior feature selection,
only applied to a randomly selected sample of 75% of the feature database (FNtrM : training
subset). The remaining 25% (FNteM : testing subset) is then used for model validation.
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Figure 4.2– The raw feature dataset extracted from the previous step RNM is standardized, leading to
FNM . Then, a class balancing method is repeated 50 times, so the final value for the balanced dataset FNbM
is obtained as the mean from all realizations.
4.1.2.1. ReliefF filter method
The first step in the feature selection process is a simple filter method based on the ReliefF
algorithm (Robnik-Šikonja et al., 2003). Since this approach ignores the effects of attributes
on classification, it can rapidly remove some irrelevant and redundant features.
The algorithm estimates feature weights W according to their capability of distinguishing
between data from different classes, here symptomatic and asymptomatic patients. First, it
randomly selects n data samples or observations. For each data sample xi, it searches for k
nearest neighbors from the same class (known as nearest hits) and for other k from the other
class (known as nearest misses), and averages the contribution of all k nearest hits/misses, here
noted as xHi and xMi . The weight allocated to each attribute results from:
W =
n∑
i=1
xi − xMi
n
−
n∑
i=1
xi − xHi
n
(4.6)
where the first term refers to the mean difference between the feature value of all analyzed
data samples and the nearest misses contributions, and the second term is the mean difference
between the same feature values and the nearest hits contributions.
The best feature should present the same value for samples of the same class and differentiate
between instances from different classes. Therefore, the algorithm assigns a relevance weight
ranged from -1 to 1 to each feature, with large positive weights allocated to significant attributes.
However, it should be noted that, since this method is based on a k-NN approach, feature weights
usually depend on k. For small values of k, the estimates can be unreliable for noisy data; while
for k values comparable with the number of observations, the algorithm can fail to find significant
attributes. Thus, ReliefF is computed for k = 10, · · · , 19 and W is obtained as the average of all
the obtained weights.
Moreover, since extracted feature values are supposed to significantly vary over patients, a
bootstrap technique is applied (Guyon et al., 2003). The algorithm is run 50 times on different
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randomly chosen subsets including 60% of the training dataset FNtrM , here represented as FNtriM .
Then, the relevance of each feature is obtained as the median of the 50 realizations analyzed.
Figure 4.3 displays the methodology followed to select Mf as the 75% most relevant attributes
that are kept for further analysis.
Figure 4.3– In this step, the complete training dataset FNtrM is employed. For each iteration i, a
random subset composed of 60% of the training data is defined. The weight of all features W iM in this
subset is computed as the averaged weight along k = 10, · · · , 19. This process is repeated 50 times and
the final weight of each feature is obtained as the median from all realizations. Finally, the Mf most
relevant features are selected and FNtrMf is kept as input for the wrapper feature selection step.
4.1.2.2. LDA-based wrapper method
For final feature selection, a second step is applied on the reduced subset of attributes resulting
from the previous stage. It consists in a wrapper algorithm based on a Linear Discriminant
Analysis (LDA) classifier as a black box, implemented using the floating search method. Since
this approach is based on classification performance, the final subset is only optimized for this
particular classifier (Kohavi et al., 1997).
The floating method combines the application of both sequential forward and backward
selection strategies (Pudil et al., 1994). The former, is a bottom-up search process that, after the
inclusion of a new feature (forward step), it performs a series of successive conditional exclusions
(backward steps) as long as the resulting subset improves the previously evaluated solution.
Conversely, the backward selection strategy is a top-down search process that begins with the
elimination of a feature (backward step) and re-selects previously removed features (forward
steps) while they improve classification performance. Since in the top-down search discarded
features cannot be re-selected, as well as in the bottom-up search selected features cannot be
later discarded, the combination of both strategies overcomes limitations encountered when these
methods are applied separately.
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Linear discriminant analysis (LDA) is a simple and robust classification method which
searches for the linear combination of features best separating two classes (Kuncheva, 2004),
here symptomatic and asymptomatic patients. Being xi, where i = 1, 2, · · · , d, the input features,
the LDA model is defined as:
Z = β1x1 + β2x2 + · · ·+ βdxd (4.7)
where βi, hereafter β, are the linear model coefficients to be estimated based on the maxi-
mization of the score function S(β):
S(β) = β
Tµs − βTµa
βTCβ
(4.8)
Being µs and µa the mean vectors, Cs and Ca the covariance matrices, as well as ns and na
the number of samples in each class, the coefficients are identified by the following equations:
β = C−1(µs − µa) (4.9)
C = naCa + nsCs
ns + na
(4.10)
Figure 4.4 represents the wrapper feature selection process in more detail. As in the previous
step, it is repeated 50 times on different randomly chosen subsets of training data FNtriMf . Those
features appearing more than L times, among the 50 realizations, are kept for the final subset
FNtrMw . The value of L is optimized, based on performance metrics, so as to find the best
selection of features Mw leading to the finest classifier distinguishing between symptomatic and
asymptomatic BS patients.
Figure 4.4– Starting from the training set obtained from the filter feature selection step FNtrMf , for
each iteration i, a subset with 75% of the data FNtriMf is chosen to tune and train an LDA-based classifier,
then evaluated with the remaining 25% of the random subset FNteiMf . The strategy is repeated 50 times
and those attributes appearing more than L times among all realizations are kept for the final feature
subset FNtrMw .
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4.1.3. LDA-based classifier
After selecting the best set of features, an LDA classifier is implemented using a 5-fold
cross-validation approach in order to reduce overfitting. This technique divides the entire training
subset FNtrMw into 5 blocks where each classifier is firstly trained on 4 portions and then tested
on the 5th block. This is performed for the 5 different possible combinations of blocks for
training/testing so the outputs of each solution are then averaged.
In addition, to estimate the classifier’s mean performance variability when applied to testing
data, 5-fold cross-validation is run 10 times on differently divided subsets of training data.
Figure 4.5 illustrates the steps followed to train and test the LDA classifier. As specified in
previous sections, 75% of the data FNtrMw are used for training, and the remaining 25% F
Nte
Mw for
testing.
Figure 4.5– After feature extraction, conditioning and selection, a 5-fold cross-validation is run 10
times in order to assess the classifier performance, tuned using the training subset FNtrMw and evaluated on
the testing subset FNteMw .
Finally, model performance is evaluated, based on the resulting confusion matrix, which
specifies the number of true positives (TP ), true negatives (TN), false positives (FP ) and
false negatives (FN), when comparing true and predicted labels if symptomatic patients are
considered as positives.
First, the AUC or area under the ROC (Receiver Operating Characteristic) curve is computed
to quantify the classifier performance. This measure is also assessed in order to optimize the
threshold L that leads to the best performing classifier after wrapper feature selection.
Moreover, classical sensitivity (Se = TP/(TP +FN)) and specificity (Sp = TN/(TN +FP ))
measures, associated with the optimal operating point in the ROC curve, are calculated to
quantify the classifier capability of correctly detecting symptomatic and asymptomatic patients,
respectively.
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4.2. Multivariate classification
The described classification methodology was first applied on features extracted during
exercise testing in 105 BS patients. Then, in order to compare the classification performance of
predictive models designed with features obtained during different autonomic tests, a reduced
clinical database acquired overnight, and during exercise and HUT testing including 44 patients
was analyzed.
4.2.1. Classification results during exercise
HRV features extracted from a time-frequency analysis performed during exercise testing in
105 BS patients, were included in the proposed machine learning approach, in order to design a
predictive model capable of distinguishing between symptomatic and asymptomatic BS patients.
4.2.1.1. Clinical data description
Table 4.1 summarizes patients’ clinical characteristics. Their ages ranged from 19 to 74 years
old (45.17 ± 13.62 years old) and 76.2% were males. Twenty-four patients presented documented
symptoms of ventricular origin: syncope (50%), cardiac arrest (41.7%), dizziness (12.5%) and,
less frequently, palpitations and nocturnal convulsions (4.2%). ICDs had been implanted in 18 of
81 (22.2%) asymptomatic patients, based on a positive EPS (Electrophysiological Study) test,
whereas all symptomatic patients had ICDs implanted. Among 76 patients (19 were symptomatic)
in whom genetic analysis was performed, an SCN5A mutation was found in 27 (35.5%).
Table 4.1– Symptomatic and asymptomatic patients’ clinical characteristics for classification based on
HRV features extracted during exercise testing.
Symptomatic Asymptomatic p-value
(n=24) (n=81)
Age, years old 46.25 ± 15.23 44.85 ± 13.20 0.852
Male sex, n (%) 60 (74.1%) 20 (83.3%) 0.352
ICD implantation, n (%) 24 (100%) 18 (22.2%) < 0.001
Presence of SCN5A mutation, n (%) 6 (31.6%) 21 (36.8%) 0.680
Values are mean ± standard deviation or number of observations (%).
All between-groups differences, apart from ICD implantation, are statistically non-significant.
4.2.1.2. Feature extraction
Estimated features from time-frequency analysis (Section 3.3.2.) included the following
averaged non-overlapped windows of 1 minute: LF i, LF inu, HF i, HF inu and LF/HF i, where i ∈
{WU1,WU2, EX1, EX2, EX3, PE,AR1, AR2, AR3, PR1, PR2, PR3}. Since each test differed
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in the incremental exercise phase duration and the shortest case in the clinical series lasted less
than 5 minutes, only the first 3 minutes of incremental exertion (EX1, EX2 and EX3), as well
as the last minute before peak effort (PE), were added to the pool of features. In addition, the
entire warm-up (WU1 and WU2) and active (AR1, AR2 and AR3) and passive recovery (PR1,
PR2 and PR3) phases were included. Thus, from each HRV time series, 12 intra-patient 1-min
means composed the matrix RNM , containing M = 60 HRV markers for the N = 105 patients.
4.2.1.3. Classification results
After standardization, in order to attenuate the effect of imbalanced classes, 55 synthetic
symptomatic samples were generated and included in the analysis leading toNb = 160 observations
before feature selection, composed of 79 symptomatic and 81 asymptomatic samples. At this
point, data were divided in the training (75%) and testing (25%) subsets, including Ntr = 119
(59 symptomatic and 60 asymptomatic) and Nte = 41 (20 symptomatic and 21 asymptomatic)
observations, respectively.
Then, a two-step feature selection process was applied to the training subset. After filter
selection, the 15, or 25%, least relevant HRV features were removed from the analysis. Then, a
wrapper method based on an LDA classifier, using both forward search and backward elimination,
was applied on the feature subset obtained from the filter step, containing Mf = 45 features.
Since the algorithm was run 50 times, the number of times each feature was kept along
realizations was calculated. The final subset contained those features appearing more than a
specific number of times L, optimized based on the performance metric AUC. Figure 4.6 displays
the mean and standard deviation of AUC associated with each value of L.
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Figure 4.6– Mean and standard deviation of AUC for each value of L.
Based on these results, the final classifier placed the threshold at L = 18, where a maximum
AUC using the minimum number of features was found. When only those parameters appearing
more than 18 times were kept, the final subset contained Mw =22 features (listed in Appendix
B.1), leading to: AUC = 0.92± 0.01, Se = 0.91± 0.06 and Sp = 0.90± 0.05.
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Figure 4.7 displays the mean ROC curves resulting from each 5-fold cross-validation, as well
as the global ROC curve and its optimal operating point, for the proposed classifier.
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Figure 4.7– Mean ROC curves for each cross-validation and global ROC (dashed black line), when
features appearing more than 18 times were kept.
4.2.2. Comparison of classification results overnight and during exercise
and head-up tilt testing
The same classification strategy was applied to a clinical database including cardiac signals
overnight, and during exercise and HUT testing from 44 BS patients. The aim of the study was
to validate the model developed in the previous section on independent datasets. Moreover, the
predictive values of classifiers designed from features extracted during each autonomic test, as
well as from the combination of such tests, were compared; in order to identify those markers
and autonomic protocols best distinguishing between symptomatic and asymptomatic groups.
4.2.2.1. Clinical data description
Patients’ age ranged from 19 to 73 years old (45.45± 12.78 years old) and 38 (86.4%) were
males. Eleven patients had the following documented symptoms: syncope (72.7%), cardiac
arrest (18.2%) and, less frequently, dizzines, palpitations and nocturnal convulsions (9.1%).
ICD implantation had been performed in 10 of 33 (30.3%) asymptomatic patients, based on a
positive EPS test, whereas all symptomatic patients were ICD carriers. Among 34 patients (10
were symptomatic) in whom genetic screening was performed, an SCN5A mutation was found
in 11 (32.4%), from whom 4 were symptomatic. Table 4.2 summarizes participants’ baseline
characteristics.
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Table 4.2– Symptomatic and asymptomatic patients’ clinical characteristics for classification, based on
features extracted overnight, and during exercise and HUT testing.
Symptomatic Asymptomatic p-value
(n=11) (n=33)
Age, years old 47.09 ± 15.98 44.91 ± 11.77 0.724
Male sex, n (%) 9 (81.8%) 29 (87.9%) 0.632
ICD implantation, n (%) 11 (100%) 10 (30.3%) <0.001
Presence of SCN5A mutation, n (%) 4 (40%) 7 (29.2%) 0.560
Values are mean ± standard deviation or number of observations (%).
All between-groups differences, apart from ICD implantation, are statistically non-significant.
4.2.2.2. Feature extraction
Regarding data extracted during exercise testing, as in the previous section, candidate features
were those estimated from the time-frequency analysis described in Section 3.3.2., including the
following averaged non-overlapped windows of 1 minute: LF i, LF inu, HF i, HF inu and LF/HF i,
where i ∈ {WU1,WU2, EX1, EX2, EX3, PE,AR1, AR2, AR3, PR1, PR2, PR3}. Moreover,
HRC information was added to the pool of features by including the β values obtained during
exercise and recovery phases (βex, βrecov).
For the design of classifiers based on HUT testing data, candidate features were extracted
by means of the time-frequency analysis described in Section 3.3.4. The mean for the whole
baseline period (B) was subtracted from each estimated HRV time series, then averaged in
temporal non-overlapped windows of 1 minute, leading to the following features: ∆LF i, ∆HF i,
∆LF inu, ∆HF inu and ∆LF/HF i, where i ∈ {T11, T12, T13, T14, T15, S1, S2, S3, S4, S5}. For
classification purposes, in order to reduce computational cost, only the first 5 minutes after
tilting and the time period between 11-15 minutes in upright position were included.
Finally, regarding night analysis, the mean at each hour from midnight to 6 a.m. of the
following HRV and HRC parameters were included as candidate features: RR, SDNN , NN50,
MIRR, SDANN , SDNN5min, rMSSD, LFnu, HFnu, LF/HF and SampEn.
4.2.2.3. Single-test classification results
In a first phase, three single-test classifiers were built from features extracted during each
autonomic test. Regarding the classifier based on exercise testing data, after feature extraction,
the input matrix RNM contained M = 62 markers for the N = 44 patients; whereas M = 50
features were employed to design the classifier based on HUT testing data, andM = 66 candidate
features were included in the classifier developed from night information.
For each single-test process, after standardization, in order to attenuate the bias introduced
by imbalanced classes, 22 synthetic symptomatic samples were generated, leading to Nb = 66
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observations before feature selection. Then, data were divided in the training and testing subsets,
including Ntr = 48 (24 symptomatic and asymptomatic) and Nte = 18 (9 symptomatic and
asymptomatic) observations, respectively.
As aforementioned, filter selection discarded the 25% least relevant markers and, the final
feature subset contained those markers appearing more than a specific number of times L after
the application of the wrapper method, optimized based on the maximum AUC value. Figure 4.8
displays the mean and standard deviation of AUC associated with each value of L, for each
autonomic test.
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Figure 4.8– Mean and standard deviation of AUC values depending on L, for classifiers based on
data extracted during A) exercise, B) HUT testing and C) night analysis.
Based on the results, regarding exercise analysis (Figure 4.8A), the final classifier placed
the threshold at L = 18, being consistent with the previous study where the same optimal L
value was selected. When only those parameters appearing more than 18 times after wrapper
feature selection were kept, the final subset contained Mw= 31 features (listed in Appendix
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B.1), leading to an AUC = 0.89 ± 0.03, Se = 0.88 ± 0.04 and Sp = 0.74 ± 0.11. Although
this predictive model did not reach the classifier designed in previous section performance
(AUC = 0.92± 0.01 for Mw = 22 features), probably due to a reduced amount of observations
for model training, the proposed global classification methodology demonstrated an acceptable
generalization capability. Moreover, since an excessive amount of variables when a reduced sample
of observations is available may confound classification results, the rebound effect observed in
the mean L-dependent AUC became more evident when using a smaller sample of patients.
The optimal AUC for the classifier based on HUT testing data (Figure 4.8B) was found for
L = 12, leading to a final subset containing Mw= 31 features (listed in Appendix B.2) with a
performance of AUC = 0.88± 0.06, Se = 0.74± 0.08 and Sp = 0.86± 0.15. Similar results were
observed for both classifiers; HUT classification, though, improved specificity at the expense of
worsening sensitivity.
Finally, the optimal AUC regarding night analysis (Figure 4.8C) was found for L = 15,
leading to the best performance among single-test classifiers (AUC = 0.95±0.03, Se = 0.94±0.08,
Sp = 0.80 ± 0.12), with the least amount of features (Mw= 26). The final subset is listed in
Appendix B.3.
4.2.2.4. Multiple-test classification results
In order to evaluate if the combination of different autonomic test could outperform the
results found for night analysis, classifiers designed from features of different autonomic tests
were characterized and compared. Table 4.3 includes the optimal AUC values obtained for
each single-test classifier, as well as for each classifier built from the combination of different
autonomic tests.
Table 4.3– Mean and standard deviation of optimal AUC values, for all single- and mutiple-test
classifiers.
Classifier Performance (AUC)
Exercise 0.89± 0.03
HUT 0.88± 0.06
Night 0.95± 0.03
Exercise - HUT 0.91± 0.04
Exercise - Night 0.84± 0.08
HUT - Night 0.89± 0.04
Exercise - HUT - Night 0.92± 0.04
Based on the results, the predictive value of exercise testing (AUC = 0.89± 0.03) increased
by adding information from HUT testing (AUC = 0.91± 0.04), and it was even improved by
including night information (AUC = 0.92± 0.04). However, the best results were found when
nighttime was separately analyzed (AUC = 0.95± 0.03).
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4.3. Discussion
The proposed model was first optimized and evaluated on a clinical database of 105 BS
patients, during exercise testing, leading to a mean AUC of 92% only using about one third of
the total amount of HRV features included at the first step. Filter feature selection discarded
the least relevant and most redundant features, holding the 75% of the initial features subset,
to which the LDA-based wrapper algorithm was applied. On the one hand, the results after
filtering show that all autonomic markers during the last minutes of incremental exercise and
recovery were kept, evidencing the relevance of these test segments in classifying BS patients.
On the other hand, although HFEX2nu lead to significant results in univariate analysis, ReliefF
identified this marker as a redundant feature and only kept LFEX2nu for further analysis.
Since classification performance significantly depends on the number of chosen features
after wrapper feature selection, the algorithm was optimized to obtain the best AUC using
the minimum number of features. Thus, when selecting only those features appearing more
than 35% of times after wrapper application, an optimal classifier containing 22 parameters
was implemented. Among the final subset of features, only one LF
HF
marker was kept, acquired
during the second minute of active recovery. The remaining parameters equally belonged to LF
and LFnu or HF and HFnu measures. Regarding test phases, only one feature came from the
warm-up phase (HFWU1nu ) and other 5 markers were acquired during the passive recovery stage;
but most parameters were measured during incremental exercise and active recovery, and more
specifically during the last minutes of both phases.
In a second study, in order to determine which autonomic tests and indicators yield the
highest predictive values to identify BS patients at high risk of SCD, several classifiers designed
from features extracted during different autonomic tests in 44 BS patients were designed and
compared. Although exercise and HUT testing together lead to better predictive results than
when their markers were analyzed separately, the classifier based on autonomic features obtained
during nighttime analysis presented the best performance (AUC = 95%).
Among the 26 final features composing this optimal classifier, only one SampEn marker
was kept, acquired between 4 a.m. - 5 a.m. The remaining parameters mostly belonged to
temporal HRV measures, although 6 spectral features were also retained. Regarding analyzed
hours, parameters were obtained along the whole night; however, the time period including more
features was between 4 a.m - 5 a.m.
Thus, findings provide further evidence for the relevant role of night analysis to identify BS
patients at high risk, when parasympathetic activity is predominant. The results concur with
previous studies reporting that most major cardiac events in BS occur at rest and during sleep
(Kies et al., 2004; Matsuo et al., 1999). Moreover, although recent studies have also proposed
prediction models for risk stratification in BS patients using non-invasive parameters (Kawazoe
et al., 2016), this model outperformed previous approaches, evidencing the interest of analyzing
HRV and HRC features overnight to better understand VF risk in this population.
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4.4. Conclusion
This chapter proposes a multivariate method based on a step-based machine learning approach,
designed to optimally combine the previously extracted autonomic features in order to improve
classification of BS patients, based on their symptomatic status.
A predictive model based on a two-step feature selection strategy captured the most discrim-
inant HRV features in order to distinguish between symptomatic and asymptomatic patients.
Despite the difficulty in finding differences between these populations, classification results show
the potential of autonomic markers extracted at night for the identification of symptoms in
Brugada syndrome. Thus, the proposed model is presented as a potential instrument to better
identify those asymptomatic BS patients at high risk who may benefit from an ICD implantation.
Moreover, it might be used for processing HRV data acquired from the ICD on implanted BS
patients, in order to control their risk of VF occurrence during follow-up.
However, since this predictive model does not integrate explicit biological a priori knowledge,
the next chapter introduces a model-based approach based on computational models integrating
physiological information on interactions between the cardiac function, and the circulatory and
autonomic systems, in order to provide a step forward towards the understanding of autonomic
modulation in BS.
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CHAPTER5
Cardiovascular response to
autonomic nervous system
stimulation in Brugada syndrome:
model-based feature extraction
The previous chapter proposes a multivariate approach based on a step-based machine learning
method so as to identify BS patients at high risk of major cardiac arrhythmias. Although the
developed predictive models demonstrated an improved performance with respect to previous
works in the field, they are based on generic models assuming strong hypotheses about data
statistical properties, and do not integrate explicit biological a priori knowledge. Thus, the
description of computational models describing interactions between the cardiac function and the
circulatory and autonomic nervous systems could be a step forward towards the interpretation of
the autonomic function in Brugada syndrome (Coatrieux et al., 2006).
This chapter introduces two system-level model-based approaches to analyze the mechanic,
circulatory and autonomic function of BS patients. First, by the introduction of a cardiovascular
model and its short-term autonomic regulation in response to HUT testing, followed by a
two-step sensitivity analysis, and the development of patient-specific models for both healthy
and BS subjects. In a second study, recursive model identifications are applied to estimate the
time-varying autonomic response to exercise in symptomatic and asymptomatic patients.
However, these approaches are limited to a univariate analyis of model parameters. Since
these markers may provide complementary information with respect to other autonomic indices,
such as those studied in Chapter 3, a multivariate analysis including model-based parameters
and/or classical autonomic markers may be useful to improve the characterization of BS patients.
Therefore, a prospective study in order to evaluate this hypothesis is also presented.
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5.1. Autonomic response to head-up tilt testing
In this section, a coupled model integrating the cardiac electrical activity, the cardiovascular
system and the baroreceptors reflex control of the autonomic function in response to HUT testing,
is implemented. Then, a thorough two-step parameter sensitivity analysis based on a screening
method and a global approach is applied to the model to identify the most relevant variables
affecting BP and HR in supine and upright postures. Finally, the most relevant parameters found
in sensitivity analysis are estimated through an approach based on evolutionary algorithms in 20
subjects (8 controls and 12 BS patients), enabling the assessment of subject-specific cardiovascular
conditions.
5.1.1. Global model-based strategy
In order to design model-based subject-specific estimations of the autonomic regulation of
cardiovascular dynamics in response to HUT testing, the following three main steps, represented
in Figure 5.1 and explained in more detail in the subsequent sections, were applied:
Construction of the computational model capturing interactions between the cardiovascular
system (CVS) and the autonomic nervous system (ANS).
Selection of the most influential model parameters on outputs, by means of an exhaustive
sensitivity analysis.
Design of subject-specific models by identifying selected parameters, based on experimental
and simulated heart rate (HR) and systolic blood pressure (SBP) data.
Figure 5.1– Diagram of the global model-based approach. After the construction of a computational
model, a sensitivity analysis is applied to select the most relevant parameters identified in the design of
subject-specific models based on the experimental data of each patient.
5.1.2. Experimental data description
HUT tests were performed in fasting conditions on 8 controls and 12 BS patients. Controls
were healthy subjects without classical cardiovascular risk factors (diabetes, dislypidemia or
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hypertension), non-smokers, asymptomatic and not taking cardioactive medication. Five BS
patients presented documented symptoms of ventricular origin: cardiac arrest (60%) and syncope
(40%). An ICD had been placed in one asymptomatic patient, based on a positive EPS test,
whereas all symptomatic patients had ICDs implanted. Three BS patients (2 were symptomatic)
presented an SCN5A mutation (25%).
Table 5.1– Participants’ baseline characteristics.
Symptomatic Asymptomatic Controls
(n=5) (n=7) (n=8)
Age, years old 48.0 ± 11.5 51.6 ± 13.2 30.8 ± 5.7
Male sex, n (%) 5 (100%) 5 (71.4%) 8 (100%)
ICD implantation, n (%) 5 (100%) 1 (14.3%) -
SCN5A mutation, n (%) 2 (40%) 1 (14.3%) -
Values are mean ± standard deviation or number of observations (%).
Cardiovascular signals from BS patients were obtained from the Task Force database, and
the same recording system and protocol were followed to acquire the ECG and BP signals of
healthy subjects. SBP and RR series were extracted by means of the same process described in
Section 3.1. Then, in order to ease the comparison with model simulations, experimental data
were low-pass filtered at 0.04 Hz with a 4th order Butterworth filter applied in both forward
and backward directions so as to remove phase distortion. Finally, cardiac signals were only
analyzed for 2.5 minutes before and after tilting onset, where the response induced by changing
from supine to upright posture is represented.
5.1.3. Computational model
A computational model integrating the cardiovascular system and its short-term autonomic
modulation in response to HUT testing was implemented by means of the M2SL simulation
library (Hernández et al., 2009). It consists of 4 coupled submodels representing: 1) the cardiac
electrical system (CES), 2) the cardiovascular system (CVS), 3) the baroreceptors reflex system
(BRS), and 4) the head-up tilt test (HUTT). Figure 5.2 illustrates the submodels composing the
closed-loop system, described in more detail in the following subsections.
5.1.3.1. Cardiac electrical system
The cardiac electrical conduction system, represented in Figure 5.3, was based on a simplified
discrete model adapted from (Hernández et al., 2002). It is defined as a set of interconnected
cellular automata, each one explaining the electrical activation of a group of cardiac cells: the
sinoatrial node (SAN), the left atrium (LA), the atrioventricular node (AVN), the upper bundle
of His (UBH), the lower bundle of His (LBH), left and right bundle branches (LBB and RBB),
and left and right ventricles (LV and RV).
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Figure 5.2– Diagram of the integrated model including the cardiac electrical system (CES), the
cardiovascular system (CVS), the baroreceptors reflex system (BRS) and the head-up tilt test (HUTT)
submodels. Heart rate (HR) and systolic blood pressure (SBP) are the model outputs under study. Pahead:
arterial pressure at the head; Palegs: arterial pressure at the legs; Pghead: pressure due to gravity at
the head; Pglegs: pressure due to gravity at the legs; ts: cardiac cycle onset determined by ventricular
electrical activation.
Each automaton state periodically changes among the four main electrophysiological activation
periods: slow diastolic depolarization (SDD) for nodal cells or Idle for myocardial cells, upstroke
depolarization period (UDP), absolute refractory period (ARP) and relative refractory period
(RRP). When a given cell is activated (at the end of UDP phase), it sends an output activation
signal to neighboring cells.
The slope of the SDD phase in SAN, and thus its SDD period, depends on the HR that results
from the BRS model; as well as the output electrical activations of LV and RV are connected to
the CVS model by triggering the mechanical contractions of each ventricular chamber. Values
for most cell parameters were based on (Hernandez Rodriguez, 2000); however, since BS
patients present ECG patterns of right bundle branch block, the RBB automata of these patients
were adjusted based on their baseline QRS durations, which were generally enlarged with respect
to controls. Specifically, to simulate each patient’s ventricular depolarization duration, the UDP
phase of these automata was manually modified for each case. However, since no spontaneous
Brugada-like patterns were identified during the recordings, ECGs were simulated with normal
morphologies.
5.1.3.2. Cardiovascular system
In order to represent the hemodynamic effects of postural changes, the cardiovascular model
defined in (Ojeda et al., 2015, 2013; Romero-Ugalde et al., 2015; Smith et al., 2004) was
adapted. As illustrated in Figure 5.4 and described in previous models of our team (Le Rolle
et al., 2008), both pulmonary and systemic circulations were integrated, dividing the latter into
three parallel vascular branches: 1) head or higher parts of the body, 2) hydrostatic indifference
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Figure 5.3– Diagram of the simplified CES submodel. Top: automata involved on the cardiac electrical
system. Yellow boxes represent nodal cell automata and orange boxes, myocardial cells. Bottom: state
diagram representing the cycle of a nodal (yellow, left) and a myocardial automaton (orange, right); along
with their respective action potential waveforms. Modified from (Ojeda Avellaneda, 2013).
point (HIP) or heart level, and 3) legs or lower parts of the body. This subdivision allows to
account for differences in heights and, thus, in regulatory mechanisms’ impact at each branch,
based on its mean distance from the HIP.
For each ventricular chamber, volumes (V ) are computed from the integral of their respective
net flow (Qin−Qout). Blood pressure (P ) is then calculated from the pressure-volume relationships
associated with systole and diastole: the End Systolic Pressure-Volume Relationship (ESPVR)
and the End Diastolic Pressure-Volume Relationship (EDPVR). A periodic function (e(t)) drives
the transition between the end systolic (Pes) and end diastolic (Ped) pressures as follows:
P (V, t) = e(t)Pes(V ) + (1− e(t))Ped(V ) , (5.1)
Pes(V ) = Ees · (V − Vd) , (5.2)
Ped(V ) = P0 · (eλ(V−V0) − 1) , (5.3)
e(t) = A · e−B·((t−ts)−C)2 . (5.4)
In these equations, the end systolic elastance (Ees) and the dead volume (Vd), or volume
at zero pressure, represent the slope and intercept of the linear relationship between pressure
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Figure 5.4– Closed-loop model of the cardiovascular system. E: elastance; R: resistance; P: pressure;
V: volume; pul: pulmonary; pv: pulmonary vein; pa: pulmonary artery; pu:pulmonary valve; av: aortic
valve; ao: aorta; vc: venae cavae; LA: left atrium; LV: left ventricle; RA: right atrium; RV: right ventricle.
and volume during systole. During diastole, this relationship is non-linear and described by
a gradient (P0), curvature (λ) and volume at zero pressure (V0). The diastolic and systolic
dynamics are driven by a Gaussian function (eq. 5.4) described by its amplitude (A), width (B)
and center (C). The onset of the cardiac cycle, denoted ts, is determined by the activation
instant of the corresponding chamber in the CES model presented in the previous section.
Atria were not included in the model since they minimally contribute to main cardiac trends.
However, in order to account for relevant ventricular interactions, ventricles were coupled through
the septum, represented as a flexible common wall between the LV and the RV. The LV free wall
volume (VLV f ) and the RV free wall volume (VRV f ) are defined as:
VLV f = VLV − Vspt , (5.5)
VRV f = VRV + Vspt . (5.6)
where Vspt, VLV and VRV are respectively the septum, LV and RV volumes. Then, the septum
volume results from linking the septum pressure (Pspt) to the difference between left and right
ventricular pressures:
Pspt = PLV − PRV , (5.7)
Pspt = e(t)Ees,spt · (Vspt − Vd,spt) (5.8)
+(1− e(t))P0,spt(expλ(V − V0)− 1). (5.9)
R represents the resistance experienced by blood when passing through blood vessels and
valves. Diodes simulate the one-way direction of blood when passing through valves located at
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the inlet and exit of ventricles.
Pressures on the peripheral circulation systems are calculated as a linear relationship between
their volume and vascular elastance, following eq. 5.2. These pressures are then used to calculate
flows between chambers as Q = ∆P
R
, where ∆P is the pressure gradient of two chambers and R
is the corresponding vascular resistance connecting them.
5.1.3.3. Baroreflex system
Sympathetic and parasympathetic efferent responses to arterial blood pressure regulation
were modeled based on (Le Rolle et al., 2008; Ursino et al., 2000). Since arterial baroreceptors
are located above the heart level, the input pressure for the BRS model was extracted from
the higher systemic compartment. Baroreceptors’ dynamics are represented in Figure 5.5 by a
first-order transfer function, whose gain and time constant are denoted KB and TB.
Figure 5.5– Diagram of the BRS model. From the arterial pressure registered at the higher systemic
circulation, the baroreflex system regulates heart rate, peripheral resistance, venous volume and heart
contractility.
Then, five different efferent pathways control heart rate, peripheric resistance, venous volume
and cardiac contractility, and each output is added to the baseline response of each regulated
variable.
Chronotropic control is divided in the sympathetic and parasympathetic branches, whereas
systemic resistance, venous volume and ventricular elastance are only influenced by the sympa-
thetic system. The same structure, based on a normalization function, a delay and a first-order
filter is applied to each efferent pathway. The normalization function is represented by the
following sigmoid input-output relationship:
Fx(t) = ax +
bx
eλx(PB(t)−Mx) + 1
(5.10)
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where PB is the arterial baroreceptors’ pressure; ax, bx, λx and Mx are used to adjust the
sigmoidal shape; and x ∈ {V, S,R, V V,C} refers to vagal heart rate, sympathetic heart rate,
systemic resistance, venous volume and cardiac contractility control, respectively. The same
notation was used for the gains (Kx), delays (Dx) and time constants (Tx) describing the
first-order transfer functions:
∆x = Kx
e−Dxs
1 + Txs
(5.11)
5.1.3.4. Head-up tilt test
Upright posture stimulates blood pressure variations in different body parts. As in (Heldt
et al., 2002; Le Rolle et al., 2008), the effect of gravity was implemented at each systemic
branch, based on its distance to HIP. Being Pak the arterial pressure in supine rest for each
systemic branch where k ∈ {head, heart, legs}, the arterial pressure at each compartment Pk
during tilting is described as:
Pk =
Pak + Pgk · sin(α(t)), t0 < t < ttilt,Pak + Pgk · sin(αmax), t > t0 + ttilt. (5.12)
Where α(t) is the table angle going from 0 to αmax, t0 is the table inclination onset, ttilt is
the time to αmax and Pgk is the pressure due to gravity at each branch, defined as:
Pgk = ρ · g · hk, (5.13)
where ρ is the fluid density, g the gravitational constant and hk the mean distance between
the systemic branch and HIP.
5.1.4. Sensitivity analysis
In order to identify the most influential model parameters on HR and SBP, a two-step
sensitivity analysis based on (Hernandez et al., 2011; Le Rolle et al., 2011; Ojeda et al.,
2014) was performed. First, by applying the screening method of Morris (Morris, 1991) on
parameters coming from the BRS and CVS submodels. A table including the physiological ranges
used, based on the litterature (Heldt et al., 2002; Le Rolle et al., 2008; Ursino et al., 2000), is
provided in Appendix C. This method not only evaluates non-linearities and interactions between
parameters, but it also quantifies each variable’s significance with limited computational costs.
Hence, it permits excluding unimportant model parameters so as to reduce the dimensionality of
subsequent analyses.
Then, to analyze in more detail the source of the variability found in Morris’ results, a global
sensitivity analysis based on a Sobol approach (Saltelli et al., 2010) was performed. Since the
estimation of Sobol’s indices requires a significant amount of simulations, only the most relevant
parameters after Morris’ evaluation were included in the analysis.
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5.1.4.1. Screening sensitivity analysis
The sensitivity analysis proposed by Morris consists in the generation of several random
trajectories through the parameter space; each trajectory being associated with an estimation of
the Elementary Effects EEij of a parameter xi on output yj :
EEij =
∣∣∣∣yj(x1, · · · , xi + ∆, · · · , xk)− yj(x1, · · · , xi, · · · , xk)∆
∣∣∣∣ , (5.14)
where ∆ = p2(p− 1) , p is defined as the number of levels dividing the parameter space
Ω and yj stands for each analyzed model output expressed as a function of k parameters
(yj = f(x1, · · · , xi, · · · , xk)).
Each trajectory is generated from a value x∗, randomly selected from the p-level grid Ω.
Although x∗ is not part of the trajectory, it is the base used to generate all the trajectory points,
always included in Ω. First, x(1) is obtained increasing one or more components of x∗ by ∆.
The second trajectory point, x(2), is generated by differing from x(1) in its ith component, being
increased or decreased by ∆ as follows: x(2) = x(1) +ei∆ or x(2) = x(1)−ei∆, where i is randomly
selected from the set {1, 2, · · · , k}. The third sampling point, x(3), is generated by differing from
x(2) in only another component i, different from the previously used to generate x(2). It can
be either x(3) = x(2) + ei∆ or x(3) = x(2) − ei∆. And so on, until x(k+1) closes the trajectory.
This design produces a trajectory of (k + 1) sampling points {x(1), x(2), · · · , x(k+1)} where two
consecutive points differ in only one component. Figure 5.6 represents an example of trajectory
in a space of k = 3 parameters.
Figure 5.6– Exemplifying trajectory in a space of k = 3 parameters (Saltelli et al., 2008).
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Globally, trajectories are defined through a matrix B∗ with dimension (k + 1) × k, whose
rows are composed of the vectors x(1), x(2), · · · , x(k+1) and which is calculated as follows:
B∗ = (Jk+1,kx∗ + (∆/2)[(2B− Jk+1,k)D∗ + Jk+1,k])P∗ (5.15)
B is a (k + 1)× k matrix formed by 0’s and 1’s where, for every column j = 1, · · · , k, there
are two rows of B that differ only in the jth entry, as in a strictly lower triangular matrix of
1’s. Jk+1,k is a (k + 1)× k matrix of 1’s and x∗ are the randomly chosen base values. D∗ is a
k-dimensional diagonal matrix in which each element is either +1 or -1 with equal probability,
and P∗ refers to a k × k random permutation matrix in which each row contains one element
equal to 1, the rest are 0, and where two columns never have 1’s in the same position. P∗ defines
the moving order of factors and D∗ determines whether these factors increase or decrease along
the trajectory. Finally, B∗ provides the elementary effect of each randomly selected input.
For each combination of parameter xi and output yj , the mean µ∗ij and standard deviation
σij of r elementary effects (EEij) are calculated. A large value of µ∗ij indicates a significant
effect of xi on yj , whereas a large σij value is related to either non-linear or strongly interacting
variables. Thereby, parameters can be classified in negligible (low µ∗ij and σij), linear (non-zero
µ∗ij > σij) and non-linear or strongly interacting with other parameters (non-zero µ∗ij ≤ σij),
based on their location in the µ∗ − σ plane (Figure 5.7A).
Since BP recordings were acquired from the patient’s finger positioned next to the legs, the
SBP detected at the lower systemic compartment (CVS model), as well as the HR resulting from
the BRS submodel were analyzed as model outputs. Thus, elementary effects were evaluated on
the mean HR and on the mean SBP, in supine and upright postures as cardiac signals present
different behaviors for each postural status: y ∈ {HRsupine, SBPsupine, HRtilt, SBPtilt}.
In order to establish a global rank of importance among parameters, the Euclidean distance
in the µ∗ − σ plane, Dij , from the origin to each (µ∗ij , σij) point was calculated as:
Dij =
√
(µ∗ij)2 + σ2ij , (5.16)
being parameters with high sensitivity or strong interactions those presenting the highest
values for Dij . Thus, as illustrated in Figure 5.7B, model parameters were sorted according to
their Dij value.
5.1.4.2. Global sensitivity analysis
The variance-based global sensitivity analysis approach first introduced by Sobol (Sobol,
2001) quantifies the uncertainty of output y explained by the variability of each parameter xi.
Sobol defined the first-order effect, or main effect, as the influence of varying xi on the output y:
Si =
V ar[E[y|xi]]
V ar[y] , (5.17)
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Figure 5.7– A) Exemplifying elementary effects results. From the mean and standard deviation of
their elementary effects, parameters are classified in having negligible, linear or non-linear effects on model
outputs. B) Parameters’ relevance quantification, ranked according to Dij indices.
Similarly, higher-order effects are defined as the impact of variations in two or more parameters.
Based on variance decomposition, since all effects are strictly positive and the sum of all of them
is equal to 1, each effect is within [0,1].
∑
i
Si +
∑
i
∑
i<j
Sij +
∑
i
∑
i<j
∑
j<l
Sijl + · · · = 1. (5.18)
However, due to the great number of possible combinations introduced by higher-order effects,
Saltelli (Saltelli et al., 2010) proposed a simpler approach, where only the main and total
indices are calculated, whereas all higher-order effects are grouped in the total-order effect:
STi = Si +
∑
i 6=j
Sij +
∑
i 6=j 6=l
Sijl + · · ·+ S123...k = 1. (5.19)
By means of Sobol’s main and total indices, the amount of variability explained by each
parameter alone (Si) and by the interaction of such parameter with the others (STi) was
quantified, on the mean HR and SBP in supine and upright postures. Since these indices are
computationally expensive to calculate, 106 Monte-Carlo evaluations of quasi-random parameter
configurations, designed using a Latin Hypercube Sampling (LHS) approach (McKay et al.,
1979), were computed.
LHS is a statistical method for generating near-random samples of parameter values from a
multidimensional distribution. A square grid is known as a Latin square if, and only if, contains
only one sample in each row and each column. Thus, a Latin hypercube is the generalisation of
this concept to an arbitrary number of dimensions, whereby each sample is the only one in each
axis-aligned hyperplane containing it. By avoiding the probability that all sampling points come
from the same local region, this method allows to obtain a stable output with a much smaller
number of samples than simple Monte Carlo simulation. However, even with LHS, Monte Carlo
analysis requires a great amount of sampling points.
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Thus, to reduce the computational cost of estimating variances for the calculation of Si and
STi indices, the following strategy, described in (Saltelli et al., 2008), was performed:
1. First, a N × 2k matrix of quasi-random numbers, based on LHS, where k is the number of
parameters, was generated to define the data matrices A and B, each containing half of
the sample. N defines the number of performed simulations.
A =

x
(1)
1 x
(1)
2 · · · x(1)i · · · x(1)k
x
(2)
1 x
(2)
2 · · · x(2)i · · · x(2)k
· · · · · · · · · · · · · · · · · ·
x
(N−1)
1 x
(N−1)
2 · · · x(N−1)i · · · x(N−1)k
x
(N)
1 x
(N)
2 · · · x(N)i · · · x(N)k

(5.20)
B =

x
(1)
k+1 x
(1)
k+2 · · · x(1)k+i · · · x(1)2k
x
(2)
k+1 x
(2)
k+2 · · · x(2)k+i · · · x(2)2k
· · · · · · · · · · · · · · · · · ·
x
(N−1)
k+1 x
(N−1)
k+2 · · · x(N−1)k+i · · · x(N−1)2k
x
(N)
k+1 x
(N)
k+2 · · · x(N)k+i · · · x(N)2k

(5.21)
2. Then, a matrix formed by all columns of B except for the ith column which was taken
from A, was defined as Ci:
Ci =

x
(1)
k+1 x
(1)
k+2 · · · x(1)i · · · x(1)2k
x
(2)
k+1 x
(2)
k+2 · · · x(2)i · · · x(2)2k
· · · · · · · · · · · · · · · · · ·
x
(N−1)
k+1 x
(N−1)
k+2 · · · x(N−1)i · · · x(N−1)2k
x
(N)
k+1 x
(N)
k+2 · · · x(N)i · · · x(N)2k

(5.22)
3. Model outputs were then computed for all the input values in matrices A, B and Ci,
obtaining the following three vectors of model outputs of length N :
yA = f(A) yB = f(B) yCi = f(Ci) (5.23)
The cost of this approach is N model simulations for matrix A, plus N runs for matrix B,
plus k times N to estimate the k output vectors coming from matrix Ci. The total cost is,
thus, N(k + 2), much lower than the N2 simulations needed in the brute-force method.
4. First-order sensitivity indices are then estimated as follows:
Si =
V ar[E[y|xi]]
V ar[y] =
yA · yCi − f20
yA · yA − f20
=
(1/N)∑Nj=1 y(j)A y(j)Ci − f20
(1/N)∑Nj=1(y(j)A )2 − f20 (5.24)
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where f20 is calculated as:
f20 =
 1
N
N∑
j=1
y
(j)
A
2 (5.25)
5. Finally, total-order indices are estimated as:
STi = 1−
V ar[E[y|x i]]
V ar[y] = 1−
yB · yCi − f20
yA · yA − f20
= 1− (1/N)
∑N
j=1 y
(j)
B y
(j)
Ci
− f20
(1/N)∑Nj=1(y(j)A )2 − f20 (5.26)
5.1.5. Parameter identification
Based on sensitivity results, a reduced group of parameters were selected for subject-specific
model identification. The optimization process was computed by comparing experimental signals
acquired during HUT testing with simulation outputs, through the minimization of the error
function , defined as:
(θ) =
4∑
j=1
Nj∑
i=1
∣∣∣∣∣∣Y
j
sim,θ(i)− Y jexp(i)
max(Y jexp(i))
∣∣∣∣∣∣
2
(5.27)
Y jexp(i) and Y
j
sim,θ(i) are the i
th experimental value and the ith model output sample for
the simulation of Y j when using the set of parameters θ, respectively. Moreover, Nj in-
dicates the number of samples for each output being compared and Y j refers to HR and
SBP signals for the whole test and only during the transition of table inclination: Y ∈
{SBPtotal, SBPtransition, HRtotal, HRtransition}. Note that identification is based on both HR
and SBP signals, and mainly on their transitory periods since they are accounted twice to ensure
that errors in this segment are particularly penalized. Transitory periods in SBP and HR signals
are specially relevant since they respectively reflect the cardiovascular and autonomic responses
to postural change.
As in previous works of our team (Le Rolle et al., 2015, 2011; Ojeda et al., 2014), the best
set of parameters for each subject were identified through an approach based on evolutionary
algorithms (EA). These stochastic search methods are founded on theories of natural evolution,
such as selection, crossover and mutation (Goldberg et al., 1988). Being an individual an
optimization solution (a parameter value set), the algorithm started with the initialization of
50 random individuals, each parameter value of the individual being randomly selected from a
specified parameter space. By quantifying each individual fitness through the error function ,
the population was continuously evolved for 30 generations, following four main steps:
1. Selection of parent individuals for combination, biased towards those having the best errors.
2. According to a probability pc, combination of parent individuals through crossover to
generate new children. Then, with a probability pm, modification of these individuals by
mutations.
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3. Fitness assessment in new individuals.
4. Replacement of individuals having the lowest fitness.
5.1.6. Results and discussion
5.1.6.1. Sensitivity analysis
As in (Le Rolle et al., 2011), the screening method of Morris was applied with a grid of
p = 20 and r = 5 · k = 310 elementary effects, performing a total of almost 20,000 simulations.
Figure 5.8 represents Morris sensitivity results on the mean SBP and HR signals for supine and
tilt phases, only labeling the most relevant parameters in order to improve readability.
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Figure 5.8– Absolute mean (µ∗) and standard deviation (σ) of the elementary effects for the mean
SBP and HR, during supine and tilt phases. Only the most significant parameters are labeled: λLV
(LV end-diastolic exponent), V dLV (LV volume at zero end-systolic pressure), V 0LV (LV volume at zero
end-diastolic pressure), KR (gain for peripheral resistance regulation), P0LV (intrinsic LV pressure), HR0
(intrinsic heart rate), KV (gain of the vagal HR regulation), KS (sympathetic gain), TS (sympathetic
time constant), and Pglegs (pressure due to gravity at the lower systemic compartment).
Overall, the distribution of model parameters in the µ∗− σ space indicates effects on HR and
SBP that are either non-linear or caused by the interaction with other parameters. Although
some of them are close to the µ∗ = σ reference line, Pglegs was the most linearly related parameter
to SBPtilt.
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Nevertheless, many parameters showed a significant effect on the analyzed outputs. In order
to identify those variables having the highest sensitivities or the strongest interactions, Figure 5.9
displays the 15 most influential parameters on each analyzed output based on their Di index,
represented along with their µ∗i and σi values.
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Figure 5.9– Most influential parameters on HR and SBP in supine and upright postures, based on
the Morris distance Di (green bars). For each parameter, the absolute mean µ∗i (purple bars) and the
standard deviation σi (yellow bars) of the elementary effects are also displayed.
Similar results were obtained for supine and upright postures. Regarding SBP, the main
difference concerned Pglegs, being negligible in supine rest but turning into a significant parameter
during tilting. Concerning HR, the most influential variables in supine remained the same during
tilting. However, KS gained importance with respect to supine rest, probably due to the
sympathetic activation caused by postural change.
As expected, HR was mostly modulated by BRS variables, whereas SBP was more affected
by CVS parameters coming from the LV. However, the effect of some RV variables was still
considerable. This may be relevant in BS, where patients present ECG patterns of RBBB. Indeed,
the model defines that RV parameters can affect LV through the septum wall, as well as through
the closed-loop circulation.
Table 5.2 specifies those parameters retained for further analysis. Although they were mainly
selected based on Morris’ results, MS was also added in order to evaluate the MV complementary
parameter, since it could be relevant during the sympathetic activation stimulated by postural
change. Likewise, KC was included so as to analyze the effect of HUT testing in heart contractility
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regulation and, although RV parameters were not as significant as those coming from the LV,
λRV was also included in the analysis.
Table 5.2– Parameters selected for global sensitivity analysis.
Parameter description Submodel
λLV LV end-diastolic exponent CVS
V dLV LV volume at zero end-systolic pressure CVS
V 0LV LV volume at zero end-diastolic pressure CVS
KR Gain for peripheral resistance regulation BRS
P0LV intrinsic LV pressure CVS
HR0 Intrinsic heart rate BRS
Eartlegs Arterial elastance under HIP CVS
KB Baroreceptors gain BRS
KS Gain of the sympathetic HR regulation BRS
KV Vagal gain BRS
ELV LV elastance BRS
TS Sympathetic time constant BRS
aV Vagal normalization independent term BRS
bS Sympathetic normalization gain BRS
MV Vagal normalization center BRS
Pglegs Pressure due to gravity under HIP CVS
MS Sympathetic normalization center BRS
KC Contractility gain BRS
λRV RV end-diastolic exponent CVS
Regarding global sensitivity analysis, since results were similar to those found in Morris
analysis, in order to identify those parameters causing the greatest changes between supine and
upright postures, not only the mean HR and SBP in supine rest, but also the Sobol indices on the
percentage ratio between supine and upright postures were analyzed: %HR,%SBP . Figure 5.10
shows the estimated Sobol’s main and total indices for the analyzed outputs.
According to the results, SBP showed a significant dependence on λLV , V 0LV and V dLV ,
whereas HR was mostly modulated by HR0, KV and KS . Moreover, these parameters not
only presented the highest total effects, but also the greatest main effects, suggesting that a
non-negligible part of their effect is due to the parameter variation itself.
Thus, HR was found to be further affected by autonomic parameters than by CVS variables;
particularly, by intrinsic HR and baroreflex gains modulating the sympathetic and parasympa-
thetic chronotropic branches, the ANS component responsible for regulating HR. Since BP and
HR are closely connected through the baroreflex arc, SBP was also significantly affected by these
autonomic variables. However, results seem to indicate that SBP is primarily affected by those
parameters modulating diastole in the left ventricle.
Although HR0 demonstrated high sensitivities in both Morris and Sobol analyses, in order to
reduce computational cost, it was not included in the identification process. In exchange, HR0
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Figure 5.10– Results for global sensitivity analysis based on Sobol indices for mean SBP and HR
values in supine rest and for the percentage ratio between the mean at supine and tilting positions. Yellow
bars indicate first-order effects Si (sensitivity to parameter variations alone) and green bars indicate
total-order effects STi (sensitivity to parameter interactions). The parameters are sorted in descending
STi values.
was estimated for each participant as the mean HR in supine position. Likewise, all normalization
centers in the BRS model (MV , MS , MR, MC , MV V ) were estimated as the mean SBP in supine
rest, and only one LV zero-pressure volume was identified, assuming V 0LV = V dLV .
KS and KV were identified for each subject, and due to their non-negligible importance in
Sobol’s results, λRV , KR and KC were also added to the identification process. Moreover, since
Pglegs demonstrated a rather linear effect on SBPtilt, proved by the elevated main index in Sobol
analysis for %SBP , this parameter was also included in the estimation step. Finally, since it
was experimentally remarked that better estimations of the rebounds caused by postural change
were obtained by identifying the sympathetic and vagal time constants, TS and TV estimations
were added. Similarly, higher and lower systemic time constants (τhead and τlegs) were included
to better estimate the progressive adaptation of systemic circulation.
5.1.6.2. Parameter identification
Figure 5.11 displays representative examples of fit between simulated and experimental SBP
and HR signals for a control (C1), a symptomatic (S1) and an asymptomatic (A1) BS patient.
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In Figure 5.12, boxplots of the resulting parameters for the control (C), asymptomatic (A) and
symptomatic (S) groups are represented.
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Figure 5.11– Representative examples of fit between simulated (black) and experimental (grey) SBP
and HR signals for a control, a symptomatic and an asymptomatic BS patients.
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Figure 5.12– Boxplots of identified parameters; for controls (C), asymptomatic (A) and symptomatic
(S) groups.
Table 5.3 includes the percentage errors of SBP and HR (ESBP , EHR) for each subject.
Based on visual inspection and resulting errors (ESBP = 2.90 ± 1.63 %; EHR = 3.39 ± 1.00 %),
an acceptable agreement between observed and estimated signals was noted; specially during
transitory periods, which demonstrates the capability of the model to reproduce HR and SBP
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adaptations to HUT testing. Although some small variations coming from exogenous phenomena,
such as temperature, respiration or the central nervous system, could not be simulated, the
degree of similarity between signals was significant.
Table 5.3– Percentage errors in SBP and HR, for controls (C), symptomatic (S) and asymptomatic (A)
BS patients.
ESBP (%) EHR (%)
C1 2.46 4.51
C2 5.13 3.51
C3 1.69 2.49
C4 1.98 5.17
C5 1.93 3.70
C6 3.31 3.00
C7 8.37 4.04
C8 3.61 3.32
S1 2.70 3.50
S2 4.15 5.63
S3 2.91 2.56
S4 3.67 2.40
S5 1.68 2.91
A1 1.15 2.02
A2 2.60 3.38
A3 3.22 3.22
A4 1.96 4.77
A5 1.59 2.23
A6 2.06 3.02
A7 1.87 2.49
In addition to identified parameters, the dynamical properties of baroreflex responses to
HUT were also assessed and compared between groups. Defining the sympathetic HR regulation
difference from baseline as ∆S = Stilt − Ssupine, we found statistically significant differences
between controls and BS patients. Likewise, V dLV , and thus V 0LV , were significantly different
between symptomatic and asymptomatic patients. Table 5.4 summarizes the mean ± standard
deviation values for each group, as well as the associated p-values.
V dLV refers to the blood volume at zero pressure, included in the linear relationship between
the LV end-systolic pressure and volume. Likewise, since V dLV = V 0LV , it also represents
the blood volume at zero pressure in the non-linear relationship between the LV end-diastolic
pressure and volume. Thus, based on the results of the passive mechanics captured by V dLV
and V 0LV , symptomatic patients presented significantly higher values of LV volumes at zero
pressure than asymptomatic patients. This shifts arterial elastance, end-systolic and end-diastolic
relationships describing the pressure-volume (PV) loop to the right; leading to reduced stroke
works (SW), measured as the area enclosed by the PV loop. Due to higher V dLV values, the
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Table 5.4– Mean ± standard deviation and p-values for statistically significant variables, for a p < 0.05
using Mann-Whitney U tests.
Controls BS patients p-value
(n=8) (n=12)
∆S 0.19 ± 0.04 0.13 ± 0.06 0.019
Symptomatic Asymptomatic p-value
(n=5) (n=7)
V dLV 24.00 ± 4.48 11.47 ± 7.46 0.010
cardiac PV cycle is shortened, suggesting a decreased inotropy and an increased compliance in
symptomatic patients. Figure 5.13 illustrates changes in the PV loop (and in the SW as the
area enclosed) when V d is increased. Since SW quantifies contractility, the results may suggest a
reduced LV pumping function in symptomatic patients.
Figure 5.13– PV loop changes (in red) after an increase in blood volume at zero pressure V d. Ea refers
to the arterial elastance, ESPV R and EDPV R are the end-systolic and end-diastolic PV relationships
and SW accounts for the stroke work.
Regarding ∆S, BS patients presented a decreased sympathetic HR regulation difference from
baseline in relation to healthy subjects. The results are in line with previous studies where
sympathetic dysfunctions have been reported in BS patients (Kies et al., 2004; Paul et al.,
2011; Wichter et al., 2002). Moreover, the study of (Nakazawa et al., 2003) analyzed the
24-hour autonomic properties of 27 BS patients and 26 healthy subjects, finding higher vagal
and reduced sympathetic tones in symptomatic BS patients.
5.2. Recursive model identification of the time-varying autonomic response to exercise 113
5.2. Recursive model identification of the time-varying
autonomic response to exercise
The system-level model proposed in the previous section can only explain the mechanical,
circulatory and autonomic sympathetic functions of the cardiovascular system. To tackle this
limitation, recursive identifications can simulate the high-frequency oscillations representing the
parasympathetic regulation of the ANS. Therefore, in this section, a recursive identification
is applied to a simplified version of the previous model in order to estimate the time-varying
sympathetic and parasympathetic responses to exertion and subsequent recovery in 44 BS
patients.
5.2.1. Experimental data description
Patients’ age ranged from 19 to 74 years old (45.07 ± 12.59 years old) and 33 (75%) were
males. Thirteen patients had the following documented symptoms: syncope (61.5%), cardiac
arrest (38.5%) and dizziness (15.4%). ICD implantation had been performed in 6 of 31 (19.4%)
asymptomatic patients, based on a positive EPS test, whereas all symptomatic patients were ICD
carriers. Among 31 patients (11 were symptomatic) in whom genetic screening was performed,
an SCN5A mutation was found in 13 (41.9%), from whom 6 were symptomatic. Table 5.5
summarizes participants’ baseline characteristics.
Table 5.5– Patients’ baseline characteristics.
Symptomatic Asymptomatic p-value
(n=13) (n=31)
Age, years old 43.62 ± 14.51 45.68 ± 11.90 0.322
Male sex, n (%) 11 (84.6%) 22 (71%) 0.355
ICD implantation, n (%) 13 (100%) 6 (19.4%) <0.001
Presence of SCN5A mutation, n (%) 6 (46.2%) 5 (25%) 0.311
Values are mean ± standard deviation or number of observations (%).
All between-groups differences, apart from ICD implantation, are statistically non-significant.
5.2.2. Computational model
Since exertion and post-exercise recovery equivalently influence all body parts, mainly affecting
the heart rate, a simplified version of the model proposed in Section 5.1 was implemented.
Although it is composed of the same CES submodel, CVS is modeled as in Section 5.1.3.2, but
with only one systemic branch, as illustrated in Figure 5.14. Moreover, the baroreflex model,
represented in Figure 5.15, only includes chronotropic regulation, adding 2 new time-varying
parameters: ZV and ZS .
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Figure 5.14– Closed-loop model of the simplified cardiovascular system. E: elastance; R: resistance; P:
pressure; V: volume; pul: pulmonary; pv: pulmonary vein; pa: pulmonary artery; pu:pulmonary valve; av:
aortic valve; ao: aorta; vc: venae cavae; LA: left atrium; LV: left ventricle; RA: right atrium; RV: right
ventricle.
As in Section 5.1.3.3, CVS and BRS models are coupled by the systemic arterial pressure.
Then, baroreceptors’ dynamical properties are represented by a first-order filter, whose gain and
time constant are KB and TB. The cardiovascular control center is simulated in both sympathetic
and vagal branches by a sigmoidal function and delays DS and DV , respectively.
Figure 5.15– Diagram of the baroreflex model for chronotropic regulaton. From the arterial pressure
registered at the systemic circulation, the baroreflex system controls heart rate.
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Sympathetic and parasympathetic contributions are modulated by two time-varying variables,
ZS(t) and ZV (t), to account for the influence of exogenous phenomena, such as different brain
structures, on both autonomic pathways. Indeed, these two variables collect all the variability
caused by sources other than blood pressure fluctuations.
Each efferent pathway is finally modeled with a first-order filter, characterized by a gain
(KV , KS) and a time constant (TV , TS). The output heart rate is the result of adding the
contributions of both sympathetic (S) and vagal (V ) branches to an intrinsic heart rate (HR0):
HR = HR0 + S − V (5.28)
5.2.3. Recursive identification
All model parameters other than ZS and ZV were fixed based on values reported in the
litterature (Hernandez Rodriguez, 2000; Le Rolle et al., 2008; Smith et al., 2004). In the
recursive identification process, at each step i of the algorithm, parameters ZS and ZV were
identified on a time interval TI of duration largely inferior to the RR series length (TI << TTOT ).
Simulated and experimental signals were compared in order to minimize the error function RR:
RR(i) =
(i+1)TL∑
te=iTL
|RRsim(te)−RRexp(te)|+
iTL+TI∑
te=iTL
|RRsim(te)−RRexp(te)|, i ∈ [0, · · · , N ]
(5.29)
where te is the time elapsed since the onset of the identification period, TL corresponds to the
overlap time between each interval and N = bTTOT /TLc is the number of identification intervals.
Figure 5.16 illustrates the time windows involved in the recursive identification algorithm.
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Figure 5.16– Representative time windows involved in the recursive identification of RR series. TL:
overlap window; TI : identification window.
The overlap time duration TL was set equal to the parasympathetic time constant (TV )
to capture rapid fluctuations due to the vagal response; whereas interval TI was set as the
sympathetic time constant (TS) in order to take into account the low frequency component
causing RR series slow variations.
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The error function was minimized on each interval i through the approach based on evolu-
tionary algorithms described in Section 5.1.5. The initial population, or first set of candidate
optimization solutions, was randomly generated. For the following steps, assuming limited
parameter variations between intervals, the initial population was set equal to that obtained
from the previous interval i− 1. Although this approach limits parameter variations, mutation
probability was set to pm = 0.2 in order to stimulate the exploration of the entire search space
and prevent from convergence to local minima.
These recursive identifications were separately performed during exercise and recovery. Since
each patient’s test differed in the incremental exercise phase duration and the shortest case in
our clinical series lasted less than 5 minutes, for exercise analysis, only the warm-up phase and
the first 3 minutes of incremental exertion were identified. Moreover, for recovery analysis, the
last minute of exertion and the first 3 minutes of recovery, were assessed.
In order to quantify identification performance, the error between simulated and experimental
RR series for both exercise and recovery phases was expressed in percentage and computed as:
E = 1
n
n∑
i=1
|100 · RRsim(i)−RRexp(i)
RRexp(i)
| (5.30)
where n is the number of samples being compared. Due to identification errors caused by
initialization, the first minute of warm-up was removed from exercise analysis, as well as the first
30 seconds of the last minute of exertion were removed from recovery analysis.
The identified time-varying sympathetic and parasympathetic contributions to exercise and
recovery were then compared between symptomatic and asymptomatic patients, by Mann-
Whitney U non-parametric tests. In order to compare the last minute of exertion and recovery,
all patients had to be synchronized with respect to the peak effort instant.
5.2.4. Results and discussion
Figure 5.17 illustrates an example of simulated and experimental RR series during exercise.
Based on visual inspection and error results (Eexercise = 1.10± 0.54%, Erecovery = 0.52± 0.16%),
a satisfactory agreement was observed between simulated signals and real data, leading to errors
always inferior to 3.5%.
Figure 5.18 shows the mean vagal and sympathetic contributions of the autonomic response
to exertion, for symptomatic and asymptomatic patients. In both groups, vagal tone remained
low along the whole exercise phase and decreased as the test progressed. Conversely, sympathetic
tone increased during exercise, and specially after warm-up. Moreover, symptomatic patients
presented significantly higher parasympathetic values around the second minute of incremental
exercise, and mainly at the end of warm-up, where this group also presented significantly higher
sympathetic values.
The results show similar trends to those found in the time-frequency analysis performed
in chapter 3 (Section 3.3.2), where a higher vagal tone, according to HFnu, was observed in
symptomatic patients during the second minute of incremental exercise. Although after recursive
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Figure 5.17– Simulated (blue) and experimental (black) RR series during the last minute of warm-up
and the first 3 minutes of incremental exercise. E = 1.7%.
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Figure 5.18– Mean vagal (ZV ) and sympathetic (ZS) tones, for symptomatic (blue) and asymptomatic
(black) patients, during exercise. Dashed vertical lines delimit the end of warm-up and subsequent
incremental exercise onset. Pointed boxes indicate those segments where significant differences between
groups (∗p < 0.05) were found.
model identification some significant differences were also found in this period, the largest and
most significant segment was observed at the end of warm-up. Moreover, sympathetic activity
in this phase was also found to be higher in symptomatic patients, contrary to the tendencies
found in LFnu. Nevertheless, time-frequency approaches are an approximation of the autonomic
function and several works report the influence of both sympathetic and parasympathetic systems
on LFnu (Malliani et al., 1994; Ori et al., 1992). Nonetheless, results on the vagal tone were
found to be consistent with previous studies where symptomatic BS patients showed enhanced
parasympathetic activities (Behar et al., 2016; Nakazawa et al., 2003; Tokuyama et al.,
2014).
Finally, in Figure 5.19, the mean vagal and sympathetic tones during recovery, for symptomatic
and asymptomatic patients, are represented. After the peak effort, an increase in parasympathetic
activity, as well as a decrease in the sympathetic tone can be observed for both groups. Although
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no statistically significant differences related to symptomatic status were found on the vagal
tone, at the end of the second minute of recovery, symptomatic patients presented significantly
lower sympathetic values. These findings concur with a previous work where a lower sympathetic
activity was reported in symptomatic patients (Nakazawa et al., 2003).
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Figure 5.19– Mean vagal (ZV ) and sympathetic (ZS) tones, for symptomatic (blue) and asymptomatic
(black) patients, during post-exercise recovery. Dashed vertical lines delimit the end of exertion and
subsequent recovery onset.
5.3. Multivariate model-based classification
Amultivariate classifier combining model parameters identified in Section 5.1 was implemented.
Although it is based on a small sample of 5 symptomatic and 7 asymptomatic BS patients, it is
presented as a first step towards the study of physiological model parameters for risk stratification
in BS patients.
5.3.1. Clinical data description
As in Section 5.1.2, five BS patients presented documented symptoms of ventricular origin:
cardiac arrest (60%) and syncope (40%). An ICD had been placed in one asymptomatic patient,
based on a positive EPS test, whereas all symptomatic patients had ICDs implanted. Three
BS patients (2 were symptomatic) presented an SCN5A mutation (25%). Table 5.6 summarizes
patients’ clinical characteristics.
5.3.2. Multivariate classification method
The LDA-based classifier described in chapter 4 was optimized in order to distinguish
symptomatic and asymptomatic groups. However, due to the reduced sample of patients included
in this study, all the observations were used for training and performance evaluation.
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Table 5.6– Patients’ baseline characteristics for multivariate model-based classification.
Symptomatic Asymptomatic p-value
(n=5) (n=7)
Age, years old 48.0 ± 11.5 51.6 ± 13.2 0.604
Male sex, n (%) 5 (100%) 5 (71.4%) 0.636
ICD implantation, n (%) 5 (100%) 1 (14.3%) 0.015
SCN5A mutation, n (%) 2 (40%) 1 (14.3%) 0.727
Values are mean ± standard deviation or number of observations (%).
All between-groups differences, apart from ICD implantation, are statistically non-significant.
This LDA classifier was designed as the linear combination of model parameters best distin-
guishing between symptomatic and asymptomatic patients. Being xi ∈ {λLV , V dLV , λRV , KV ,
TV , KS , TS , KR, KC , Pglegs} the input features, the LDA predictive model was defined as:
Z = β1x1 + β2x2 + · · ·+ β10x10 (5.31)
where βi were the estimated linear model coefficients.
5.3.3. Results and discussion
Table 5.7 summarizes the optimized model coefficients β. According to these coefficients,
TS , KC and KV negatively contributed to the classification decision. Thus, higher values in the
sympathetic time constant and gains related to cardiac contractility and vagal tone increased
the probability of classifying a patient as asymptomatic. Conversely, model parameters more
positively contributing to linear classification were KS , V dLV , KR and λRV , providing further
evidence in the combination of CVS and BRS variables for the identification of BS patients at
high risk.
As expected from sensitivity analysis, sympathetic and parasympathetic gains (KS , KV ), as
well as the LV volume at zero pressure (V dLV ), had a relevant impact on the classification of
BS patients. However, a higher contribution was placed on the end-diastolic exponent of the
RV (λRV ) than that of the LV (λLV ). Although sensitivity analysis identified the latter as a
more relevant parameter causing a greater influence on model outputs, in the context of Brugada
syndrome where patients present ECG patterns of RBBB, λRV seems to be more conclusive for
classification purposes.
Finally, by the application of these coefficients on the entire clinical database, only one
symptomatic patient was identified as asymptomatic and, thus, the 91.7% of patients were
correctly classified, leading to a sensitivity of the 80% and a specificity of the 100%.
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Table 5.7– LDA-model coefficients for each independent variable.
β
λLV 0.887
V dLV 2.139
λRV 1.074
KV -1.397
TV 0.998
KS 5.770
TS -5.100
KR 1.096
KC -2.019
Pglegs 0.064
5.4. Conclusion
In this chapter, two system-level model-based approaches were proposed in order to study
the mechanic, circulatory and autonomic function of BS patients. First, by the integration and
evaluation of a computational model capturing the cardiovascular system’s dynamics and its
autonomic response to HUT testing. After a thorough two-step parameter sensitivity analysis
to identify the most relevant variables affecting model outputs, results showed that SBP was
mainly modulated by CVS parameters, whereas HR was mostly affected by autonomic variables
coming from the BRS model. Then, subject-specific model parameters were estimated by
comparing cardiac experimental data and simulated signals through evolutionary algorithms.
The results showed significant differences between asymptomatic and symptomatic BS patients
in the left ventricle zero-pressure volumes, suggesting a reduced contractility function in the
latter. Moreover, controls showed an increased sympathetic regulation after tilting with respect
to BS patients.
Since this model can only explain the mechanical, circulatory and autonomic sympathetic
function of the cardiovascular system, a second approach based on a recursive identification
of the sympathetic and parasympathetic contributions to ANS regulation was proposed. It
was applied to a simplified version of the previous model in order to estimate the time-varying
autonomic response to exertion and subsequent recovery in 44 BS patients. According to the
results, a significantly higher parasympathetic activity in symptomatic patients, with respect to
asymptomatic subjects, was observed during exercise; providing further evidence for the role of
vagal tone in BS patients’ prognosis.
In both approaches, in order to reduce computational cost in parameter identification, a
small amount of parameters were selected, probably absorbing changes in other previously fixed
variables. For instance, significant results for LV parameters in the first approach may have
been affected by RV variations. Thus, a more extensive evaluation including a wider range
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of parameters should be performed in the future. Moreover, studies were based on a small
population of BS patients and, thus, conclusions on risk stratification cannot be extracted.
Nevertheless, the results indicate important trends of clinical relevance in autonomic, circulatory
and mechanical variables never studied before in BS that provide new insights into the disease.
Finally, in order to capture the multifactorial etiology of the syndrome, a multivariate
approach integrating model-based results was implemented. Although it was performed with an
insufficient amount of observations so as to infer conclusions, it is presented as a prospective
study introducing the next step in the development of a robust Brugada-based methodology to
identify patients at high risk for SCD.
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CHAPTER6
Conclusion
Brugada syndrome (BS) is a genetic arrhythmogenic disease associated with a distinctive
ECG pattern and an elevated risk for sudden cardiac death (SCD) due to ventricular fibrillation
(VF) in absence of structural cardiopathies (Priori et al., 2015). To date, the only proven
effective treatment for the prevention of SCD is the implantation of cardioverter defibrillators
(ICD). However, since they can present some complications, such as inappropriate shocks or
risks related to surgery (Miyazaki et al., 2013), these devices are recommended in patients with
documented life-threatening arrhythmias or presenting a spontaneous type 1 ECG and a history
of syncope (Priori et al., 2015). Thus, the decision of implanting an ICD on asymptomatic
subjects, who represent around 60% of diagnosed patients and present a relatively low risk for
cardiac events estimated at less than 1% (Probst et al., 2010), is still complex.
Since autonomic imbalance has been reported to play a determinant role in the patho-
physiology, arrhythmogenesis and prognosis of the disease, the characterization of autonomic
alterations induced by different ANS stimulations on patients at high risk having already suffered
symptoms could provide new insights into the autonomic mechanisms underlying the disease,
with a potential impact on risk stratification and, thus, on therapeutic strategies.
In this contex, the thesis was focused on the assessment of the autonomic function in Brugada
syndrome through the application of previously described methods for the study of heart rate
variability (HRV), heart rate complexity (HRC) and baroreflex sensitivity (BRS); and by the
development of novel approaches better accounting for the complexity and multifactorial nature
of biomedical signals. They were applied on clinical databases composed of cardiovascular data
from subjects at different levels of risk (symptomatic and asymptomatic BS patients), acquired
for 24 hours including exercise testing and a head-up tilt (HUT) test. The autonomic function
was evaluated by three main approaches:
Characterization and comparison of HRV, HRC and BRS indices, in order to identify
cardiac markers capable of distinguishing between symptomatic and asymptomatic BS
patients.
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Development, analysis and comparison of system-level patient-specific models describing
interactions between the cardiovascular and autonomic nervous systems, in order to better
understand the autonomic mechanisms underlying the disease and find new biomarkers
capable of identifying a high-risk group of patients.
Optimization of a multivariate approach based on a step-based machine learning method
built with features extracted from previous approaches, in order to design predictive models
improving classification perfomance and, thus, better identifying BS patients at high risk.
According to univariate analysis, symptomatic patients showed lower heart rate variability
and complexity, as well as a greater SA node sensitivity at night. During exercise testing,
symptomatic patients showed an increased vagal function and a reduced sympathetic activity,
with respect to asymptomatic BS patients, under conditions of incremental exercise. Moreover,
lower HRC values were noted in symptomatic patients under conditions of post-exercise recovery
and rest after recovery. Regarding the autonomic response to HUT testing, symptomatic
patients presented an increased parasympathetic tone and a reduced sympathovagal balance with
respect to asymptomatic patients during tilting, and specially before the 15th minute in upright
posture. After tilting, sympathovagal balance was more rapidly restored to baseline values in the
asymptomatic group. The results concur with previous publications reporting higher vagal and
lower sympathetic tones, as well as lower HRV values, in symptomatic patients (Behar et al.,
2016; Nakazawa et al., 2003; Tokuyama et al., 2014). However, since univariate comparisons
can only explain the effect of isolated factors on BS prognosis, a multivariate approach capable
of capturing the multifactorial nature of the disease was proposed.
When extracted autonomic features were included in multivariate models designed from a
step-based machine learning method, although exercise and HUT testing together lead to better
predictive results than when they were assessed separately, the classifier based on autonomic
features obtained during nighttime analysis presented the best performance (AUC = 95%),
improving previously reported predictive models of risk in BS based on non-invasive parame-
ters (Kawazoe et al., 2016). Previous studies have reported that most major cardiac events
in BS occur at rest and during sleep (Kies et al., 2004; Matsuo et al., 1999), and that the
occurrence of Brugada-like ECG changes increases with vagal stimulation (Ikeda et al., 2005).
Thus, these findings provide further evidence for the relevant role of autonomic night analysis to
identify BS patients at high risk, when parasympathetic activity is predominant.
However, since these multivariate predictive models do not integrate explicit physiological a
priori knowledge, two system-level model-based methods were proposed in order to study the
hemodynamic and autonomic function of BS patients. First, by the integration and evaluation
of a computational model capturing the cardiovascular system’s dynamics and its autonomic
response to HUT testing. After a thorough two-step parameter sensitivity analysis to identify
the most relevant variables affecting model outputs, results showed that systolic blood pressure
was mainly modulated by cardiovascular parameters, whereas heart rate was mostly affected
by autonomic variables coming from the BRS model. Then, subject-specific model parameters
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were estimated in 8 controls and 12 BS patients, by comparing cardiac experimental data and
simulated signals through evolutionary algorithms. The results showed significant differences
between asymptomatic and symptomatic BS patients in the left ventricle zero-pressure volumes,
suggesting a reduced contractility function in the latter. Moreover, controls showed an increased
sympathetic regulation after tilting with respect to BS patients.
A second model-based approach, integrating an original recursive identification algorithm
for the estimation of time-varying sympathetic and parasympathetic activities, was applied to a
simplified version of the previous model during exertion and subsequent recovery. A remarkable
agreement was noted between experimental and simulated signals (mean error = 0.81%) and esti-
mations of the sympathetic and parasympathetic components were consistent with physiological
knowledge. Moreover, a significantly higher parasympathetic activity in symptomatic patients,
with respect to asymptomatic subjects, was observed during exercise; providing further evidence
for the role of vagal tone in BS patients’ prognosis. Regarding sympathetic tone, significantly
higher values at the end of warm-up and lower values during recovery were observed in symp-
tomatic patients. To our knowledge, these contributions on recursive model-based autonomic
analysis are original and represent one of the main methodological contributions of this work.
Finally, in order to capture the multifactorial etiology of the syndrome, a multivariate classi-
fication approach integrating model-based features was proposed. More specifically, parameters
identified from the physiological model more accurately representing the cardiovascular and
autonomic response to HUT testing were included in a multivariate predictive LDA-based model.
Although classification performance could have been improved by means of the complete step-
based machine learning method previously proposed, the reduced sample of BS patients available
limited the study to a simpler approach.
From a methodological point of view, this work presents some limitations that should be
mentioned. On one hand, studies were based on a relatively small population of BS patients
and, thus, results should be confirmed by applying the proposed methods on larger clinical series.
Moreover, databases under study only included the blood pressure and ECG recordings acquired
for a specific moment. Since HRV measures have been reported to depend on day-to-day random
variations (Pinna et al., 2007), the repeatibility of computed HRV, HRC and BRS indices should
be proved stable and therefore characteristic of each patient, as in (Sinnreich et al., 1998).
Measures’ reliability is of major importance so as to be proposed as consistent markers of risk.
Moreover, since some patients classified as asymptomatic may develop symptoms in the future
and thus present high-risk patterns during the analyzed recordings, a more suitable clinical
database for risk stratification should include follow-up information so as to relate autonomic
changes to the probability of developing symptoms and not to the identification of a high-risk
group having already suffered these symptoms.
On the other hand, in order to reduce computational cost in model-based parameter iden-
tifications, a small amount of variables were identified, probably absorbing changes in other
previously fixed parameters. Thus, a more extensive evaluation including a wider range of
parameters should be performed in the future. Moreover, model-based approaches could be
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improved by including the effect of respiration on the vagal tone response and by integrating a
Brugada-based cardiac electrical system coupling the electrophysiological aspects characterizing
the disease with autonomic modulation. Apart from the need of integrating models capable of
representing the ionic currents leading to the Brugada-like ECG pattern; according to higher
circadian fluctuations found in symptomatic patients (Behar et al., 2016), an increased SA node
response to ANS seems to be associated with patients at high risk for SCD. Since this increased
response can be due to wider fluctuations in autonomic tone, but also due to a greater SA node
autonomic receptors sensitivity, improved versions of the integrated cardiac electrical system
should include an SA node sensitivity regulation.
Electrophysiological models simulating BS mutations should also be coupled since they cause
ionic imbalances heterogeneously affecting ventricular action potentials, which lead to alterations
causing Brugada-like ECG manifestations. Parasympathetic stimulation potentiates the ionic
imbalance caused by these BS mutations and accentuates the ionic and cellular alterations that
underlie the risk for ventricular arrhythmias in BS patients. Indeed, some approaches based
on the simulation of Brugada electrophysiological characteristics through mathematical models
have been reported (Clancy et al., 2002; Hoogendijk et al., 2011; Miyoshi et al., 2003; Xia
et al., 2006). Nevertheless, the proposed approach would be the first model integrating Brugada
electrophysiological knowledge on interactions between the cardiac function and the circulatory
and autonomic systems.
Furthermore, as proposed in (Le Rolle et al., 2015, 2016), identifications should be performed
in two steps combining a batch identification of model parameters, followed by a recursive
estimation of the time-varying autonomic response. Finally, features extracted from these
improved model-based approaches should be included in multivariate classifiers based on machine-
learning methods accounting for the multifactorial etiology of the disease. Final predictive models
responsible for the detection of patients at high risk should be based on physiological models
representing cardiac conditions characterizing the Brugada syndrome.
Nonetheless, the results thus far indicate important trends of clinical relevance that provide
new insights into the underlying autonomic mechanisms regulating the cardiovascular system
in BS, improving physiopathology and prognosis interpretation, with a potential future impact
on therapeutic strategies. The proposed approach is presented as a potential instrument for
the identification of those asymptomatic patients at high risk who may benefit from an ICD
implantation. Moreover, since the analyzed features can be automatically extracted from cardiac
signals, the methodological approach presented in this thesis might be applied to data acquired
from ICDs on implanted BS patients, in order to control their risk of SCD occurrence at follow-up.
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APPENDIXB
Multivariate classification results
This appendix contains the final feature subsets composing the single-test classifiers presented
in Chapter 4. The first section includes the resulting subsets when features extracted during
exercise testing were included in the multivariate classification approach, first for the example
based on 105 BS patients (Table B.1), and then for the result of applying this method on a
reduced clinical database of 44 patients (Table B.2). The next two sections include the final
subsets obtained for classifiers built from features extracted during HUT testing (Table B.3) and
overnight (Table B.4), in the same database of 44 BS patients.
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B.1. Exercise testing
Table B.1– Selected features for multivariate classification based on exercise testing in 105 BS patients.
Feature description
HFWU1nu Mean HFnu for the first minute of warm-up
HFEX3nu Mean HFnu for the third minute of incremental exercise
HFPEnu Mean HFnu for the last minute before peak effort
HFAR1nu Mean HFnu for the first minute of active recovery
HFAR3nu Mean HFnu for the third minute of active recovery
HFPR1nu Mean HFnu for the first minute of passive recovery
LF/HFAR2 Mean LF/HF for the second minute of active recovery
LFEX1 Mean LF for the first minute of incremental exercise
LFEX2 Mean LF for the second minute of incremental exercise
LFEX3 Mean LF for the third minute of incremental exercise
LFAR3 Mean LF for the third minute of active recovery
LFPR2 Mean LF for the second minute of passive recovery
LFPR3 Mean LF for the third minute of passive recovery
HFPE Mean HF for the last minute before peak effort
HFAR3 Mean HF for the third minute of active recovery
HFPR2 Mean HF for the second minute of passive recovery
HFPR3 Mean HF for the third minute of passive recovery
LFEX3nu Mean LFnu for the third minute of incremental exercise
LFPEnu Mean LFnu for the last minute before peak effort
LFAR1nu Mean LFnu for the first minute of active recovery
LFAR2nu Mean LFnu for the second minute of active recovery
LFAR3nu Mean LFnu for the third minute of active recovery
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Table B.2– Selected features for multivariate classification based on exercise testing in 44 BS patients.
Feature description
HFWU1nu Mean HFnu for the first minute of warm-up
HFEX1nu Mean HFnu for the first minute of incremental exercise
HFPEnu Mean HFnu for the last minute before peak effort
HFAR1nu Mean HFnu for the first minute of active recovery
HFPR2nu Mean HFnu for the second minute of passive recovery
HFPR3nu Mean HFnu for the third minute of passive recovery
LF/HFWU2 Mean LF/HF for the second minute of warm-up
LF/HFEX1 Mean LF/HF for the first minute of incremental exercise
LF/HFEX2 Mean LF/HF for the second minute of incremental exercise
LF/HFEX3 Mean LF/HF for the third minute of incremental exercise
LF/HFPE Mean LF/HF for the last minute before peak effort
LF/HFAR1 Mean LF/HF for the first minute of active recovery
LF/HFAR2 Mean LF/HF for the second minute of active recovery
LF/HFAR3 Mean LF/HF for the third minute of active recovery
LF/HFPR3 Mean LF/HF for the third minute of passive recovery
LFWU1 Mean LF for the first minute of warm-up
LFEX1 Mean LF for the first minute of incremental exercise
LFEX3 Mean LF for the third minute of incremental exercise
LFPE Mean LF for the last minute before peak effort
LFAR1 Mean LF for the first minute of active recovery
LFAR3 Mean LF for the third minute of active recovery
LFPR3 Mean LF for the third minute of passive recovery
HFWU2 Mean HF for the second minute of warm-up
HFEX1 Mean HF for the first minute of incremental exercise
HFPE Mean HF for the last minute before peak effort
HFAR2 Mean HF for the second minute of active recovery
HFAR3 Mean HF for the third minute of active recovery
LFWU2nu Mean LFnu for the second minute of warm-up
LFEX1nu Mean LFnu for the first minute of incremental exercise
LFPR3nu Mean LFnu for the third minute of passive recovery
βexercise Mean β for the whole exercise period
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B.2. HUT testing
Table B.3– Selected features for multivariate classification based on HUT testing in 44 BS patients.
Feature description
∆HF T11nu Mean ∆HFnu for the eleventh minute of tilting
∆HF T12nu Mean ∆HFnu for the twelfth minute of tilting
∆HF T13nu Mean ∆HFnu for the thirteenth minute of tilting
∆HF T14nu Mean ∆HFnu for the fourteenth minute of tilting
∆HFS1nu Mean ∆HFnu for the first minute in supine position after tilting
∆HFS2nu Mean ∆HFnu for the second minute in supine position after tilting
∆HFS3nu Mean ∆HFnu for the third minute in supine position after tilting
∆HFS5nu Mean ∆HFnu for the fifth minute in supine position after tilting
∆LF/HF T12 Mean ∆LF/HF for the twelfth minute of tilting
∆LF/HFS1 Mean ∆LF/HF for the first minute in supine position after tilting
∆LF/HFS2 Mean ∆LF/HF for the second minute in supine position after tilting
∆LF/HFS3 Mean ∆LF/HF for the third minute in supine position after tilting
∆LF/HFS4 Mean ∆LF/HF for the fourth minute in supine position after tilting
∆LF T11 Mean ∆LF for the eleventh minute of tilting
∆LF T14 Mean ∆LF for the fourteenth minute of tilting
∆LF T15 Mean ∆LF for the fifteenth minute of tilting
∆HF T11 Mean ∆HF for the eleventh minute of tilting
∆HF T12 Mean ∆HF for the twelfth minute of tilting
∆HF T13 Mean ∆HF for the thirteenth minute of tilting
∆HF T14 Mean ∆HF for the fourteenth minute of tilting
∆HF T15 Mean ∆HF for the fifteenth minute of tilting
∆HFS1 Mean ∆HF for the first minute in supine position after tilting
∆HFS2 Mean ∆HF for the second minute in supine position after tilting
∆HFS4 Mean ∆HF for the fourth minute in supine position after tilting
∆HFS5 Mean ∆HF for the fifth minute in supine position after tilting
∆LF T11nu Mean ∆LFnu for the eleventh minute of tilting
∆LF T12nu Mean ∆LFnu for the twelfth minute of tilting
∆LF T13nu Mean ∆LFnu for the thirteenth minute of tilting
∆LF T14nu Mean ∆LFnu for the fourteenth minute of tilting
∆LFS2nu Mean ∆LFnu for the second minute in supine position after tilting
∆LFS5nu Mean ∆LFnu for the fifth minute in supine position after tilting
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B.3. Night analysis
Table B.4– Selected features for multivariate classification based on overnight analysis in 44 BS patients.
Feature description
SDNN01 SDNN between midnight and 1 a.m.
rMSSD01 rMSSD between midnight and 1 a.m.
LF 01nu LFnu between midnight and 1 a.m.
HF 01nu HFnu between midnight and 1 a.m.
LF/HF 01 LF/HF between midnight and 1 a.m.
RR12 RR between 1 a.m. and 2 a.m.
SDNN12 SDNN between 1 a.m. and 2 a.m.
rMSSD12 rMSSD between 1 a.m. and 2 a.m.
SDNN5min12 SDNN5min between 1 a.m. and 2 a.m.
HF 12nu HFnu between 1 a.m. and 2 a.m.
RR23 RR between 2 a.m. and 3 a.m.
SDNN23 SDNN between 2 a.m. and 3 a.m.
NN5023 NN50 between 2 a.m. and 3 a.m.
rMSSD34 rMSSD between 3 a.m. and 4 a.m.
MIRR34 MIRR between 3 a.m. and 4 a.m.
HF 34nu HFnu between 3 a.m. and 4 a.m.
LF/HF 34 LF/HF between 3 a.m. and 4 a.m.
rMSSD45 rMSSD between 4 a.m. and 5 a.m.
SDANN45 SDANN between 4 a.m. and 5 a.m.
SDNN5min45 SDNN5min between 4 a.m. and 5 a.m.
NN5045 NN50 between 4 a.m. and 5 a.m.
MIRR45 MIRR between 4 a.m. and 5 a.m.
SampEn45 SampEn between 4 a.m. and 5 a.m.
SDNN56 SDNN between 5 a.m. and 6 a.m.
rMSSD56 rMSSD between 5 a.m. and 6 a.m.
SDNN5min56 SDNN5min between 5 a.m. and 6 a.m.

APPENDIXC
Parameter values of baroreflex and
cardiovascular models
In this appendix, a detailed list of the model parameters used in sensitivity analysis is provided.
Their values have been adapted from cited publications. Table C.1 includes model parameters
coming from the BRS submodel, while Table C.2 specifies the CVS submodel parameter ranges
employed.
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Table C.1– Ranges of BRS parameters used for sensitivity analysis. When parameters are unitless,
units are expressed as n.u.
Parameter Units Norminal value Min Max Reference
HR0 Hz 1.72 0.7667 2.667 (Roossien et al., 1997; Ursino et al., 2000)
(Heldt, 2004; Korakianitis et al., 2006)
KB n.u. 1 0.5 2 (Ursino et al., 2000)
TB s 2 0.1 2.5 (Van Roon et al., 2004)
KV n.u. 1 0.5 2 (Lu et al., 2001)
TV s 1.8 1.5 2.2 (Lu et al., 2001; Ursino et al., 2000)
(Van Roon et al., 2004)
aV n.u. 0.7 0.56 0.84 (Lu et al., 2001)
bV n.u. 1 0.8 1.2 (Lu et al., 2001)
MV n.u. 110 60 140 (Lu et al., 2001)
λV n.u. -0.04 -0.048 -0.032 (Lu et al., 2001)
DV s 0.2 0.16 0.24 (Lu et al., 2001; Ursino et al., 2000)
(Van Roon et al., 2004)
KS n.u. 1 0.5 2 (Lu et al., 2001)
TS s 10 2 12 (Lu et al., 2001; Ursino et al., 2000)
(Van Roon et al., 2004)
aS n.u. 0.3 0.24 0.36 (Lu et al., 2001)
bS n.u. 0.7 0.56 0.84 (Lu et al., 2001)
MS n.u. 100 60 140 (Lu et al., 2001)
λS n.u. 0.09 0.072 0.108 (Lu et al., 2001)
DS s 3 2 3.6 (Lu et al., 2001; Ursino et al., 2000)
(Van Roon et al., 2004)
KR n.u. 1 0.5 2 (Lu et al., 2001)
TR s 6 4.8 7.2 (Lu et al., 2001; Van Roon et al., 2004)
aR n.u. 0.3 0.24 0.36 (Lu et al., 2001)
bR n.u. 0.7 0.56 0.84 (Lu et al., 2001)
MR n.u. 110 60 140 (Lu et al., 2001)
λR n.u. 0.04 0.032 0.048 (Lu et al., 2001)
DR s 3 2.4 3.6 (Lu et al., 2001; Van Roon et al., 2004)
KV V n.u. 1 0.5 2 (Lu et al., 2001)
TV V s 6 4.8 7.2 (Lu et al., 2001; Van Roon et al., 2004)
aV V n.u. 0.3 0.24 0.36 (Lu et al., 2001)
bV V n.u. 0.7 0.56 0.84 (Lu et al., 2001)
MV V n.u. 110 60 140 (Lu et al., 2001)
λV V n.u. 0.04 0.032 0.048 (Lu et al., 2001)
DV V s 3 2.4 3.6 (Lu et al., 2001; Van Roon et al., 2004)
KC n.u. 1 0.5 2 (Lu et al., 2001)
TC s 10 8 12 (Lu et al., 2001; Van Roon et al., 2004)
aC n.u. 0.3 0.24 0.36 (Lu et al., 2001)
bC n.u. 0.7 0.56 0.84 (Lu et al., 2001)
MC n.u. 110 60 140 (Lu et al., 2001)
λC n.u. 0.04 0.032 0.048 (Lu et al., 2001)
DC s 3 2.4 3.6 (Lu et al., 2001; Van Roon et al., 2004)
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Table C.2– Ranges of CVS parameters used for sensitivity analysis.
Parameter Units Norminal value Min Max Reference
Eahead mmHg· ml−1 0.7051 0.62 3.246 (Davis, 1991)
(Smith et al., 2004)
Evhead mmHg·ml−1 0.0113 0.01 0.015 (Davis, 1991)
(Smith et al., 2004)
V da,head ml 240 192 288 (Van Roon et al., 2004)
V dv,head ml 650 520 780 (Van Roon et al., 2004)
Rhead mmHg·s·ml−1 0.125 0.1 0.15 (Van Roon et al., 2004)
V 0head ml 1250 1000 1500 (Van Roon et al., 2004)
Pghead mmHg -20 -30 -10 (Le Rolle et al., 2008)
Ealegs mmHg·ml−1 0.7051 0.62 3.246 (Davis, 1991)
(Smith et al., 2004)
Evlegs mmHg·ml−1 0.0113 0.01 0.015 (Davis, 1991)
(Smith et al., 2004)
V da,legs ml 240 192 288 (Van Roon et al., 2004)
V dv,legs ml 350 280 420 (Van Roon et al., 2004)
Rlegs mmHg·s·ml−1 0.0526 0.042 0.063 (Van Roon et al., 2004)
V 0legs ml 850 680 1020 (Van Roon et al., 2004)
Pglegs mmHg 60 40 80 (Le Rolle et al., 2008)
ELV mmHg·ml−1 3.4053 0.1 8 (Chung et al., 1997)
(Davis, 1991)
V dLV ml 5 0 71.44 (Burkhoff et al., 1993)
(Lu et al., 2001)
V 0LV ml 5 0 71.44 (Lu et al., 2001)
(Ursino et al., 2000)
λLV ml−1 0.015 0.014 0.1 (Luo et al., 2011)
(Ursino et al., 2000)
P0LV mmHg 1.2751 0.2 4 (Burkhoff et al., 1993)
(Luo et al., 2011)
ERV mmHg·ml−1 0.6526 0.34 2.87 (Davis, 1991)
(Dell’italia et al., 1988)
V dRV ml 5 0 89 (Burkhoff et al., 1993)
(Heldt, 2004)
V 0RV ml 5 0 89 (Lu et al., 2001)
(Ursino et al., 2000)
λRV ml−1 0.015 0.01 0.06 (Chung et al., 1997)
P0RV mmHg 1 0.35 1.2 (Burkhoff et al., 1993)
(Smith et al., 2004)
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